Medtronic (MDT) 10-Q 4 Dec 17 2018 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Oct. 27, 2017	Nov. 28, 2017
Document and Entity Information [Abstract]
Entity Registrant Name	Medtronic plc
Entity Central Index Key	1,613,103
Document Period End Date	Oct. 27, 2017
Current Fiscal Year End Date	--04-27
Document Type	10-Q
Amendment Flag	false
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Large Accelerated Filer
Ordinary Shares Outstanding		1,353,498,000
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2,018

Consolidated Statements of Inco

Consolidated Statements of Income - USD ($) shares in Millions	3 Months Ended		6 Months Ended
	Oct. 27, 2017	Oct. 28, 2016	Oct. 27, 2017	Oct. 28, 2016
Income Statement [Abstract]
Net sales	$ 7,050,000,000	$ 7,345,000,000	$ 14,440,000,000	$ 14,511,000,000
Costs and expenses:
Cost of products sold	2,120,000,000	2,326,000,000	4,469,000,000	4,587,000,000
Research and development expense	555,000,000	554,000,000	1,103,000,000	1,110,000,000
Selling, general, and administrative expense	2,438,000,000	2,416,000,000	4,923,000,000	4,844,000,000
Amortization of intangible assets	460,000,000	500,000,000	914,000,000	987,000,000
Restructuring charges, net	8,000,000	47,000,000	16,000,000	141,000,000
Acquisition-related items	7,000,000	28,000,000	51,000,000	80,000,000
Certain litigation charges	0	0	0	82,000,000
Divestiture-related items	67,000,000	0	114,000,000	0
Gain on sale of businesses	(697,000,000)	0	(697,000,000)	0
Special charge	80,000,000	0	80,000,000	0
Other expense, net	111,000,000	89,000,000	177,000,000	128,000,000
Operating profit	1,901,000,000	1,385,000,000	3,290,000,000	2,552,000,000
Interest income	(100,000,000)	(91,000,000)	(192,000,000)	(184,000,000)
Interest expense	273,000,000	264,000,000	559,000,000	536,000,000
Interest expense, net	173,000,000	173,000,000	367,000,000	352,000,000
Income before income taxes	1,728,000,000	1,212,000,000	2,923,000,000	2,200,000,000
Income tax (benefit) provision	(285,000,000)	101,000,000	(99,000,000)	160,000,000
Net income	2,013,000,000	1,111,000,000	3,022,000,000	2,040,000,000
Net loss attributable to noncontrolling interests	4,000,000	4,000,000	11,000,000	4,000,000
Net income attributable to Medtronic	$ 2,017,000,000	$ 1,115,000,000	$ 3,033,000,000	$ 2,044,000,000
Basic earnings per share (usd per share)	$ 1.49	$ 0.81	$ 2.23	$ 1.47
Diluted earnings per share (usd per share)	$ 1.48	$ 0.80	$ 2.21	$ 1.46
Basic weighted average shares outstanding (shares)	1,355.1	1,380	1,358.5	1,386.5
Diluted weighted average shares outstanding (shares)	1,365.8	1,392.5	1,370.8	1,400.2
Cash dividends declared per ordinary share (usd per share)	$ 0.46	$ 0.43	$ 0.92	$ 0.86

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 27, 2017	Oct. 28, 2016	Oct. 27, 2017	Oct. 28, 2016
Statement of Comprehensive Income [Abstract]
Net income	$ 2,013	$ 1,111	$ 3,022	$ 2,040
Other comprehensive income (loss), net of tax:
Unrealized gain (loss) on available-for-sale securities	25	(40)	55	75
Translation adjustment	(203)	(336)	628	(686)
Net change in retirement obligations	15	19	14	44
Unrealized gain (loss) on derivatives	27	53	(144)	107
Other comprehensive (loss) income	(136)	(304)	553	(460)
Comprehensive income including noncontrolling interests	1,877	807	3,575	1,580
Comprehensive loss attributable to noncontrolling interests	4	4	11	4
Comprehensive income attributable to Medtronic	$ 1,881	$ 811	$ 3,586	$ 1,584

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Millions	Oct. 27, 2017	Apr. 28, 2017
Current assets:
Cash and cash equivalents	$ 5,529	$ 4,967
Investments	7,997	8,741
Accounts receivable, less allowances of $168 and $155, respectively	5,752	5,591
Inventories, net	3,638	3,338
Other current assets	2,246	1,865
Current assets held for sale	0	371
Total current assets	25,162	24,873
Property, plant, and equipment	10,115	9,691
Accumulated depreciation	(5,674)	(5,330)
Property, plant, and equipment, net	4,441	4,361
Goodwill	39,077	38,515
Other intangible assets, net	22,625	23,407
Tax assets	1,749	1,509
Other assets	1,404	1,232
Noncurrent assets held for sale	0	5,919
Total assets	94,458	99,816
Current liabilities:
Current debt obligations	3,131	7,520
Accounts payable	1,718	1,731
Accrued compensation	1,502	1,860
Accrued income taxes	872	633
Other accrued expenses	3,273	2,442
Current liabilities held for sale	0	34
Total current liabilities	10,496	14,220
Long-term debt	25,941	25,921
Accrued compensation and retirement benefits	1,475	1,641
Accrued income taxes	2,194	2,405
Deferred tax liabilities	1,841	2,978
Other liabilities	933	1,515
Noncurrent liabilities held for sale	0	720
Total liabilities	42,880	49,400
Commitments and contingencies
Shareholders’ equity:
Ordinary shares— par value $0.0001, 2.6 billion shares authorized, 1,353,591,988 and 1,369,424,818 shares issued and outstanding, respectively	0	0
Additional paid-in capital	28,091	29,551
Retained earnings	25,438	23,356
Accumulated other comprehensive loss	(2,060)	(2,613)
Total shareholders’ equity	51,469	50,294
Noncontrolling interests	109	122
Total equity	51,578	50,416
Total liabilities and equity	$ 94,458	$ 99,816

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Oct. 27, 2017	Apr. 28, 2017
Statement of Financial Position [Abstract]
Allowances for accounts receivable	$ 168	$ 155
Ordinary shares, par value (usd per share)	$ 0.0001	$ 0.0001
Ordinary shares authorized (in shares)	2,600,000,000	2,600,000,000
Ordinary shares issued (in shares)	1,353,591,988	1,369,424,818
Ordinary shares outstanding (in shares)	1,353,591,988	1,369,424,818

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Millions	6 Months Ended
	Oct. 27, 2017	Oct. 28, 2016
Operating Activities:
Net income	$ 3,022	$ 2,040
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	1,314	1,469
Amortization of debt premium, discount, and issuance costs	(20)	14
Acquisition-related items	(25)	(47)
Provision for doubtful accounts	20	18
Deferred income taxes	(830)	(50)
Stock-based compensation	198	190
Gain on sale of businesses	(697)	0
Other, net	4	(105)
Change in operating assets and liabilities, net of acquisitions and divestitures:
Accounts receivable, net	(68)	(89)
Inventories, net	(273)	(187)
Accounts payable and accrued liabilities	(307)	(306)
Other operating assets and liabilities	(694)	75
Net cash provided by operating activities	1,644	3,022
Investing Activities:
Acquisitions, net of cash acquired	(76)	(1,306)
Proceeds from sale of businesses	6,058	0
Additions to property, plant, and equipment	(524)	(598)
Purchases of investments	(1,685)	(2,110)
Sales and maturities of investments	2,354	3,625
Other investing activities, net	(2)	32
Net cash provided by (used in) investing activities	6,125	(357)
Financing Activities:
Acquisition-related contingent consideration	(39)	(36)
Change in current debt obligations, net	(190)	1,154
Proceeds from short-term borrowings (maturities greater than 90 days)	0	4
Issuance of long-term debt	20	131
Payments on long-term debt	(4,161)	(252)
Dividends to shareholders	(1,247)	(1,192)
Issuance of ordinary shares	230	260
Repurchase of ordinary shares	(1,888)	(2,794)
Other financing activities	(2)	74
Net cash used in financing activities	(7,277)	(2,651)
Effect of exchange rate changes on cash and cash equivalents	70	64
Net change in cash and cash equivalents	562	78
Cash and cash equivalents at beginning of period	4,967	2,876
Cash and cash equivalents at end of period	5,529	2,954
Cash paid for:
Income taxes	674	258
Interest	$ 587	$ 559

Basis of Presentation

Basis of Presentation	6 Months Ended
	Oct. 27, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation The accompanying unaudited consolidated financial statements of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the consolidated financial statements include all of the adjustments necessary for a fair statement in conformity with U.S. GAAP. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates. The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been fully eliminated in consolidation. The accompanying unaudited consolidated financial statements and related notes should be read in conjunction with the audited consolidated financial statements of the Company and related notes included in the Company’s Annual Report on Form 10-K for the fiscal year ended April 28, 2017 . The Company’s fiscal years 2018 , 2017 , and 2016 will end or ended on April 27, 2018 , April 28, 2017 , and April 29, 2016 , respectively.

New Accounting Pronouncements

New Accounting Pronouncements	6 Months Ended
	Oct. 27, 2017
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
New Accounting Pronouncements	New Accounting Pronouncements Recently Adopted In March 2016, the Financial Accounting Standards Board (FASB) issued guidance to simplify the accounting for share-based payment transactions by requiring all excess tax benefits and deficiencies to be recognized in income tax expense or benefit in earnings; eliminating the requirement to classify the excess tax benefits and deficiencies as additional paid-in capital. Cash flows related to excess tax benefits are to be classified in operating activities in the statement of cash flows rather than financing. Under the new guidance, an entity makes an accounting policy election to either estimate the expected forfeiture awards or account for forfeitures as they occur. The standard also allows an entity to withhold up to the maximum statutory tax rate and classify the awards as equity. The Company prospectively adopted this guidance in the first quarter of fiscal year 2018. The Company has elected to continue to estimate forfeitures. The adoption of this guidance resulted in no cumulative adjustment to retained earnings and increases to net income of $17 million and $41 million , respectively, and increases to diluted earnings per share of $0.01 and $0.03 , respectively, for the three and six months ended October 27, 2017 . In October 2016, the FASB issued guidance that requires the tax effect of intra-entity transactions, other than sales of inventory, to be recognized when the transaction occurs. Previously, U.S. GAAP prohibited the recognition of current and deferred income taxes associated with an intra-entity asset transfer until an asset had been sold to a third-party. This update requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset, such as equipment or intangibles, when the transfer occurs. The adoption of this pronouncement is to be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The Company has early adopted this guidance, as permitted, in the first quarter of fiscal year 2018. As a result of this adoption, the Company increased its beginning retained earnings by $296 million . The adoption of this guidance also resulted in increases to net income of $582 million and $557 million , respectively, and increases to diluted earnings per share of $0.43 and $0.41 , respectively, for the three and six months ended October 27, 2017 . Not Yet Adopted In May 2014, the FASB issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue in an amount that reflects the consideration to which an entity expects to be entitled in exchange for the transfer of goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2019, and may be applied either retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of the change recognized at the date of initial application (modified retrospective method). The Company intends to adopt this guidance under the modified retrospective method. Based on the Company's evaluation performed of the amended revenue recognition guidance to date, the Company does not expect the adoption of the amended guidance to have a material impact on the Company's consolidated financial statements. The Company is continuing to evaluate the impact of the amended guidance in the areas of performance obligations, presentation, and new disclosure requirements. Additionally, the Company will continue to monitor any modifications, clarifications, and interpretations communicated by the FASB that may impact its conclusions. In January 2016, the FASB issued guidance which requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. The guidance also includes a simplified impairment assessment of equity investments without readily determinable fair values and presentation and disclosure changes. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2019. The Company is unable to estimate the impact of the future adoption of this guidance on its financial statements as it will depend on the equity investments at the adoption date. In February 2016, the FASB issued guidance which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. The guidance is to be applied using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements and is effective for the Company beginning in the first quarter of fiscal year 2020. Early adoption is permitted. The Company is evaluating the impact of the lease guidance on the Company's consolidated financial statements and anticipates recording additional assets and corresponding liabilities on its consolidated balance sheets related to operating leases within its lease portfolio upon adoption of the guidance. In January 2017, the FASB issued guidance which simplifies the accounting for goodwill impairment. The guidance requires a goodwill impairment to be measured as the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The Company is required to adopt this guidance beginning in the first quarter of fiscal year 2021. Early adoption is permitted, and the guidance must be applied prospectively. The Company is unable to estimate the impact of the future adoption of this guidance on its financial statements, as it is dependent on the specific facts and circumstances of future impairments, if any.

Acquisitions and Acquisition-Re

Acquisitions and Acquisition-Related Items	6 Months Ended
	Oct. 27, 2017
Business Combinations [Abstract]
Acquisitions and Acquisition-Related Items	Acquisitions and Acquisition-Related Items The Company had acquisitions and other acquisition-related activity during the six months ended October 27, 2017 . The Company accounted for the acquisitions as business combinations using the acquisition method of accounting. The assets and liabilities of the businesses acquired were recorded and consolidated on the acquisition date at their respective fair values. Goodwill resulting from business combinations is largely attributable to future yet to be defined technologies, new customer relationships, existing workforce of the acquired businesses, and synergies expected to arise after the Company's acquisition of these businesses. The pro forma impact of these acquisitions was not significant, either individually or in the aggregate, to the results of the Company for the three and six months ended October 27, 2017 . The results of operations of acquired businesses have been included in the Company's consolidated statements of income since the date each business was acquired. HeartWare International, Inc. On August 23, 2016, the Company's Cardiac and Vascular Group acquired HeartWare International, Inc. (HeartWare), a medical device company that develops and manufactures miniaturized implantable heart pumps, or ventricular assist devices, to treat patients around the world suffering from advanced heart failure. Total consideration for the transaction was approximately $1.1 billion . The Company acquired $602 million of technology-based and customer-related intangible assets and $23 million of tradenames, with estimated useful lives of 15 and 5 years, respectively, and $481 million of goodwill. The acquired goodwill is not deductible for tax purposes. In addition, the Company acquired $245 million of debt through the acquisition, of which the Company redeemed $203 million as part of a cash tender offer in August 2016 and the remaining $42 million of debt acquired is due December 2017. During the measurement period, which ended on August 22, 2017, adjustments were made to finalize the allocation of purchase price related to other assets, goodwill, and contingent liabilities. The acquisition date fair values of the assets and liabilities acquired were as follows: (in millions) HeartWare International, Inc. All Other Other current assets $ 351 $ 2 Property, plant, and equipment 14 6 Other intangible assets 625 68 Goodwill 481 15 Other assets 84 — Total assets acquired 1,555 91 Current liabilities 143 1 Deferred tax liabilities 6 — Long-term debt 245 — Other liabilities 89 — Total liabilities assumed 483 1 Net assets acquired $ 1,072 $ 90 For additional information on the Company's fiscal year 2017 acquisitions, refer to Note 2 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 28, 2017 . Acquisition-Related Items Acquisition-related items includes expenses incurred in connection with the integration of Covidien, our $50.0 billion acquisition completed in the fourth quarter of fiscal year 2015, expenses incurred in connection with business acquisitions, and changes in fair value of contingent consideration. During the three and six months ended October 27, 2017 , the Company recognized acquisition-related items expense of $18 million and $71 million , respectively, including $11 million and $20 million , respectively, recognized within cost of products sold in the consolidated statements of income. For the three and six months ended October 27, 2017 , acquisition-related items expense includes $44 million and $90 million , respectively, of costs associated with the integration of Covidien manufacturing, distribution, and administrative facilities as well as IT system implementation, partially offset by changes in fair value of contingent consideration as a result of revised revenue forecasts and the timing of anticipated regulatory payments. During the three and six months ended October 28, 2016 , the Company recognized acquisition-related items expense of $28 million and $80 million , respectively. For the three and six months ended October 28, 2016 , acquisition-related items expense includes $59 million and $102 million , respectively, of costs associated with the integration of Covidien manufacturing, distribution, and administrative facilities as well as IT system implementation and benefits harmonization, and $9 million and $16 million , respectively, of accelerated and incremental stock compensation expense, partially offset by changes in fair value of contingent consideration as a result of revised revenue forecasts and the timing of anticipated regulatory payments. Contingent Consideration Certain of the Company’s business combinations involve potential payments of future consideration that is contingent upon the achievement of product development milestones and/or contingent on the acquired business reaching performance milestones. A liability is recorded for the estimated fair value of the contingent consideration on the acquisition date. The fair value of the contingent consideration is remeasured at each reporting period using Level 3 inputs, and the change in fair value is recognized within acquisition-related items in the consolidated statements of income. Contingent consideration payments related to the acquisition date fair value are reported as financing activities in the consolidated statements of cash flows. Amounts paid in excess of the original acquisition date fair value are reported as operating activities in the consolidated statements of cash flows. The fair value of contingent consideration is measured using projected payment dates, discount rates, probabilities of payment, and projected revenues (for revenue-based consideration). Projected revenues are based on the Company's most recent internal operational budgets and long-range strategic plans. Changes in projected revenues, probabilities of payment, discount rates, and projected payment dates may result in adjustments to the fair value measurement. The recurring Level 3 fair value measurements of contingent consideration include the following significant unobservable inputs: Fair Value at (in millions) October 27, 2017 Valuation Technique Unobservable Input Range Discount rate 11% - 32.5% Revenue-based payments $85 Discounted cash flow Probability of payment 30% - 100% Projected fiscal year of payment 2018 - 2026 Discount rate 0.7% - 5.5% Product development and other milestone-based payments $105 Discounted cash flow Probability of payment 50% - 100% Projected fiscal year of payment 2018 - 2025 The fair value of contingent consideration at October 27, 2017 and April 28, 2017 was $190 million and $246 million , respectively. At October 27, 2017 , $70 million was recorded in other liabilities and $120 million was recorded in other accrued expenses in the consolidated balance sheets. At April 28, 2017 , $180 million was recorded in other liabilities and $66 million was recorded in other accrued expenses in the consolidated balance sheets. The following table provides a reconciliation of the beginning and ending balances of contingent consideration: Three months ended Six months ended (in millions) October 27, 2017 October 28, 2016 October 27, 2017 October 28, 2016 Beginning Balance $ 242 $ 379 $ 246 $ 377 Purchase price contingent consideration 15 11 15 32 Payments (43 ) (25 ) (46 ) (39 ) Change in fair value (24 ) (80 ) (25 ) (85 ) Ending Balance $ 190 $ 285 $ 190 $ 285

Divestiture and Divestiture-Rel

Divestiture and Divestiture-Related Items	6 Months Ended
	Oct. 27, 2017
Discontinued Operations and Disposal Groups [Abstract]
Divestiture and Divestiture-Related Items	Divestiture and Divestiture-Related Items Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency Businesses In April 2017, the Company entered into a definitive agreement for the sale of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses within the Minimally Invasive Therapies Group segment to Cardinal Health, Inc. (Cardinal). The divestiture was completed on July 29, 2017. As a result of the transaction, the Company received proceeds of $6.1 billion , which was recorded in the line item proceeds from sale of businesses in the consolidated statements of cash flows, and recognized a before-tax gain of $697 million , which was recognized within gain on sale of businesses in the consolidated statements of income. Among the product lines included in the divestiture are the dental and animal health, chart paper, wound care, incontinence, electrodes, SharpSafety, thermometry, perinatal protection, blood collection, compression, and enteral feeding offerings. The divestiture also included 17 dedicated manufacturing sites. In connection with the transaction, the Company entered into Transition Service Agreements (TSAs) and Transition Manufacturing Agreements (TMAs) with Cardinal designed to ensure and facilitate an orderly transfer of business operations. The TSAs are primarily related to administrative services and are expected to continue for 12 months from the divestiture date, with an ability to extend upon mutual agreement of both parties. Under the TMAs, both the Company and Cardinal will manufacture and supply certain products to each other for a transition period of up to 5 years. The divestiture of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses did not meet the criteria to be classified as discontinued operations, as such, the results of operations of these businesses are included within net income through the date of the divestiture. The Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses met the criteria to be classified as held for sale in the fourth quarter of fiscal year 2017, at which time the Company ceased depreciation and amortization of property, plant, and equipment and intangible assets classified as held for sale. The following table presents information related to the assets and liabilities that were classified as held for sale in the consolidated balance sheets: (in millions) April 28, 2017 Inventories, net $ 371 Property, plant, and equipment, net 689 Goodwill 2,910 Other intangible assets, net 2,320 Total assets held for sale $ 6,290 Other accrued expenses $ 34 Accrued compensation and retirement benefits 12 Deferred tax liabilities 707 Other liabilities 1 Total liabilities held for sale $ 754 Divestiture-Related Items Divestiture-related items includes expenses incurred in connection with the divestiture of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses. During the three months ended October 27, 2017 , the Company recognized divestiture-related items expense of $67 million primarily comprised of expenses incurred for professional services, including banker, legal, tax, and advisory fees. During the six months ended October 27, 2017 , the Company recognized divestiture-related items expense of $114 million , primarily comprised of expenses incurred for professional services, including banker, legal, tax, and advisory fees, as well as $16 million of accelerated stock compensation expense related to the acceleration of the vesting period for employees that transferred with the divestiture. There were no divestiture-related items expenses for the three or six months ended October 28, 2016 .

Special Charge

Special Charge	6 Months Ended
	Oct. 27, 2017
Commitments and Contingencies Disclosure [Abstract]
Special Charge	Special Charge During the three and six months ended October 27, 2017 , continuing the Company's commitment to improve the health of people and communities throughout the world, the Company recognized a charge of $80 million for a commitment to fund the Medtronic Foundation. During the three and six months ended October 28, 2016 , the Company did no t recognize a special charge.

Restructuring Charges

Restructuring Charges	6 Months Ended
	Oct. 27, 2017
Restructuring and Related Activities [Abstract]
Restructuring Charges	Restructuring Charges Cost Synergies Initiative The cost synergies initiative is the Company's restructuring program primarily related to the integration of Covidien. This initiative contributes to the approximately $850 million in cost synergies expected to be achieved as a result of the integration of the Covidien acquisition through fiscal year 2018, including administrative office optimization, manufacturing and supply chain infrastructure, certain program cancellations, and reduction of general and administrative redundancies. Restructuring charges are primarily related to employee termination costs and costs related to manufacturing and facility closures and affect all reportable segments. Cash outlays for the cost synergies initiative restructuring program are scheduled to be substantially complete by the end of fiscal year 2019. A summary of the restructuring accrual, recorded within other accrued expenses and other liabilities in the consolidated balance sheets, and related activity is presented below: (in millions) Employee Termination Costs Other Costs Total April 28, 2017 $ 261 $ 30 $ 291 Charges 25 20 45 Cash payments (85 ) (26 ) (111 ) Accrual adjustments (14 ) 1 (13 ) October 27, 2017 $ 187 $ 25 $ 212 For the three and six months ended October 27, 2017 , the Company recognized $26 million and $45 million in charges, respectively, which were partially offset by accrual adjustments of $8 million and $13 million , respectively. Accrual adjustments relate to certain employees identified for termination finding other positions within the Company, cancellations of employee terminations, and employee termination costs being less than initially estimated. For the three and six months ended October 27, 2017 , charges included $7 million and $12 million , respectively, recognized within cost of products sold and $3 million and $4 million , respectively, recognized within selling, general and administrative expense . For the three and six months ended October 28, 2016 , the Company recognized $47 million and $158 million in charges, respectively. The Company recognized no reversals of excess restructuring reserves for the three months ended October 28, 2016. As a result of certain employees identified for termination finding other positions within the Company, the Company recognized a $7 million reversal of excess restructuring reserves for the six months ended October 28, 2016. For the three months and six months ended October 28, 2016, charges included asset write-downs included $3 million and $7 million , respectively, related to property, plant, and equipment impairments, and $10 million related to inventory write-offs recognized within cost of products sold in the consolidated statements of income.

Financial Instruments

Financial Instruments	6 Months Ended
	Oct. 27, 2017
Investments [Abstract]
Financial Instruments	Financial Instruments The Company holds investments such as marketable debt and equity securities that are classified and accounted for as available-for-sale and are remeasured on a recurring basis. The Company also holds cost method, equity method, and other investments which are measured at fair value on a nonrecurring basis. For information regarding the valuation techniques and inputs used in the fair value measurements, refer to Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 28, 2017. The following table summarizes the Company's investments by significant investment category and the related consolidated balance sheet classification at October 27, 2017 : Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Available-for-sale securities: Level 1: U.S. government and agency securities $ 613 $ 1 $ (8 ) $ 606 $ 606 $ — Marketable equity securities 84 115 (1 ) 198 — 198 Total Level 1 697 116 (9 ) 804 606 198 Level 2: Corporate debt securities 4,165 64 (16 ) 4,213 4,213 — U.S. government and agency securities 870 — (12 ) 858 858 — Mortgage-backed securities 768 7 (19 ) 756 756 — Foreign government and agency securities 52 — — 52 52 — Other asset-backed securities 341 1 (1 ) 341 341 — Debt funds 939 6 (168 ) 777 777 — Total Level 2 7,135 78 (216 ) 6,997 6,997 — Level 3: Corporate debt securities 1 — — 1 — 1 Auction rate securities 47 — (3 ) 44 — 44 Total Level 3 48 — (3 ) 45 — 45 Investments measured at net asset value (1) : Debt Funds 400 — (6 ) 394 394 — Total available-for-sale securities 8,280 194 (234 ) 8,240 7,997 243 Cost method, equity method, and other investments: Level 3: Cost method, equity method, and other investments 626 — — N/A — 626 Total Level 3 626 — — N/A — 626 Total cost method, equity method, and other investments 626 — — N/A — 626 Total investments $ 8,906 $ 194 $ (234 ) $ 8,240 $ 7,997 $ 869 (1) Certain investments that are measured at the net asset value per share (or its equivalent) as a practical expedient are excluded from the fair value hierarchy. The fair value amounts presented herein are intended to permit reconciliation to the consolidated balance sheets. The following table summarizes the Company's investments by significant investment category and the related consolidated balance sheet classification at April 28, 2017 : Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Available-for-sale securities: Level 1: U.S. government and agency securities $ 613 $ 2 $ (5 ) $ 610 $ 610 $ — Marketable equity securities 58 49 (4 ) 103 — 103 Total Level 1 671 51 (9 ) 713 610 103 Level 2: Corporate debt securities 4,643 62 (23 ) 4,682 4,682 — U.S. government and agency securities 860 — (10 ) 850 850 — Mortgage-backed securities 766 9 (16 ) 759 759 — Foreign government and agency securities 49 — — 49 49 — Other asset-backed securities 228 1 (1 ) 228 228 — Debt funds 1,246 4 (178 ) 1,072 1,072 — Total Level 2 7,792 76 (228 ) 7,640 7,640 — Level 3: Corporate debt securities 1 — — 1 — 1 Auction rate securities 47 — (3 ) 44 — 44 Total Level 3 48 — (3 ) 45 — 45 Investments measured at net asset value (1) : Debt funds 497 — (6 ) 491 491 — Total available-for-sale securities 9,008 127 (246 ) 8,889 8,741 148 Cost method, equity method, and other investments: Level 3: Cost method, equity method, and other investments 589 — — N/A — 589 Total Level 3 589 — — N/A — 589 Total cost method, equity method, and other investments 589 — — N/A — 589 Total investments $ 9,597 $ 127 $ (246 ) $ 8,889 $ 8,741 $ 737 (1) Certain investments that are measured at the net asset value per share (or its equivalent) as a practical expedient are excluded from the fair value hierarchy. The fair value amounts presented herein are intended to permit reconciliation to the consolidated balance sheets. Marketable Debt and Equity Securities The following tables present the gross unrealized losses and fair values of the Company’s available-for-sale securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at October 27, 2017 and April 28, 2017 : October 27, 2017 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 946 $ (9 ) $ 209 $ (7 ) Auction rate securities — — 44 (3 ) Mortgage-backed securities 296 (4 ) 97 (15 ) U.S. government and agency securities 877 (15 ) 216 (5 ) Debt funds 7 (1 ) 958 (173 ) Other asset-backed securities 201 (1 ) — — Marketable equity securities — — 2 (1 ) Total $ 2,327 $ (30 ) $ 1,526 $ (204 ) April 28, 2017 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 1,263 $ (19 ) $ 46 $ (4 ) Auction rate securities — — 44 (3 ) Mortgage-backed securities 276 (4 ) 95 (12 ) U.S. government and agency securities 896 (15 ) — — Other asset-backed securities 127 (1 ) — — Debt funds 173 (1 ) 1,125 (183 ) Marketable equity securities 14 (3 ) 2 (1 ) Total $ 2,749 $ (43 ) $ 1,312 $ (203 ) The following table presents the unobservable inputs utilized in the fair value measurement of the auction rate securities classified as Level 3 at October 27, 2017 : Valuation Technique Unobservable Input Range (Weighted Average) Auction rate securities Discounted cash flow Years to principal recovery 2 yrs. - 12 yrs. (3 yrs.) Illiquidity premium 6% The Company reviews the fair value hierarchy classification on a quarterly basis. Changes in the ability to observe valuation inputs may result in a reclassification of levels for certain securities within the fair value hierarchy. The Company’s policy is to recognize transfers into and out of levels within the fair value hierarchy at the end of the fiscal quarter in which the actual event or change in circumstances that caused the transfer occurs. There were no transfers between Level 1, Level 2, or Level 3 during the three and six months ended October 27, 2017 and October 28, 2016 . When a determination is made to classify an asset or liability within Level 3, the determination is based upon the significance of the unobservable inputs to the overall fair value measurement. The following tables provide a reconciliation of the beginning and ending balances of items measured at fair value on a recurring basis that used significant unobservable inputs (Level 3): Three months ended October 27, 2017 (in millions) Total Level 3 Corporate Debt Auction Rate July 28, 2017 $ 45 $ 1 $ 44 Total unrealized gains (losses) included in other comprehensive income — — — October 27, 2017 $ 45 $ 1 $ 44 Three months ended October 28, 2016 (in millions) Total Level 3 Corporate Debt Auction Rate July 29, 2016 $ 45 $ 1 $ 44 Total unrealized gains (losses) included in other comprehensive income — — — October 28, 2016 $ 45 $ 1 $ 44 Six months ended October 27, 2017 (in millions) Total Level 3 Corporate Debt Auction Rate April 28, 2017 $ 45 $ 1 $ 44 Total unrealized gains (losses) included in other comprehensive income — — — October 27, 2017 $ 45 $ 1 $ 44 Six months ended October 28, 2016 (in millions) Total Level 3 Corporate Debt Auction Rate April 29, 2016 $ 45 $ 1 $ 44 Total unrealized gains (losses) included in other comprehensive income — — — October 28, 2016 $ 45 $ 1 $ 44 Activity related to the Company’s investment portfolio is as follows: Three months ended October 27, 2017 October 28, 2016 (in millions) Debt (1) Equity (2) Debt (1) Equity (2) Proceeds from sales $ 1,383 $ — $ 2,444 $ 76 Gross realized gains 11 — 57 25 Gross realized losses (12 ) — (37 ) — Impairment losses recognized — (1 ) — (7 ) Six months ended October 27, 2017 October 28, 2016 (in millions) Debt (1) Equity (2) Debt (1) Equity (2) Proceeds from sales $ 2,354 $ — $ 3,542 $ 82 Gross realized gains 19 7 64 29 Gross realized losses (15 ) — (49 ) — Impairment losses recognized — (1 ) — (10 ) (1) Includes available-for-sale debt securities and debt funds. (2) Includes marketable equity securities and cost and equity method investments. Credit losses represent the difference between the present value of cash flows expected to be collected on certain mortgage-backed securities and auction rate securities and the amortized cost of these securities. Based on the Company’s assessment of the credit quality of the underlying collateral and credit support available to each of the remaining securities in which the Company is invested, the Company believes it has recognized all necessary other-than-temporary impairments, as the Company does not have the intent to sell, nor is it more likely than not that the Company will be required to sell, before recovery of the amortized cost. At October 27, 2017 and April 28, 2017 , the credit loss portion of other-than-temporary impairments on debt securities was no t significant. The total reductions of available-for-sale debt securities sold during the three and six months ended October 27, 2017 and October 28, 2016 were no t significant. The October 27, 2017 balance of available-for-sale debt securities, excluding debt funds which have no single maturity date, by contractual maturity is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. (in millions) October 27, 2017 Due in one year or less $ 865 Due after one year through five years 2,601 Due after five years through ten years 3,298 Due after ten years 107 Total $ 6,871 The Company holds investments in marketable equity securities, which are classified as other assets in the consolidated balance sheets. The aggregate carrying amount of these investments was $198 million and $103 million at October 27, 2017 and April 28, 2017 , respectively. The Company did no t recognize any significant impairment charges related to marketable equity securities during the three and six months ended October 27, 2017 and October 28, 2016 . Cost method, equity method, and other investments The Company holds investments in equity and other securities that are accounted for using the cost or equity method, which are classified as other assets in the consolidated balance sheets. At October 27, 2017 and April 28, 2017 , the aggregate carrying amount of equity and other securities without a quoted market price and accounted for using the cost or equity method was $626 million and $589 million , respectively. Cost and equity method investments are measured at fair value on a nonrecurring basis. Changes in circumstance or the occurrence of events that suggest the Company’s investment may not be recoverable are assessed quarterly. If events or changes in circumstances are identified that may have a material adverse effect on the fair value of the investment, the investment is assessed for impairment. Cost and equity method investments fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value, as the investments are in privately-held entities without quoted market prices. To determine the fair value of these investments, the Company uses all pertinent financial information available related to the entities, including financial statements and market participant valuations from recent and proposed equity offerings. During the three and six months ended October 27, 2017 , the Company did no t recognize any significant impairment charges related to cost method investments. During the three and six months ended October 28, 2016 , the Company determined that the fair values of certain cost method investments were below their carrying values and that the carrying values of these investments were not expected to be recoverable within a reasonable period of time. As a result, the Company recognized $7 million and $10 million in impairment charges during the three and six months ended October 28, 2016, respectively, which were recognized in other expense, net in the consolidated statements of income.

Financing Arrangements

Financing Arrangements	6 Months Ended
	Oct. 27, 2017
Debt Disclosure [Abstract]
Financing Arrangements	Financing Arrangements Commercial Paper The Company maintains a commercial paper program that allows the Company to have a maximum of $3.5 billion in commercial paper outstanding. Commercial paper outstanding at October 27, 2017 was $700 million , as compared to $901 million at April 28, 2017 . During the three and six months ended October 27, 2017 , the weighted average original maturity of the commercial paper outstanding was approximately 30 and 31 days, respectively, and the weighted average interest rate was 1.31 percent and 1.27 percent , respectively. The issuance of commercial paper reduces the amount of credit available under the Company’s existing Credit Facility, as defined below. Line of Credit The Company has a $3.5 billion five year revolving syndicated line of credit facility (Credit Facility) which provides back-up funding for the commercial paper program described above. At October 27, 2017 and April 28, 2017 , no amounts were outstanding. Interest rates on advances on the Credit Facility are determined by a pricing matrix, based on the Company’s long-term debt ratings, assigned by Standard & Poor’s Ratings Services and Moody’s Investors Service. Facility fees are payable on the Credit Facility and are determined in the same manner as the interest rates. The agreements also contain customary covenants, all of which the Company remained in compliance with at October 27, 2017 . Debt Obligations The Company's debt obligations consisted of the following: (in millions, except interest rates) Maturity by Fiscal Year October 27, 2017 April 28, 2017 Current debt obligations 2018 $ 3,131 $ 7,520 Long-term debt 5.600 percent ten-year 2009 senior notes 2019 400 400 1.700 percent two-year 2017 senior notes 2019 1,000 1,000 4.450 percent ten-year 2010 senior notes 2020 766 766 2.500 percent five-year 2015 senior notes 2020 2,500 2,500 Floating rate five-year 2015 senior notes 2020 500 500 4.200 percent ten-year 2010 CIFSA senior notes 2021 600 600 4.125 percent ten-year 2011 senior notes 2021 500 500 3.125 percent ten-year 2012 senior notes 2022 675 675 3.150 percent seven-year 2015 senior notes 2022 2,500 2,500 3.200 percent ten-year 2012 CIFSA senior notes 2023 650 650 2.750 percent ten-year 2013 senior notes 2023 530 530 2.950 percent ten-year 2013 CIFSA senior notes 2024 310 310 3.625 percent ten-year 2014 senior notes 2024 850 850 3.500 percent ten-year 2015 senior notes 2025 4,000 4,000 3.350 percent ten-year 2017 senior notes 2027 850 850 4.375 percent twenty-year 2015 senior notes 2035 2,382 2,382 6.550 percent thirty-year 2008 CIFSA senior notes 2038 374 374 6.500 percent thirty-year 2009 senior notes 2039 300 300 5.550 percent thirty-year 2010 senior notes 2040 500 500 4.500 percent thirty-year 2012 senior notes 2042 400 400 4.000 percent thirty-year 2013 senior notes 2043 325 325 4.625 percent thirty-year 2014 senior notes 2044 650 650 4.625 percent thirty-year 2015 senior notes 2045 4,150 4,150 Interest rate swaps (Note 9) 2021 - 2022 30 40 Capital lease obligations 2019 - 2025 22 23 Bank borrowings 2019 - 2021 169 139 Debt premium, net 2019 - 2045 127 135 Deferred financing costs 2019 - 2045 (119 ) (128 ) Long-term debt $ 25,941 $ 25,921 Senior Notes The Company has outstanding unsecured senior obligations, described as senior notes as well as included within current debt obligations in the debt obligations table above (collectively, the Senior Notes). The Senior Notes rank equally with all other unsecured and unsubordinated indebtedness of the Company. The indentures under which the Senior Notes were issued contain customary covenants, all of which the Company remained in compliance with at October 27, 2017 . For additional information regarding the terms of these agreements, refer to Note 8 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 28, 2017 . Financial Instruments Not Measured at Fair Value At October 27, 2017 , the estimated fair value of the Company’s Senior Notes, including the current portion, was $29.5 billion compared to a principal value of $27.8 billion . At April 28, 2017 , the estimated fair value was $30.4 billion compared to a principal value of $28.9 billion . The fair value was estimated using quoted market prices for the publicly registered Senior Notes, which are classified as Level 2 within the fair value hierarchy. The fair values and principal values consider the terms of the related debt and exclude the impacts of debt discounts and derivative/hedging activity.

Derivatives and Currency Exchan

Derivatives and Currency Exchange Risk Management	6 Months Ended
	Oct. 27, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives and Currency Exchange Risk Management	Derivatives and Currency Exchange Risk Management The Company uses operational and economic hedges, as well as currency exchange rate derivative contracts and interest rate derivative instruments, to manage the impact of currency exchange and interest rate changes on earnings and cash flows. In addition, the Company uses cross currency interest rate swaps to manage currency risk related to certain debt. In order to minimize earnings and cash flow volatility resulting from currency exchange rate changes, the Company enters into derivative instruments, principally forward currency exchange rate contracts. These contracts are designed to hedge anticipated foreign currency transactions and changes in the value of specific assets and liabilities. At inception of the contract, the derivative is designated as either a freestanding derivative or a cash flow hedge. The primary currencies of the derivative instruments are the Euro and Japanese Yen. The Company does not enter into currency exchange rate derivative contracts for speculative purposes. The gross notional amount of all currency exchange rate derivative instruments outstanding was $12.0 billion and $10.8 billion at October 27, 2017 and April 28, 2017 , respectively. The information that follows explains the various types of derivatives and financial instruments used by the Company, reasons the Company uses such instruments, and the impact such instruments have on the Company’s consolidated balance sheets, statements of income, and statements of cash flows. Freestanding Derivative Contracts Freestanding derivative contracts are used to offset the Company’s exposure to the change in value of specific foreign currency denominated assets and liabilities and to offset variability of cash flows associated with forecasted transactions denominated in foreign currencies. These derivatives are not designated as hedges, and therefore, changes in the value of these contracts are recognized in earnings, thereby offsetting the current earnings effect of the related change in value of foreign currency denominated assets, liabilities, and cash flows. The gross notional amount of these contracts outstanding at October 27, 2017 and April 28, 2017 was $5.7 billion and $4.9 billion , respectively. The amounts and classification of the losses in the consolidated statements of income related to derivative instruments, not designated as hedging instruments, for the three and six months ended October 27, 2017 and October 28, 2016 were as follows: Three months ended Six months ended (in millions) Classification October 27, 2017 October 28, 2016 October 27, 2017 October 28, 2016 Currency exchange rate contract losses Other expense, net $ 42 $ 38 $ 137 $ 41 Cash Flow Hedges Currency Exchange Rate Risk Forward contracts designated as cash flow hedges are designed to hedge the variability of cash flows associated with forecasted transactions denominated in a foreign currency that will take place in the future. For derivative instruments that are designated and qualify as a cash flow hedge, the effective portion of the gain or loss on the derivative instrument is reported as a component of accumulated other comprehensive loss . The effective portion of the gain or loss on the derivative instrument is reclassified into earnings and is included in other expense, net in the consolidated statements of income in the same period or periods during which the hedged transaction affects earnings. No gains or losses relating to ineffectiveness of cash flow hedges were recognized in earnings during the three and six months ended October 27, 2017 and October 28, 2016 . No components of the hedge contracts were excluded in the measurement of hedge ineffectiveness and no hedges were derecognized or discontinued during the three and six months ended October 27, 2017 and October 28, 2016 . The gross notional amount of these contracts, designated as cash flow hedges, outstanding at October 27, 2017 and April 28, 2017 , was $6.2 billion and $5.8 billion , respectively, and will mature within the subsequent three -year period. The amount of gross gains (losses), classification of the gains (losses) in the consolidated statements of income, and the accumulated other comprehensive income (loss) (AOCI) related to the effective portion of currency exchange rate contract derivative instruments designated as cash flow hedges for the three and six months ended October 27, 2017 and October 28, 2016 were as follows: Three months ended October 27, 2017 Recognized in AOCI Recognized in Income (in millions) Amount Classification Amount Currency exchange rate contracts $ 30 Other expense, net $ (10 ) Total $ 30 $ (10 ) Three months ended October 28, 2016 Recognized in AOCI Recognized in Income (in millions) Amount Classification Amount Currency exchange rate contracts $ 69 Other expense, net $ 6 Total $ 69 $ 6 Six months ended October 27, 2017 Recognized in AOCI Recognized in Income (in millions) Amount Classification Amount Currency exchange rate contracts $ (220 ) Other expense, net $ 12 Total $ (220 ) $ 12 Six months ended October 28, 2016 Recognized in AOCI Recognized in Income (in millions) Amount Classification Amount Currency exchange rate contracts $ 190 Other expense, net $ 22 Total $ 190 $ 22 Forecasted Debt Issuance Interest Rate Risk Forward starting interest rate derivative instruments designated as cash flow hedges are designed to manage the exposure to interest rate volatility with regard to future issuances of fixed-rate debt. The effective portion of the gains or losses on forward starting interest rate derivative instruments that is designated and qualify as cash flow hedges is reported as a component of accumulated other comprehensive loss . Beginning in the period in which the planned debt issuance occurs and the related derivative instruments are terminated, the effective portion of the gains or losses are then reclassified into interest expense, net over the term of the related debt. Any portion of the gains or losses that is determined to be ineffective is immediately recognized in interest expense, net . The Company had $300 million of fixed pay, forward starting interest rate swaps with a weighted average fixed rate of 3.10 percent in anticipation of planned debt issuances. During the fourth quarter of fiscal year 2017 , in connection with the issuance of the 2017 Senior Notes, these swaps were terminated. For the three and six months ended October 28, 2016 , there were $17 million and $(6) million , respectively, of unrealized gains (losses) recorded in accumulated other comprehensive loss . No gains or losses relating to ineffectiveness of forward starting interest rate derivative instruments were recognized in interest expense, net during the three and six months ended October 28, 2016 . No components of the hedge contracts were excluded in the measurement of hedge ineffectiveness during the three and six months ended October 28, 2016 . For the three and six months ended October 28, 2016 , the reclassification of the effective portion of the net losses on forward starting interest rate derivative instruments from accumulated other comprehensive loss to interest expense, net was no t significant. At October 27, 2017 and April 28, 2017 , the Company had $(107) million and $37 million , respectively, in after-tax net unrealized (losses) gains associated with cash flow hedging instruments recorded in accumulated other comprehensive loss . The Company expects that $33 million of after-tax net unrealized losses at October 27, 2017 will be recognized in the consolidated statements of income over the next 12 months. Fair Value Hedges Interest rate derivative instruments designated as fair value hedges are designed to manage the exposure to interest rate movements and to reduce borrowing costs by converting fixed-rate debt into floating-rate debt. Under these agreements, the Company agrees to exchange, at specified intervals, the difference between fixed and floating interest amounts calculated by reference to an agreed-upon notional principal amount. Changes in the fair value of the derivative instruments are recognized in interest expense, net , and are offset by changes in the fair value of the underlying debt instrument. The gains (losses) from terminated interest rate swap agreements are recognized in long-term debt , increasing (decreasing) the outstanding balances of the debt, and amortized as a reduction of (addition to) interest expense, net over the remaining life of the related debt. The cash flows from the termination of interest rate swap agreements are reported as operating activities in the consolidated statements of cash flows. At both October 27, 2017 and April 28, 2017 , the Company had interest rate swaps in gross notional amounts of $1.2 billion , designated as fair value hedges of underlying fixed-rate senior note obligations, including the Company's $500 million 4.125 percent 2011 Senior Notes due 2021 and the $675 million 3.125 percent 2012 Senior Notes due 2022 . At October 27, 2017 and April 28, 2017 , the market value of outstanding interest rate swap agreements was an unrealized gain of $30 million and $41 million , respectively, and the market value of the hedged item was an unrealized loss of $30 million and $41 million , respectively. The amounts were recorded in other assets with the offsets recorded in long-term debt on the consolidated balance sheets. No significant hedge ineffectiveness was recognized as a result of these fair value hedges for the three and six months ended October 27, 2017 and October 28, 2016 . In addition, the Company did no t recognize any gains or losses during the three and six months ended October 27, 2017 and October 28, 2016 on firm commitments that no longer qualify as fair value hedges. Balance Sheet Presentation The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at October 27, 2017 and April 28, 2017 . The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments, and are further segregated by type of contract within those two categories. October 27, 2017 Derivative Assets Derivative Liabilities (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments Currency exchange rate contracts Prepaid expenses and other current assets $ 61 Other accrued expenses $ 113 Interest rate contracts Other assets 30 Other liabilities — Currency exchange rate contracts Other assets 41 Other liabilities 63 Total derivatives designated as hedging instruments $ 132 $ 176 Derivatives not designated as hedging instruments Currency exchange rate contracts Prepaid expenses and other current assets $ 35 Other accrued expenses $ 27 Total return swap Prepaid expenses and other current assets 8 Other accrued expenses — Stock warrants Other assets 25 Other liabilities — Cross currency interest rate contracts Other assets 6 Other liabilities 8 Total derivatives not designated as hedging instruments $ 74 $ 35 Total derivatives $ 206 $ 211 April 28, 2017 Asset Derivatives Liability Derivatives (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments Currency exchange rate contracts Prepaid expenses and other current assets $ 152 Other accrued expenses $ 43 Interest rate contracts Other assets 41 Other liabilities — Currency exchange rate contracts Other assets 48 Other liabilities 14 Total derivatives designated as hedging instruments $ 241 $ 57 Derivatives not designated as hedging instruments Currency exchange rate contracts Prepaid expenses and other current assets 16 Other accrued expenses 36 Cross currency interest rate contracts Other assets 5 Other liabilities 11 Total derivatives not designated as hedging instruments $ 21 $ 47 Total derivatives $ 262 $ 104 The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis. October 27, 2017 April 28, 2017 (in millions) Level 1 Level 2 Level 1 Level 2 Derivative assets $ 137 $ 69 $ 216 $ 46 Derivative liabilities 203 8 93 11 The Company has elected to present the fair value of derivative assets and liabilities within the consolidated balance sheets on a gross basis, even when derivative transactions are subject to master netting arrangements and may otherwise qualify for net presentation. The following table provides information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. October 27, 2017 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Collateral (Received) Posted Net Amount Derivative assets: Currency exchange rate contracts $ 137 $ (110 ) $ — $ 27 Interest rate contracts 30 (13 ) — 17 Cross currency interest rate contracts 6 (2 ) — 4 Stock warrants 25 — — 25 Total return swap 8 — — 8 $ 206 $ (125 ) $ — $ 81 Derivative liabilities: Currency exchange rate contracts $ (203 ) $ 123 $ — $ (80 ) Cross currency interest rate contracts (8 ) 2 — (6 ) (211 ) 125 — (86 ) Total $ (5 ) $ — $ — $ (5 ) April 28, 2017 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Collateral (Received) Posted Net Amount Derivative assets: Currency exchange rate contracts $ 216 $ (58 ) $ (55 ) $ 103 Interest rate contracts 41 (15 ) (5 ) 21 Cross currency interest rate contracts 5 (2 ) — 3 $ 262 $ (75 ) $ (60 ) $ 127 Derivative liabilities: Currency exchange rate contracts $ (93 ) $ 73 $ — $ (20 ) Cross currency interest rate contracts (11 ) 2 — (9 ) (104 ) 75 — (29 ) Total $ 158 $ — $ (60 ) $ 98

Inventories

Inventories	6 Months Ended
	Oct. 27, 2017
Inventory Disclosure [Abstract]
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value, with cost determined on a first-in, first-out basis. The Company reduces the carrying value of inventories for items that are potentially excess, obsolete or slow-moving based on changes in customer demand, technology developments or other economic factors. Inventory balances, net of reserves, were as follows: (in millions) October 27, 2017 April 28, 2017 Finished goods $ 2,368 $ 2,211 Work in-process 515 458 Raw materials 755 669 Total $ 3,638 $ 3,338

Goodwill and Other Intangible A

Goodwill and Other Intangible Assets	6 Months Ended
	Oct. 27, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Other Intangible Assets	Goodwill and Other Intangible Assets Goodwill The following table presents the changes in the carrying amount of goodwill by reportable segment: (in millions) Cardiac and Vascular Group Minimally Invasive Therapies Group Restorative Therapies Group Diabetes Group Total April 28, 2017 $ 6,651 $ 20,411 $ 9,600 $ 1,853 $ 38,515 Goodwill as a result of acquisitions — — 9 6 15 Purchase accounting adjustments 54 — — — 54 Currency and other adjustments, net 48 405 41 (1 ) 493 October 27, 2017 $ 6,753 $ 20,816 $ 9,650 $ 1,858 $ 39,077 The Company assesses goodwill for impairment annually in the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. Impairment testing for goodwill is performed at the reporting unit level. The test for impairment of goodwill requires the Company to make several estimates about fair value, most of which are based on projected future cash flows. The Company calculates the excess of each reporting unit's fair value over its carrying amount, including goodwill, utilizing a discounted cash flow analysis. The Company did no t recognize any goodwill impairment during the three or six months ended October 27, 2017 or October 28, 2016 . Intangible Assets The following table presents the gross carrying amount and accumulated amortization of intangible assets: October 27, 2017 April 28, 2017 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Definite-lived: Customer-related $ 16,964 $ (2,652 ) $ 16,862 $ (2,166 ) Purchased technology and patents 11,479 (4,038 ) 11,461 (3,690 ) Trademarks and tradenames 821 (544 ) 772 (461 ) Other 80 (46 ) 77 (42 ) Total $ 29,344 $ (7,280 ) $ 29,172 $ (6,359 ) Indefinite-lived: IPR&D $ 561 $ 594 The Company assesses definite-lived intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an intangible asset (asset group) may not be recoverable. When events or changes in circumstances indicate that the carrying amount of an intangible asset may not be recoverable, the Company calculates the excess of an intangible asset's carrying value over its undiscounted future cash flows. If the carrying value is not recoverable, an impairment loss is recognized based on the amount by which the carrying value exceeds the fair value. The inputs used in the fair value analysis fall within Level 3 of the fair value hierarchy due to the use of significant unobservable inputs to determine fair value. The Company did no t recognize any definite-lived intangible asset impairments during the three or six months ended October 27, 2017 or October 28, 2016 . The Company assesses indefinite-lived intangibles for impairment annually in the third quarter of the fiscal year and whenever an event occurs or circumstances change that would indicate that the carrying amount may be impaired. The Company did no t recognize any significant indefinite-lived intangibles impairments during the three or six months ended October 27, 2017 or October 28, 2016 . Due to the nature of IPR&D projects, the Company may experience future delays or failures to obtain regulatory approvals to conduct clinical trials, failures of such clinical trials, delays or failures to obtain required market clearances or other failures to achieve a commercially viable product, and as a result, may recognize impairment losses in the future. Amortization Expense Intangible asset amortization expense for the three and six months ended October 27, 2017 was $460 million and $914 million , respectively, as compared to $ 500 million and $987 million for the three and six months ended October 28, 2016 , respectively. Estimated aggregate amortization expense by fiscal year based on the carrying value of definite-lived intangible assets at October 27, 2017 , excluding any possible future amortization associated with acquired IPR&D which has not yet met technological feasibility, is as follows: (in millions) Amortization Expense Remaining 2018 $ 871 2019 1,672 2020 1,622 2021 1,601 2022 1,561 2023 1,490

Income Taxes

Income Taxes	6 Months Ended
	Oct. 27, 2017
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes The Company’s effective tax rate for the three and six months ended October 27, 2017 was (16.5) percent and (3.4) percent , respectively, as compared to 8.3 percent and 7.3 percent for the three and six months ended October 28, 2016 , respectively. The decrease in the effective tax rate for the three and six months ended October 27, 2017 was primarily due to the impacts from the divestiture of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses, the utilization of non-U.S. special deductions, and the tax effect from the intercompany sales of certain intellectual property. In August 2017, the Company received a tax ruling confirming the treatment of various intercompany transactions which have the effect of utilizing the $12.0 billion of non-U.S. special deductions previously disclosed in the Company’s Annual Report on Form 10-K for the fiscal year ended April 28, 2017 . The ruling allowed the Company to offset a portion of the gain on the sale of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses, as well as recognize a net income tax benefit associated with an intercompany sale of intellectual property and the associated elimination of a deferred tax liability. During the six months ended October 27, 2017 , the Company recognized a $344 million net benefit comprised of a $398 million net tax benefit associated with the intercompany sales of certain intellectual property and a $54 million net tax charge primarily associated with the sale of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses. Inclusive of the tax adjustments recorded during the fourth quarter of fiscal year 2017 and the six months ended October 27, 2017 , the tax adjustment related to the divestiture of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses was a net income tax charge of $175 million . These net benefits were recorded within income tax (benefit) provision in the consolidated statement of income for the six months ended October 27, 2017 . During the six months ended October 28, 2016 , the Company recognized a net tax benefit of $31 million . A $431 million tax benefit was recognized as the result of the resolution of Covidien's previously disclosed Tyco International plc intercompany debt issues with the U.S. Tax Court and the Appeals Division of the U.S. Internal Revenue Service (IRS). This benefit was partially offset by a $371 million charge associated with the expected resolution with the IRS for the Ardian, CoreValve, Inc. and Ablation Frontiers, Inc. acquisition-related issues and the allocation of income between Medtronic, Inc. and its wholly owned subsidiary operating in Puerto Rico for certain businesses. This resolution did not include the businesses that are the subject of the Medtronic, Inc. U.S. Tax Court case for fiscal years 2005 and 2006. In addition, the Company recognized a $29 million charge in connection with the redemption of an intercompany minority interest. These net benefits were recorded within income tax (benefit) provision in the consolidated statement of income for the six months ended October 28, 2016 . During the six months ended October 27, 2017 , the Company's gross unrecognized tax benefits decreased from $1.9 billion to $1.8 billion . In addition, accrued gross interest and penalties were $394 million at October 27, 2017 . If all of the Company’s unrecognized tax benefits were recognized, approximately $1.7 billion would impact the Company’s effective tax rate. At October 27, 2017 , the Company had $16 million of gross unrecognized tax benefits recorded as a current liability within accrued income taxes with the balance recorded as a noncurrent liability within accrued income taxes on the consolidated balance sheet. At April 28, 2017 , the total balance of the Company's gross unrecognized tax benefits was recorded as a noncurrent liability within accrued income taxes on the consolidated balance sheet. The Company recognizes interest and penalties related to income tax matters within income tax (benefit) provision in the consolidated statements of income and records the liability within either current or noncurrent accrued income taxes on the consolidated balance sheet. See Note 17 to the consolidated financial statements for additional information regarding the status of current tax audits and proceedings.

Earnings Per Share

Earnings Per Share	6 Months Ended
	Oct. 27, 2017
Earnings Per Share [Abstract]
Earnings Per Share	Earnings Per Share Earnings per share is calculated using the two-class method, as the Company's A Preferred Shares are considered participating securities. Accordingly, earnings are allocated to both ordinary shares and participating securities in determining earnings per ordinary share. Due to the limited number of A Preferred Shares outstanding, this allocation had no effect on ordinary earnings per share; therefore, it is not presented below. Basic earnings per share is computed based on the weighted average number of ordinary shares outstanding. Diluted earnings per share is computed based on the weighted average number of ordinary shares outstanding, increased by the number of additional shares that would have been outstanding had the potentially dilutive ordinary shares been issued, and reduced by the number of shares the Company could have repurchased with the proceeds from issuance of the potentially dilutive shares. Potentially dilutive ordinary shares include stock options and other stock-based awards granted under stock-based compensation plans and shares committed to be purchased under the employee stock purchase plan. The table below sets forth the computation of basic and diluted earnings per share: Three months ended Six months ended (in millions, except per share data) October 27, 2017 October 28, 2016 October 27, 2017 October 28, 2016 Numerator: Net income attributable to ordinary shareholders $ 2,017 $ 1,115 $ 3,033 $ 2,044 Denominator: Basic – weighted average shares outstanding 1,355.1 1,380.0 1,358.5 1,386.5 Effect of dilutive securities: Employee stock options 7.7 9.3 8.5 9.9 Employee restricted stock units 3.0 3.2 3.5 3.6 Other — — 0.3 0.2 Diluted – weighted average shares outstanding 1,365.8 1,392.5 1,370.8 1,400.2 Basic earnings per share $ 1.49 $ 0.81 $ 2.23 $ 1.47 Diluted earnings per share $ 1.48 $ 0.80 $ 2.21 $ 1.46 The calculation of weighted average diluted shares outstanding excludes options to purchase approximately 12 million and 8 million ordinary shares for the three and six months ended October 27, 2017 , respectively, and 5 million and 4 million ordinary shares for the three and six months ended October 28, 2016 , respectively, because their effect would be anti-dilutive on the Company’s earnings per share.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Oct. 27, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Stock-Based Compensation The following table presents the components and classification of stock-based compensation expense for stock options, restricted stock, and employee stock purchase plan shares recognized for the three and six months ended October 27, 2017 and October 28, 2016 : Three months ended Six months ended (in millions) October 27, 2017 October 28, 2016 October 27, 2017 October 28, 2016 Stock options $ 42 $ 53 $ 77 $ 91 Restricted stock 59 54 107 88 Employee stock purchase plan 5 4 14 11 Total stock-based compensation expense $ 106 $ 111 $ 198 $ 190 Cost of products sold $ 14 $ 15 $ 24 $ 26 Research and development expense 12 13 21 22 Selling, general, and administrative expense 79 73 134 124 Restructuring charges — 1 — 2 Acquisition-related items 1 9 3 16 Divestiture-related items — — 16 — Total stock-based compensation expense 106 111 198 190 Income tax benefits (32 ) (33 ) (57 ) (54 ) Total stock-based compensation expense, net of tax $ 74 $ 78 $ 141 $ 136

Retirement Benefit Plans

Retirement Benefit Plans	6 Months Ended
	Oct. 27, 2017
Retirement Benefits [Abstract]
Retirement Benefit Plans	Retirement Benefit Plans The Company sponsors various retirement benefit plans, including defined benefit pension plans (pension benefits), post-retirement medical plans, defined contribution savings plans, and termination indemnity plans, covering substantially all U.S. employees and many employees outside the U.S. The net periodic benefit cost of the defined benefit pension plans included the following components for the three and six months ended October 27, 2017 and October 28, 2016 : U.S. Pension Benefits Non-U.S. Pension Benefits Three months ended Three months ended (in millions) October 27, 2017 October 28, 2016 October 27, 2017 October 28, 2016 Service cost $ 29 $ 29 $ 17 $ 19 Interest cost 30 27 7 6 Expected return on plan assets (52 ) (47 ) (13 ) (12 ) Amortization of net actuarial loss 20 23 4 4 Net periodic benefit cost $ 27 $ 32 $ 15 $ 17 U.S. Pension Benefits Non-U.S. Pension Benefits Six months ended Six months ended (in millions) October 27, 2017 October 28, 2016 October 27, 2017 October 28, 2016 Service cost $ 58 $ 58 34 $ 38 Interest cost 60 54 14 12 Expected return on plan assets (104 ) (94 ) (26 ) (24 ) Amortization of net actuarial loss 40 46 8 8 Net periodic benefit cost $ 54 $ 64 $ 30 $ 34

Accumulated Other Comprehensive

Accumulated Other Comprehensive (Loss) Income and Supplemental Equity Disclosure	6 Months Ended
	Oct. 27, 2017
Equity [Abstract]
Accumulated Other Comprehensive (Loss) Income and Supplemental Equity Disclosure	Accumulated Other Comprehensive (Loss) Income and Supplemental Equity Disclosure The following table provides changes in AOCI, net of tax and by component. (in millions) Unrealized Gain (Loss) on Available-for-Sale Securities Cumulative Translation Adjustment Net Change in Retirement Obligations Unrealized Gain (Loss) on Derivative Financial Instruments Total Accumulated Other Comprehensive (Loss) Income April 28, 2017 $ (69 ) $ (1,452 ) $ (1,129 ) $ 37 $ (2,613 ) Other comprehensive income (loss) before reclassifications 63 662 (19 ) (140 ) 566 Reclassifications (8 ) (34 ) 33 (4 ) (13 ) Other comprehensive income (loss) 55 628 14 (144 ) 553 October 27, 2017 $ (14 ) $ (824 ) $ (1,115 ) $ (107 ) $ (2,060 ) (in millions) Unrealized Gain (Loss) on Available-for-Sale Securities Cumulative Translation Adjustment Net Change in Retirement Obligations Unrealized Gain (Loss) on Derivative Financial Instruments Total Accumulated Other Comprehensive (Loss) Income April 29, 2016 $ (107 ) $ (474 ) $ (1,197 ) $ (90 ) $ (1,868 ) Other comprehensive income (loss) before reclassifications 88 (686 ) — 118 (480 ) Reclassifications (13 ) — 44 (11 ) 20 Other comprehensive income (loss) 75 (686 ) 44 107 (460 ) October 28, 2016 $ (32 ) $ (1,160 ) $ (1,153 ) $ 17 $ (2,328 ) The income tax on gains and losses on available-for-sale securities in other comprehensive income before reclassifications during the six months ended October 27, 2017 and October 28, 2016 was an expense of $27 million and $44 million , respectively. During the six months ended October 27, 2017 and October 28, 2016 , realized gains and losses on available-for-sale securities reclassified from AOCI were reduced by income taxes of $4 million and $7 million , respectively. When realized, gains and losses on available-for-sale securities reclassified from AOCI are recognized within other expense, net . Refer to Note 7 to the consolidated financial statements for additional information. Taxes are not provided on cumulative translation adjustments as substantially all translation adjustments relate to earnings that are intended to be indefinitely reinvested outside the U.S. The net change in retirement obligations in other comprehensive income includes net amortization of prior service costs and actuarial losses included in net periodic benefit cost. The income tax on the net change in retirement obligations in other comprehensive income before reclassifications during the six months ended October 27, 2017 was a benefit of $4 million . During the six months ended October 28, 2016 , there was no income tax impact on the net change in retirement obligations in other comprehensive income before reclassifications. During the six months ended October 27, 2017 and October 28, 2016 , the gains and losses on defined benefit and pension items reclassified from AOCI were reduced by income taxes of $15 million and $10 million , respectively. Refer to Note 15 to the consolidated financial statements for additional information. The income tax on unrealized gains and losses on derivative financial instruments in other comprehensive income before reclassifications during the six months ended October 27, 2017 and October 28, 2016 was a benefit of $81 million and an expense of $66 million , respectively. During the six months ended October 27, 2017 and October 28, 2016 , gains and losses on derivative financial instruments reclassified from AOCI were reduced by income taxes of $4 million and $8 million , respectively. When realized, cash flow hedge gains and losses reclassified from AOCI are recognized within other expense, net, and forward starting interest rate derivative financial instrument gains and losses reclassified from AOCI are recognized within interest expense, net . Refer to Note 9 to the consolidated financial statements for additional information. The supplemental equity schedule below presents changes in the Company's total shareholders' equity and noncontrolling interests for the six months ended October 27, 2017 and October 28, 2016 . (in millions) Total Shareholders' Equity Noncontrolling Interests Total Equity April 28, 2017 $ 50,294 $ 122 $ 50,416 Net income (loss) 3,033 (11 ) 3,022 Other comprehensive income 553 — 553 Dividends to shareholders (1,247 ) — (1,247 ) Issuance of shares under stock purchase and award plans 177 — 177 Repurchase of ordinary shares (1,835 ) — (1,835 ) Stock-based compensation 198 — 198 Cumulative effect of change in accounting principle 296 — 296 Additions (reductions) of noncontrolling ownership interests — (2 ) (2 ) October 27, 2017 $ 51,469 $ 109 $ 51,578 (in millions) Total Shareholders' Equity Noncontrolling Interests Total Equity April 29, 2016 $ 52,063 $ — $ 52,063 Net income (loss) 2,044 (4 ) 2,040 Other comprehensive loss (460 ) — (460 ) Dividends to shareholders (1,192 ) — (1,192 ) Issuance of shares under stock purchase and award plans 260 — 260 Repurchase of ordinary shares (2,794 ) — (2,794 ) Tax benefit from exercise of stock-based awards 75 — 75 Stock-based compensation 190 — 190 Additions (reductions) of noncontrolling ownership interests — 111 111 October 28, 2016 $ 50,186 $ 107 $ 50,293

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Oct. 27, 2017
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Matters The Company and its affiliates are involved in a number of legal actions involving product liability, intellectual property disputes, shareholder related matters, environmental proceedings, income tax disputes, and governmental proceedings and investigations, including those described below. With respect to governmental proceedings and investigations, like other companies in our industry, the Company is subject to extensive regulation by national, state and local governmental agencies in the United States and in other jurisdictions in which the Company and its affiliates operate. As a result, interaction with governmental agencies is ongoing. The Company’s standard practice is to cooperate with regulators and investigators in responding to inquiries. The outcomes of these legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the enforcement agencies or private claimants seek damages, as well as other civil or criminal remedies (including injunctions barring the sale of products that are the subject of the proceeding), that could require significant expenditures, result in lost revenues, or limit the Company's ability to conduct business in the applicable jurisdictions. The Company records a liability in the consolidated financial statements on an undiscounted basis for loss contingencies related to legal actions when a loss is known or considered probable and the amount may be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is accrued. If a loss is reasonably possible but not known or probable, and may be reasonably estimated, the estimated loss or range of loss is disclosed. When determining the estimated loss or range of loss, significant judgment is required. Estimates of probable losses resulting from litigation and governmental proceedings involving the Company are inherently difficult to predict, particularly when the matters are in early procedural stages, with incomplete scientific facts or legal discovery, involve unsubstantiated or indeterminate claims for damages, potentially involve penalties, fines or punitive damages, or could result in a change in business practice. At October 27, 2017 and April 28, 2017 , accrued litigation was approximately $1.0 billion and $1.1 billion , respectively. The ultimate cost to the Company with respect to accrued litigation could be materially different than the amount of the current estimates and accruals and could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. The Company includes accrued litigation in other accrued expenses and other liabilities on the consolidated balance sheets. While it is not possible to predict the outcome for most of the legal matters discussed below, the Company believes it is possible that the costs associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. Product Liability Matters Sprint Fidelis In 2007, a putative class action was filed in the Ontario Superior Court of Justice in Canada seeking damages for personal injuries allegedly related to the Company's Sprint Fidelis family of defibrillation leads. On October 20, 2009, the court certified a class proceeding but denied class certification on plaintiffs' claim for punitive damages. Pretrial proceedings are underway. The Company has not recognized an expense related to damages in connection with this matter because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from this matter. INFUSE Litigation The Company estimated law firms representing approximately 6,000 claimants asserted or intended to assert personal injury claims against Medtronic in the U.S. state and federal courts involving the INFUSE bone graft product. As of June 1, 2017, the Company had reached agreements to settle substantially all of these claims, resolving this litigation. The Company's accrued expenses for this matter are included within accrued litigation as discussed above. Pelvic Mesh Litigation The Company, through the acquisition of Covidien, is currently involved in litigation in various state and federal courts against manufacturers of pelvic mesh products alleging personal injuries resulting from the implantation of those products. Two subsidiaries of Covidien supplied pelvic mesh products to one of the manufacturers, C.R. Bard (Bard), named in the litigation. The litigation includes a federal multi-district litigation in the U.S. District Court for the Northern District of West Virginia and cases in various state courts and jurisdictions outside the U.S. Generally, complaints allege design and manufacturing claims, failure to warn, breach of warranty, fraud, violations of state consumer protection laws and loss of consortium claims. In fiscal year 2016, Bard paid the Company $121 million towards the settlement of 11,000 of these claims. In May 2017, the agreement with Bard was amended to extend the terms to apply to up to an additional 5,000 claims. That agreement does not resolve the dispute between the Company and Bard with respect to claims that do not settle, if any. As part of the agreement, the Company and Bard agreed to dismiss without prejudice their pending litigation with respect to Bard’s obligation to defend and indemnify the Company. The Company estimates law firms representing approximately 15,800 claimants have asserted or may assert claims involving products manufactured by Covidien’s subsidiaries. As of December 1, 2017, the Company had reached agreements to settle approximately 13,400 of these claims. The Company's accrued expenses for this matter are included within accrued litigation as discussed above. Patent Litigation Ethicon On December 14, 2011, Ethicon filed an action against Covidien in the U.S. District Court for the Southern District of Ohio, alleging patent infringement and seeking monetary damages and injunctive relief. On January 22, 2014, the district court entered summary judgment in Covidien's favor, and the majority of this ruling was affirmed by the Federal Circuit on August 7, 2015. Following appeal, the case was remanded back to the District Court with respect to one patent. On January 21, 2016, Covidien filed a second action in the U.S. District Court for the Southern District of Ohio, seeking a declaration of non-infringement with respect to a second set of patents held by Ethicon. The court consolidated this second action with the remaining patent issues from the first action. Following consolidation of the cases, Ethicon dismissed 6 of the asserted patents, leaving a single asserted patent. In addition to claims of non-infringement, the Company asserts an affirmative defense of invalidity. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from this matter. Shareholder Related Matters INFUSE On March 12, 2012, Charlotte Kokocinski (Kokocinski) filed a shareholder derivative action against both Medtronic, Inc. and certain of its current and former officers and directors in the U.S. District Court for the District of Minnesota, setting forth certain allegations, including a claim that defendants violated various purported duties in connection with the INFUSE bone graft product and otherwise. On March 25, 2013, the District Court dismissed the case without prejudice, and Kokocinski subsequently filed an amended complaint. On March 30, 2015, the District Court granted defendants’ motion to dismiss the amended complaint, dismissing the case with prejudice. Kokocinski sought reconsideration of that decision, and, on September 30, 2015, the District Court denied Kokocinski’s request for reconsideration. Kokocinski appealed the District Court’s decision to the U.S. Court of Appeals for the Eighth Circuit. On March 1, 2017, the Eighth Circuit Court of Appeals affirmed the lower Court’s dismissal of the case with prejudice, and on April 11, 2017, the Eighth Circuit rejected Kokocinski’s request for reconsideration. In September 2017, Kokocinski filed a petition for certiorari requesting review of the Eighth Circuit decision by the United States Supreme Court. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters. West Virginia Pipe Trades and Phil Pace, on June 27, 2013 and July 3, 2013, respectively, filed putative class action complaints against Medtronic, Inc. and certain of its officers in the U.S. District Court for the District of Minnesota, alleging that the defendants made false and misleading public statements and engaged in a scheme to defraud regarding the INFUSE Bone Graft product during the period of December 8, 2010 through August 3, 2011. The matters were consolidated in September 2013, and in the consolidated complaint plaintiffs alleged a class period of September 28, 2010 through August 3, 2011. On September 30, 2015, the District Court granted defendants’ motion for summary judgment in the consolidated matters. Plaintiffs appealed the dismissal to the U.S. Court of Appeals for the Eighth Circuit, and in December of 2016 the Eighth Circuit Court reversed and remanded the case to the District Court for further proceedings. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters. COVIDIEN ACQUISITION On July 2, 2014, Lewis Merenstein filed a putative shareholder class action in Hennepin County, Minnesota, District Court seeking to enjoin the then-potential acquisition of Covidien. The lawsuit named Medtronic, Inc., Covidien, and each member of the Medtronic, Inc. Board of Directors at the time as defendants, and alleged that the directors breached their fiduciary duties to shareholders with regard to the then-potential acquisition. On August 21, 2014, Kenneth Steiner filed a putative shareholder class action in Hennepin County, Minnesota, District Court, also seeking an injunction to prevent the potential Covidien acquisition. In September 2014, the Merenstei n and Steiner matters were consolidated and in December 2014, the plaintiffs filed a preliminary injunction motion seeking to enjoin the Covidien transaction. On December 30, 2014, a hearing was held on plaintiffs’ motion for preliminary injunction and on defendants’ motion to dismiss. On January 2, 2015, the District Court denied the plaintiffs’ motion for preliminary injunction and on January 5, 2015 issued its opinion. On March 20, 2015, the District Court issued its order and opinion granting Medtronic’s motion to dismiss the case. In May of 2015, the plaintiffs filed an appeal, and, in January of 2016, the Minnesota State Court of Appeals affirmed in part, reversed in part, and remanded the case to the District Court for further proceedings. In February of 2016, the Company petitioned the Minnesota Supreme Court to review the decision of the Minnesota State Court of Appeals, and on April 19, 2016 the Minnesota Supreme Court granted the Company’s petition on the issue of whether most of the original claims are properly characterized as direct or derivative under Minnesota law. In August of 2017, the Minnesota Supreme Court affirmed the decision of the Minnesota State Court of Appeals, sending the matter back to the trial court for further proceedings. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from these matters. HEARTWARE On January 22, 2016, the St. Paul Teachers’ Retirement Fund Association filed a putative class action complaint (the “Complaint”) in the United States District Court for the Southern District of New York against HeartWare on behalf of all persons and entities who purchased or otherwise acquired shares of HeartWare from June 10, 2014 through January 11, 2016 (the “Class Period”). The Complaint was amended on June 29, 2016 and claims HeartWare and one of its executives violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 by making false and misleading statements about, among other things, HeartWare’s response to a June 2014 U.S. FDA warning letter, the development of the Miniaturized Ventricular Assist Device (MVAD) System and the proposed acquisition of Valtech Cardio Ltd. The Complaint seeks to recover damages on behalf of all purchasers or acquirers of HeartWare’s stock during the Class Period. In August of 2016 the Company acquired HeartWare. The Company's accrued expenses for this matter are included within accrued litigation as discussed above. Environmental Proceedings The Company, through the acquisition of Covidien, is involved in various stages of investigation and cleanup related to environmental remediation matters at a number of sites. These projects relate to a variety of activities, including removal of solvents, metals and other hazardous substances from soil and groundwater. The ultimate cost of site cleanup and timing of future cash flows is difficult to predict given uncertainties regarding the extent of the required cleanup, the interpretation of applicable laws and regulations, and alternative cleanup methods. The Company is a successor to a company which owned and operated a chemical manufacturing facility in Orrington, Maine from 1967 until 1982, and is responsible for the costs of completing an environmental site investigation as required by the Maine Department of Environmental Protection (MDEP). MDEP served a compliance order on Mallinckrodt LLC and U.S. Surgical Corporation, subsidiaries of Covidien, in December 2008, which included a directive to remove a significant volume of soils at the site. After a hearing on the compliance order before the Maine Board of Environmental Protection (Maine Board) to challenge the terms of the compliance order, the Maine Board modified the MDEP order and issued a final order requiring removal of two landfills, capping of the remaining three landfills, installation of a groundwater extraction system and long-term monitoring of the site and the three remaining landfills. The Company has proceeded with implementation of the investigation and remediation at the site in accordance with the MDEP order as modified by the Maine Board order. The Company has also been involved in a lawsuit filed in the U.S. District Court for the District of Maine by the Natural Resources Defense Council and the Maine People’s Alliance. Plaintiffs sought an injunction requiring Covidien to conduct extensive studies of mercury contamination of the Penobscot River and Bay and options for remediating such contamination, and to perform appropriate remedial activities, if necessary. On July 29, 2002, following a March 2002 trial, the District Court entered an opinion and order which held that conditions in the Penobscot River and Bay may pose an imminent and substantial endangerment and that Covidien was liable for the cost of performing a study of the river and bay. The District Court subsequently appointed an independent study panel to oversee the study and ordered Covidien to pay costs associated with the study. A report issued by the study panel contains recommendations for a variety of potential remedial options which could be implemented individually or in a variety of combinations, and included preliminary cost estimates for a variety of potential remedial options, which the report describes as “very rough estimates of cost,” ranging from $25 million to $235 million . The report indicates that these costs are subject to uncertainties, and that before any remedial option is implemented, further engineering studies and engineering design work are necessary to determine the feasibility of the proposed remedial options. In June of 2014, a trial was held to determine if remediation was necessary and feasible, and on September 2, 2015, the District Court issued an order concluding that further engineering study and engineering design work is appropriate to determine the nature and extent of remediation in the Penobscot River and Bay. In January of 2016, the Court appointed an engineering firm to conduct the next phase of the study. The study is targeted for completion in calendar year 2018. The Company's accrued expenses for environmental proceedings are included within accrued litigation as discussed above. Government Matters Medtronic has received subpoenas or document requests from the Attorneys General in Massachusetts, California, Oregon, Illinois, and Washington seeking information regarding sales, marketing, clinical, and other information relating to the INFUSE bone graft product. The Company's accrued expenses for these matters are included within accrued litigation as discussed above. On May 2, 2011, the U.S. Attorney’s Office for the District of Massachusetts issued a subpoena to ev3, a subsidiary of the Company, requesting production of documents relating to sales and marketing and other issues in connection with several neurovascular products. The matters under investigation relate to activities prior to Covidien's acquisition of ev3 in 2010. ev3 complied as required with the subpoena and cooperated with the investigation. The Company's accrued expenses for this matter are included within accrued litigation as discussed above. On September 2, 2014, the U.S. Department of Health and Human Services, Office of Inspector General and the U.S. Attorney’s Office for the Northern District of California, issued a subpoena requesting production of documents relating to sales and marketing practices associated with certain of ev3’s peripheral vascular products. The Company has not recognized an expense related to damages in connection with this matter, because any potential loss is not currently probable or reasonably estimable under U.S. GAAP. Additionally, the Company is unable to reasonably estimate the range of loss, if any, that may result from this matter. Income Taxes In March 2009, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2005 and 2006. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. On December 23, 2010, the IRS issued a statutory notice of deficiency with respect to the remaining issues. Medtronic, Inc. filed a petition with the U.S. Tax Court on March 21, 2011 objecting to the deficiency. During October and November 2012, Medtronic, Inc. reached resolution with the IRS on various matters, including the deductibility of a settlement payment. Medtronic, Inc. and the IRS agreed to hold one issue, the calculation of amounts eligible for the one-time repatriation holiday, because such specific issue was being addressed by other taxpayers in litigation with the IRS. The remaining unresolved issue for fiscal years 2005 and 2006 relates to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, which is one of the Company's key manufacturing sites. The U.S. Tax Court proceeding with respect to this issue began on February 3, 2015 and ended on March 12, 2015. On June 9, 2016, the U.S. Tax court issued its opinion with respect to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for fiscal years 2005 and 2006. The U.S. Tax Court generally rejected the IRS’s position, but also made certain modifications to the Medtronic, Inc. tax returns as filed. During November 2016, Medtronic and the IRS entered into a Stipulation of Settled Issues with the Tax Court which resolved the one-time repatriation holiday as an outstanding issue unless either party decided to appeal the Tax Court Opinion and a final decision is inconsistent with the U.S. Tax Court Opinion. The U.S. Tax Court entered their final decision on January 25, 2017. On April 21, 2017, the IRS filed their Notice of Appeal to the U.S. Court of Appeals for the 8th Circuit regarding the Tax Court Opinion. A hearing date for the Appeal has not been set. In October 2011, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2007 and 2008. Medtronic, Inc. reached agreement with the IRS on some, but not all matters related to these fiscal years. During the first quarter of fiscal year 2016, the Company finalized its agreement with the IRS on the proposed adjustments associated with the tax effects of the Company's acquisition of Kyphon Inc. (Kyphon). The settlement was consistent with the certain tax adjustment recorded during the fourth quarter of fiscal year 2015. During the first quarter of fiscal year 2017, an expected settlement was reached with the IRS for all outstanding issues for fiscal years 2007 and 2008 except for the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006. In April 2014, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2009, 2010, and 2011. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. During the first quarter of fiscal year 2017, an expected settlement was reached with the IRS for all outstanding issues for fiscal years 2009, 2010, and 2011 except for the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico for the businesses that are the subject of the U.S. Tax Court Case for fiscal years 2005 and 2006. In May 2017, the IRS issued its audit report on Medtronic, Inc. for fiscal years 2012, 2013, and 2014. Medtronic, Inc. reached agreement with the IRS on some but not all matters related to these fiscal years. The significant issues that remain unresolved relate to the allocation of income between Medtronic, Inc. and its wholly-owned subsidiary operating in Puerto Rico, and proposed adjustments associated with the utilization of certain net operating losses. The Company disagrees with the IRS and will attempt to resolve these matters at the IRS Appellate level. Medtronic, Inc.’s fiscal years 2015 and 2016 U.S. federal income tax returns are currently being audited by the IRS. Covidien and the IRS have concluded and reached agreement on its audit of Covidien’s U.S. federal income tax returns for all tax years through 2009. The IRS continues to audit Covidien’s U.S. federal income tax returns for the years 2010 through 2012. The statute of limitations for Covidien’s 2013 U.S. federal income tax returns lapsed during the first quarter of fiscal year 2018. While it is not possible to predict the outcome for most of the income tax matters discussed above, the Company believes it is possible that charges associated with these matters could have a material adverse impact on the Company’s consolidated earnings, financial position, and/or cash flows. See Note 12 for additional discussion of income taxes. Guarantees As a result of the acquisition of Covidien, the Company has guarantee commitments and indemnifications with Tyco International, TE Connectivity Ltd. (TE Connectivity), and Mallinckrodt plc (Mallinckrodt) which relate to certain contingent tax liabilities. On June 29, 2007, Covidien entered into the Tax Sharing Agreement, under which Covidien shares responsibility for certain of its, Tyco International’s and TE Connectivity’s income tax liabilities for periods prior to Covidien’s 2007 separation from Tyco International (2007 separation). Covidien, Tyco International and TE Connectivity share 42 percent , 27 percent , and 31 percent , respectively, of U.S. income tax liabilities that arise from adjustments made by tax authorities to Covidien's, Tyco International’s and TE Connectivity’s U.S. income tax returns, certain income tax liabilities arising from adjustments made by tax authorities to intercompany transactions or similar adjustments, and certain taxes attributable to internal transactions undertaken in anticipation of the 2007 separation. If Tyco International and TE Connectivity default on their obligations to the Company under the Tax Sharing Agreement, the Company would be liable for the entire amount of these liabilities. All costs and expenses associated with the management of these tax liabilities are being shared equally among the parties. In connection with the 2007 separation, all tax liabilities associated with Covidien business became Covidien’s tax liabilities. Following Covidien’s spin-off of its Pharmaceuticals business to Covidien shareholders through a distribution of all the outstanding ordinary shares of Mallinkrodt (2013 separation), Mallinckrodt became the primary obligor to the taxing authorities for the tax liabilities attributable to its subsidiaries, a significant portion of which relate to periods prior to the 2007 separation. However, Covidien remains the sole party subject to the Tax Sharing Agreement. Accordingly, Mallinckrodt does not share in the Company’s liability to Tyco International and TE Connectivity, nor in the receivable that the Company has from Tyco International and TE Connectivity. If any party to the Tax Sharing Agreement were to default in its obligation to another party to pay its share of the distribution taxes that arise as a result of no party’s fault, each non-defaulting party would be required to pay, equally with any other non-defaulting party, the amounts in default. In addition, if another party to the Tax Sharing Agreement that is responsible for all or a portion of an income tax liability were to default in its payment of such liability to a taxing authority, the Company could be legally liable under applicable tax law for such liabilities and be required to make additional tax payments. Accordingly, under certain circumstances, the Company may be obligated to pay amounts in excess of the Company’s agreed upon share of Covidien's, Tyco International’s and TE Connectivity’s tax liabilities. The Company has used available information to develop its best estimates for certain assets and liabilities related to periods prior to the 2007 separation, including amounts subject to or impacted by the provisions of the Tax Sharing Agreement. The actual amounts that the Company may be required to ultimately accrue or pay under the Tax Sharing Agreement, however, could vary depending upon the outcome of the unresolved tax matters. Final determination of the balances will be made in subsequent periods, primarily related to certain pre-2007 separation tax liabilities and tax years open for examination. These balances will also be impacted by the filing of final or amended income tax returns in certain jurisdictions where those returns include a combination of Tyco International, Covidien and/or TE Connectivity legal entities for periods prior to the 2007 separation. The resolutions with the U.S. Tax Court and IRS Appeals for fiscal years 1997 through 2007 were finalized during May 2016. However, the Tax Sharing Agreement remains in place with respect to income tax liabilities that are not the subject of such resolution. In conjunction with the 2013 separation, Mallinckrodt assumed the tax liabilities that are attributable to its subsidiaries, and Covidien indemnified Mallinckrodt to the extent that such tax liabilities arising from periods prior to 2013 exceed $200 million , net of certain tax benefits realized. In addition, in connection with the 2013 separation, Covidien entered into certain other guarantee commitments and indemnifications with Mallinckrodt. See Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 28, 2017 for additional information. As part of the Company’s Minimally Invasive Therapies Group sale of the Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency businesses to Cardinal on July 29, 2017, the Company has indemnified Cardinal for certain contingent tax liabilities related to the divested businesses that existed prior to the date of divestiture. The actual amounts that the Company may be required to ultimately accrue or pay could vary depending upon the outcome of the unresolved tax matters. Final determination of the balances will be made in subsequent periods, the majority of which the Company expects to be resolved within fiscal year 2018. In the normal course of business, the Company and/or its affiliates periodically enter into agreements that require one or more of them to indemnify customers or suppliers for specific risks, such as claims for injury or property damage arising out of the Company or its affiliates’ products or the negligence of any of their personnel or claims alleging that any of their products infringe third-party patents or other intellectual property. The Company also offers warranties on various products. The Company’s maximum exposure under these guarantees is unable to be estimated. Historically, the Company has not experienced significant losses on these types of guarantees. The Company believes the ultimate resolution of the above guarantees is not expected to have a material effect on the Company’s consolidated earnings, financial position, or cash flows.

Segment and Geographic Informat

Segment and Geographic Information	6 Months Ended
	Oct. 27, 2017
Segment Reporting [Abstract]
Segment and Geographic Information	Segment and Geographic Information Segment Information The Company’s management evaluates segment performance and allocates resources based on net sales and earnings before interest expense, net, income tax (benefit) provision, and amortization of intangible assets, not including centralized distribution costs and corporate charges, as presented in the table below. The accounting policies of the reportable segments are the same as those described in the summary of significant accounting policies in Note 1 to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the fiscal year ended April 28, 2017 . The financial information that is regularly reviewed by the Company's chief operating decision maker to assess performance and allocate resources changed during fiscal year 2017. As a result, the Company has revised the disclosure for the prior period to align with current presentation. Net sales of the Company’s reportable segments include end-customer revenues from the sale of products each reportable segment develops and manufactures or distributes. Segment disclosures are on a performance basis consistent with internal management reporting. Certain items are at corporate and centralized and are not allocated to the segments. Net sales and earnings before interest expense, net, income tax (benefit) provision, and amortization of intangible assets, not including centralized distribution costs and corporate charges by reportable segments are as follows: Three months ended Six months ended (in millions) October 27, 2017 October 28, 2016 October 27, 2017 October 28, 2016 Cardiac and Vascular Group $ 2,773 $ 2,584 $ 5,419 $ 5,102 Minimally Invasive Therapies Group 1,952 2,473 4,438 4,897 Restorative Therapies Group 1,863 1,826 3,672 3,598 Diabetes Group 462 462 911 914 Net Sales $ 7,050 $ 7,345 $ 14,440 $ 14,511 Three months ended Six months ended (in millions) October 27, 2017 October 28, 2016 October 27, 2017 October 28, 2016 Cardiac and Vascular Group $ 1,104 $ 1,017 $ 2,115 $ 1,971 Minimally Invasive Therapies Group 761 886 1,636 1,710 Restorative Therapies Group 750 700 1,430 1,370 Diabetes Group 91 158 202 317 Reportable segments' EBITA before other adjustments 2,706 2,761 5,383 5,368 Amortization of intangible assets (460 ) (500 ) (914 ) (987 ) Restructuring charges, net (18 ) (47 ) (32 ) (151 ) Acquisition-related items (18 ) (28 ) (71 ) (80 ) Certain litigation charges — — — (82 ) Divestiture-related items (67 ) — (115 ) — Gain on sale of businesses 697 — 697 — Special charge (80 ) — (80 ) — Hurricane Maria (34 ) — (34 ) — Impact of inventory step-up — (38 ) — (38 ) Centralized distribution costs (486 ) (446 ) (928 ) (847 ) Interest expense, net (173 ) (173 ) (367 ) (352 ) Corporate (339 ) (317 ) (616 ) (631 ) Income before income taxes $ 1,728 $ 1,212 $ 2,923 $ 2,200 Geographic Information Net sales to external customers by geography are as follows: Three months ended Six months ended (in millions) October 27, 2017 October 28, 2016 October 27, 2017 October 28, 2016 Americas (1) $ 4,090 $ 4,471 $ 8,457 $ 8,768 EMEA (2) 1,692 1,592 3,424 3,243 Asia-Pacific 434 890 1,691 1,712 Greater China 834 392 868 788 Net Sales $ 7,050 $ 7,345 $ 14,440 $ 14,511 (1) The U.S., which is included in the Americas, had net sales to external customers of $3.7 billion and $7.8 billion for the three and six months ended October 27, 2017 , respectively, compared to $4.2 billion and $8.2 billion for the three and six months ended October 28, 2016 , respectively. (2) EMEA consists of Europe, Middle East, and Africa. Sales to Ireland were insignificant during all periods presented.

Guarantor Financial Information

Guarantor Financial Information	6 Months Ended
	Oct. 27, 2017
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Guarantor Financial Information	Guarantor Financial Information Medtronic plc and Medtronic Global Holdings S.C.A. (Medtronic Luxco), a wholly-owned subsidiary guarantor, each have provided full and unconditional guarantees of the obligations of Medtronic, Inc., a wholly-owned subsidiary issuer, under the Senior Notes (Medtronic Senior Notes) and full and unconditional guarantees of the obligations of Covidien International Finance S.A. (CIFSA), a wholly-owned subsidiary issuer, under the Senior Notes (CIFSA Senior Notes). The guarantees of the CIFSA Senior Notes are in addition to the guarantees of the CIFSA Senior Notes by Covidien Ltd. and Covidien Group Holdings Ltd., both of which are wholly-owned subsidiary guarantors of the CIFSA Senior Notes. Effective March 28, 2017, Medtronic plc and Medtronic, Inc. each provided a full and unconditional guarantee of the obligations of Medtronic Luxco under the Medtronic Luxco Senior Notes. The following is a summary of these guarantees: Guarantees of Medtronic Senior Notes • Parent Company Guarantor - Medtronic plc • Subsidiary Issuer - Medtronic, Inc. • Subsidiary Guarantor - Medtronic Luxco Guarantees of Medtronic Luxco Senior Notes • Parent Company Guarantor - Medtronic plc • Subsidiary Issuer - Medtronic Luxco • Subsidiary Guarantor - Medtronic, Inc. Guarantees of CIFSA Senior Notes • Parent Company Guarantor - Medtronic plc • Subsidiary Issuer - CIFSA • Subsidiary Guarantors - Medtronic Luxco, Covidien Ltd., and Covidien Group Holdings Ltd. (CIFSA Subsidiary Guarantors) The following presents the Company’s consolidating statements of comprehensive income for the three and six months ended October 27, 2017 and October 28, 2016 , condensed consolidating balance sheets at October 27, 2017 and April 28, 2017 , and condensed consolidating statements of cash flows for the six months ended October 27, 2017 and October 28, 2016 . The guarantees provided by the parent company guarantor and subsidiary guarantors are joint and several. Condensed consolidating financial information for Medtronic plc, Medtronic Luxco, Medtronic, Inc., CIFSA, and CIFSA Subsidiary Guarantors, on a stand-alone basis, is presented using the equity method of accounting for subsidiaries. During the second quarter of fiscal year 2018, the Company undertook certain steps to reorganize ownership of various subsidiaries. The transactions were entirely among subsidiaries under the common control of Medtronic. This reorganization has been reflected as of the beginning of the earliest period presented. Consolidating Statement of Comprehensive Income Three Months Ended October 27, 2017 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 300 $ — $ 7,050 $ (300 ) $ 7,050 Costs and expenses: Cost of products sold — 228 — 2,204 (312 ) 2,120 Research and development expense — 169 — 386 — 555 Selling, general, and administrative expense 3 375 — 2,060 — 2,438 Amortization of intangible assets — 2 — 458 — 460 Restructuring charges, net — — — 8 — 8 Acquisition-related items — 14 — (7 ) — 7 Divestiture-related items — 6 — 61 — 67 Gain on sale of businesses — — — (697 ) — (697 ) Special charge — 80 — — — 80 Other (income) expense, net 12 (392 ) — 491 — 111 Operating profit (loss) (15 ) (182 ) — 2,086 12 1,901 Interest income — (64 ) (103 ) (348 ) 415 (100 ) Interest expense 60 425 48 155 (415 ) 273 Interest expense, net 60 361 (55 ) (193 ) — 173 Equity in net (income) loss of subsidiaries (2,091 ) (1,809 ) (2,036 ) — 5,936 — Income before income taxes 2,016 1,266 2,091 2,279 (5,924 ) 1,728 Income tax (benefit) provision (1 ) (158 ) — (126 ) — (285 ) Net income 2,017 1,424 2,091 2,405 (5,924 ) 2,013 Net loss attributable to noncontrolling interests — — — 4 — 4 Net income attributable to Medtronic 2,017 1,424 2,091 2,409 (5,924 ) 2,017 Other comprehensive income (loss), net of tax (136 ) (308 ) (136 ) (150 ) 594 (136 ) Other comprehensive loss attributable to noncontrolling interests — — — 4 — 4 Total comprehensive income $ 1,881 $ 1,116 $ 1,955 $ 2,259 $ (5,330 ) $ 1,881 Consolidating Statement of Comprehensive Income Six Months Ended October 27, 2017 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 604 $ — $ 14,439 $ (603 ) $ 14,440 Costs and expenses: Cost of products sold — 450 — 4,638 (619 ) 4,469 Research and development expense — 327 — 776 — 1,103 Selling, general, and administrative expense 5 675 — 4,243 — 4,923 Amortization of intangible assets — 4 — 910 — 914 Restructuring charges, net — 2 — 14 — 16 Acquisition-related items — 44 — 7 — 51 Divestiture-related items — 15 — 99 — 114 Gain on sale of businesses — — — (697 ) — (697 ) Special charge — 80 — — — 80 Other (income) expense, net 25 (870 ) — 1,022 — 177 Operating profit (loss) (30 ) (123 ) — 3,427 16 3,290 Interest income — (135 ) (212 ) (679 ) 834 (192 ) Interest expense 109 865 82 337 (834 ) 559 Interest expense, net 109 730 (130 ) (342 ) — 367 Equity in net (income) loss of subsidiaries (3,169 ) (2,623 ) (3,039 ) — 8,831 — Income before income taxes 3,030 1,770 3,169 3,769 (8,815 ) 2,923 Income tax (benefit) provision (3 ) (236 ) — 140 — (99 ) Net income 3,033 2,006 3,169 3,629 (8,815 ) 3,022 Net loss attributable to noncontrolling interests — — — 11 — 11 Net income attributable to Medtronic 3,033 2,006 3,169 3,640 (8,815 ) 3,033 Other comprehensive income (loss), net of tax 553 (317 ) 553 530 (766 ) 553 Other comprehensive loss attributable to noncontrolling interests — — — 11 — 11 Total comprehensive income $ 3,586 $ 1,689 $ 3,722 $ 4,170 $ (9,581 ) $ 3,586 Consolidating Statement of Comprehensive Income Three Months Ended October 28, 2016 Medtronic Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 337 $ — $ 7,344 $ (336 ) $ 7,345 Costs and expenses: Cost of products sold — 243 — 2,412 (329 ) 2,326 Research and development expense — 158 — 396 — 554 Selling, general, and administrative expense 3 284 — 2,129 — 2,416 Amortization of intangible assets — 3 — 497 — 500 Restructuring charges, net — 1 — 46 — 47 Acquisition-related items — 37 — (9 ) — 28 Other (income) expense, net (86 ) (597 ) — 772 — 89 Operating profit (loss) 83 208 — 1,101 (7 ) 1,385 Interest income — (59 ) (165 ) (286 ) 419 (91 ) Interest expense 25 396 11 251 (419 ) 264 Interest expense, net 25 337 (154 ) (35 ) — 173 Equity in net (income) loss of subsidiaries (1,055 ) (859 ) (901 ) — 2,815 — Income before income taxes 1,113 730 1,055 1,136 (2,822 ) 1,212 Income tax (benefit) provision (2 ) 28 — 75 — 101 Net income 1,115 702 1,055 1,061 (2,822 ) 1,111 Net loss attributable to noncontrolling interests — — — 4 — 4 Net income attributable to Medtronic 1,115 702 1,055 1,065 (2,822 ) 1,115 Other comprehensive income (loss), net of tax (304 ) 47 (304 ) (329 ) 586 (304 ) Other comprehensive loss attributable to noncontrolling interests — — — 4 — 4 Total comprehensive income $ 811 $ 749 $ 751 $ 736 $ (2,236 ) $ 811 Consolidating Statement of Comprehensive Income Six Months Ended October 28, 2016 Medtronic Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 685 $ — $ 14,510 $ (684 ) $ 14,511 Costs and expenses: Cost of products sold — 492 — 4,779 (684 ) 4,587 Research and development expense — 321 — 789 — 1,110 Selling, general, and administrative expense 6 564 — 4,274 — 4,844 Amortization of intangible assets — 6 — 981 — 987 Restructuring charges, net — 18 — 123 — 141 Certain litigation charges — — — 82 — 82 Acquisition-related items — 60 — 20 — 80 Other (income) expense, net (74 ) (1,306 ) — 1,508 — 128 Operating profit (loss) 68 530 — 1,954 — 2,552 Interest income — (121 ) (321 ) (424 ) 682 (184 ) Interest expense 41 806 12 359 (682 ) 536 Interest expense, net 41 685 (309 ) (65 ) — 352 Equity in net (income) loss of subsidiaries (2,013 ) (2,095 ) (1,704 ) — 5,812 — Income before income taxes 2,040 1,940 2,013 2,019 (5,812 ) 2,200 Income tax (benefit) provision (4 ) 50 — 114 — 160 Net income 2,044 1,890 2,013 1,905 (5,812 ) 2,040 Net loss attributable to noncontrolling interests — — — 4 — 4 Net income attributable to Medtronic 2,044 1,890 2,013 1,909 (5,812 ) 2,044 Other comprehensive income (loss), net of tax (460 ) 142 (460 ) (500 ) 818 (460 ) Other comprehensive loss attributable to noncontrolling interests — — — 4 — 4 Total comprehensive income $ 1,584 $ 2,032 $ 1,553 $ 1,409 $ (4,994 ) $ 1,584 Condensed Consolidating Balance Sheet October 27, 2017 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ 47 $ 822 $ 4,660 $ — $ 5,529 Investments — — — 7,997 — 7,997 Accounts receivable, net — — — 5,752 — 5,752 Inventories, net — 175 — 3,625 (162 ) 3,638 Intercompany receivable 55 — — 13,784 (13,839 ) — Other current assets 10 195 1 2,040 — 2,246 Total current assets 65 417 823 37,858 (14,001 ) 25,162 Property, plant, and equipment, net — 1,333 — 3,108 — 4,441 Goodwill — — — 39,077 — 39,077 Other intangible assets, net — 15 — 22,610 — 22,625 Tax assets — 792 — 957 — 1,749 Investment in subsidiaries 59,762 74,787 60,612 — (195,161 ) — Intercompany loans receivable 3,112 9,958 17,731 40,469 (71,270 ) — Other assets — 439 — 965 — 1,404 Total assets $ 62,939 $ 87,741 $ 79,166 $ 145,044 $ (280,432 ) $ 94,458 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ 2,000 $ 699 $ 432 $ — $ 3,131 Accounts payable — 317 — 1,401 — 1,718 Intercompany payable 11 13,828 — — (13,839 ) — Accrued compensation 6 604 — 892 — 1,502 Accrued income taxes 14 — — 858 — 872 Other accrued expenses 88 472 4 2,709 — 3,273 Total current liabilities 119 17,221 703 6,292 (13,839 ) 10,496 Long-term debt — 21,785 1,842 2,314 — 25,941 Accrued compensation and retirement benefits — 966 — 509 — 1,475 Accrued income taxes 10 1,620 — 564 — 2,194 Intercompany loans payable 11,316 14,835 23,868 21,251 (71,270 ) — Deferred tax liabilities — — — 1,841 — 1,841 Other liabilities 25 63 — 845 — 933 Total liabilities 11,470 56,490 26,413 33,616 (85,109 ) 42,880 Shareholders’ equity 51,469 31,251 52,753 111,319 (195,323 ) 51,469 Noncontrolling interests — — — 109 — 109 Total equity 51,469 31,251 52,753 111,428 (195,323 ) 51,578 Total liabilities and equity $ 62,939 $ 87,741 $ 79,166 $ 145,044 $ (280,432 ) $ 94,458 Condensed Consolidating Balance Sheet April 28, 2017 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 45 $ 5 $ 4,917 $ — $ 4,967 Investments — — — 8,741 — 8,741 Accounts receivable, net — — — 5,591 — 5,591 Inventories, net — 155 — 3,361 (178 ) 3,338 Intercompany receivable 63 — — 12,618 (12,681 ) — Other current assets 10 227 — 1,628 — 1,865 Current assets held for sale — — — 371 — 371 Total current assets 73 427 5 37,227 (12,859 ) 24,873 Property, plant, and equipment, net — 1,311 — 3,050 — 4,361 Goodwill — — — 38,515 — 38,515 Other intangible assets, net — 20 — 23,387 — 23,407 Tax assets — 727 — 782 — 1,509 Investment in subsidiaries 55,833 71,909 52,618 — (180,360 ) — Intercompany loans receivable 3,000 12,162 16,114 32,774 (64,050 ) — Other assets — 434 — 798 — 1,232 Noncurrent assets held for sale — — — 5,919 — 5,919 Total assets $ 58,906 $ 86,990 $ 68,737 $ 142,452 $ (257,269 ) $ 99,816 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ 5,000 $ 901 $ 1,619 $ — $ 7,520 Accounts payable — 304 — 1,427 — 1,731 Intercompany payable 12 12,669 — — (12,681 ) — Accrued compensation 9 734 — 1,117 — 1,860 Accrued income taxes 13 — — 620 — 633 Other accrued expenses — 352 4 2,086 — 2,442 Current liabilities held for sale — — — 34 — 34 Total current liabilities 34 19,059 905 6,903 (12,681 ) 14,220 Long-term debt — 21,782 1,842 2,297 — 25,921 Accrued compensation and retirement benefits — 1,120 — 521 — 1,641 Accrued income taxes 10 1,658 — 737 — 2,405 Intercompany loans payable 8,568 13,151 17,160 25,171 (64,050 ) — Deferred tax liabilities — — — 2,978 — 2,978 Other liabilities — 153 — 1,362 — 1,515 Noncurrent liabilities held for sale — — — 720 — 720 Total liabilities 8,612 56,923 19,907 40,689 (76,731 ) 49,400 Shareholders' equity 50,294 30,067 48,830 101,641 (180,538 ) 50,294 Noncontrolling interests — — — 122 — 122 Total equity 50,294 30,067 48,830 101,763 (180,538 ) 50,416 Total liabilities and equity $ 58,906 $ 86,990 $ 68,737 $ 142,452 $ (257,269 ) $ 99,816 Condensed Consolidating Statement of Cash Flows Six Months Ended October 27, 2017 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Operating Activities: Net cash provided by (used in) operating activities $ 269 $ (743 ) $ 128 $ 1,990 $ — $ 1,644 Investing Activities: Acquisitions, net of cash acquired — — — (76 ) — (76 ) Proceeds from sale of businesses — — — 6,058 — 6,058 Additions to property, plant, and equipment — (132 ) — (392 ) — (524 ) Purchases of investments — — — (1,685 ) — (1,685 ) Sales and maturities of investments — — — 2,354 — 2,354 Net (increase) decrease in intercompany loans (112 ) 2,204 (1,617 ) (7,695 ) 7,220 — Capital contribution paid — (12 ) (4,200 ) — 4,212 — Other investing activities, net — — — (2 ) — (2 ) Net cash provided by (used in) investing activities (112 ) 2,060 (5,817 ) (1,438 ) 11,432 6,125 Financing Activities: Acquisition-related contingent consideration — — — (39 ) — (39 ) Change in current debt obligations, net — — (202 ) 12 — (190 ) Issuance of long-term debt — — — 20 — 20 Payments on long-term debt — (3,000 ) — (1,161 ) — (4,161 ) Dividends to shareholders (1,247 ) — — — — (1,247 ) Issuance of ordinary shares 230 — — — — 230 Repurchase of ordinary shares (1,888 ) — — — — (1,888 ) Net intercompany loan borrowings (repayments) 2,748 1,685 6,708 (3,921 ) (7,220 ) — Capital contribution received — — — 4,212 (4,212 ) — Other financing activities — — — (2 ) — (2 ) Net cash provided by (used in) financing activities (157 ) (1,315 ) 6,506 (879 ) (11,432 ) (7,277 ) Effect of exchange rate changes on cash and cash equivalents — — — 70 — 70 Net change in cash and cash equivalents — 2 817 (257 ) — 562 Cash and cash equivalents at beginning of period — 45 5 4,917 — 4,967 Cash and cash equivalents at end of period $ — $ 47 $ 822 $ 4,660 $ — $ 5,529 Condensed Consolidating Statement of Cash Flows Six Months Ended October 28, 2016 Medtronic Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ 644 $ 513 $ 163 $ 1,702 $ — $ 3,022 Investing Activities: Acquisitions, net of cash acquired — (918 ) — (388 ) — (1,306 ) Additions to property, plant, and equipment — (161 ) — (437 ) — (598 ) Purchases of investments — — — (2,272 ) 162 (2,110 ) Sales and maturities of investments — 210 — 3,577 (162 ) 3,625 Net (increase) decrease in intercompany loans — 496 (2,117 ) (1,855 ) 3,476 — Capital contribution paid — (233 ) — — 233 — Other investing activities, net — — — 32 — 32 Net cash provided by (used in) investing activities — (606 ) (2,117 ) (1,343 ) 3,709 (357 ) Financing Activities: Acquisition-related contingent consideration — — — (36 ) — (36 ) Change in current debt obligations, net — — 1,130 24 — 1,154 Proceeds from current debt obligations (maturities greater than 90 days) — — 4 — — 4 Issuance of long-term debt — — — 131 — 131 Payments on long-term debt — — — (252 ) — (252 ) Dividends to shareholders (1,192 ) — — — — (1,192 ) Issuance of ordinary shares 260 — — — — 260 Repurchase of ordinary shares (2,794 ) — — — — (2,794 ) Net intercompany loan borrowings (repayments) 3,082 109 928 (643 ) (3,476 ) — Capital contribution received — — — 233 (233 ) — Other financing activities — — — 74 — 74 Net cash provided by (used in) financing activities (644 ) 109 2,062 (469 ) (3,709 ) (2,651 ) Effect of exchange rate changes on cash and cash equivalents — — — 64 — 64 Net change in cash and cash equivalents — 16 108 (46 ) — 78 Cash and cash equivalents at beginning of period — 55 — 2,821 — 2,876 Cash and cash equivalents at end of period $ — $ 71 $ 108 $ 2,775 $ — $ 2,954 Consolidating Statement of Comprehensive Income Three Months Ended October 27, 2017 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ — $ — $ 7,050 $ — $ 7,050 Costs and expenses: Cost of products sold — — — 2,120 — 2,120 Research and development expense — — — 555 — 555 Selling, general, and administrative expense 3 — — 2,435 — 2,438 Amortization of intangible assets — — — 460 — 460 Restructuring charges, net — — — 8 — 8 Acquisition-related items — — — 7 — 7 Divestiture-related items — — — 67 — 67 Gain on sale of businesses — — — (697 ) — (697 ) Special charge — — — 80 — 80 Other (income) expense, net 12 — — 99 — 111 Operating profit (loss) (15 ) — — 1,916 — 1,901 Interest income — (16 ) (107 ) (128 ) 151 (100 ) Interest expense 60 21 48 295 (151 ) 273 Interest expense, net 60 5 (59 ) 167 — 173 Equity in net (income) loss of subsidiaries (2,091 ) (811 ) (2,032 ) — 4,934 — Income before income taxes 2,016 806 2,091 1,749 (4,934 ) 1,728 Income tax (benefit) provision (1 ) — — (284 ) — (285 ) Net income 2,017 806 2,091 2,033 (4,934 ) 2,013 Net loss attributable to noncontrolling interests — — — 4 — 4 Net income attributable to Medtronic 2,017 806 2,091 2,037 (4,934 ) 2,017 Other comprehensive income (loss), net of tax (136 ) (295 ) (136 ) (136 ) 567 (136 ) Other comprehensive loss attributable to non-controlling interests — — — 4 — 4 Total comprehensive income $ 1,881 $ 511 $ 1,955 $ 1,901 $ (4,367 ) $ 1,881 Consolidating Statement of Comprehensive Income Six Months Ended October 27, 2017 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 14,440 $ — $ 14,440 Costs and expenses: Cost of products sold — — — 4,469 — 4,469 Research and development expense — — — 1,103 — 1,103 Selling, general, and administrative expense 5 — 1 4,917 — 4,923 Amortization of intangible assets — — — 914 — 914 Restructuring charges, net — — — 16 — 16 Acquisition-related items — — — 51 — 51 Divestiture-related items — — — 114 — 114 Gain on sale of businesses — — — (697 ) — (697 ) Special charge — — — 80 — 80 Other (income) expense, net 25 1 — 151 — 177 Operating profit (loss) (30 ) (1 ) (1 ) 3,322 — 3,290 Interest income — (32 ) (219 ) (239 ) 298 (192 ) Interest expense 109 44 82 622 (298 ) 559 Interest expense, net 109 12 (137 ) 383 — 367 Equity in net (income) loss of subsidiaries (3,169 ) (1,200 ) (3,033 ) — 7,402 — Income before income taxes 3,030 1,187 3,169 2,939 (7,402 ) 2,923 Income tax (benefit) provision (3 ) — — (96 ) — (99 ) Net income 3,033 1,187 3,169 3,035 (7,402 ) 3,022 Net loss attributable to noncontrolling interests — — — 11 — 11 Net income attributable to Medtronic 3,033 1,187 3,169 3,046 (7,402 ) 3,033 Other comprehensive loss, net of tax 553 (201 ) 553 553 (905 ) 553 Other comprehensive loss attributable to noncontrolling interests — — — 11 — 11 Total comprehensive income (loss) $ 3,586 $ 986 $ 3,722 $ 3,599 $ (8,307 ) $ 3,586 Consolidating Statement of Comprehensive Income Three Months Ended October 28, 2016 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 7,345 $ — $ 7,345 Costs and expenses: Cost of products sold — — — 2,326 — 2,326 Research and development expense — — — 554 — 554 Selling, general, and administrative expense 3 — 1 2,412 — 2,416 Amortization of intangible assets — — — 500 — 500 Restructuring charges, net — — — 47 — 47 Acquisition-related items — — — 28 — 28 Other (income) expense, net (86 ) — — 175 — 89 Operating profit (loss) 83 — (1 ) 1,303 — 1,385 Interest income — (18 ) (166 ) (102 ) 195 (91 ) Interest expense 25 23 11 400 (195 ) 264 Interest expense, net 25 5 (155 ) 298 — 173 Equity in net (income) loss of subsidiaries (1,055 ) (445 ) (901 ) — 2,401 — Income before income taxes 1,113 440 1,055 1,005 (2,401 ) 1,212 Income tax (benefit) provision (2 ) — — 103 — 101 Net income 1,115 440 1,055 902 (2,401 ) 1,111 Net loss attributable to noncontrolling interests — — — 4 — 4 Net income attributable to Medtronic 1,115 440 1,055 906 (2,401 ) 1,115 Other comprehensive income (loss), net of tax (304 ) (23 ) (304 ) (304 ) 631 (304 ) Other comprehensive loss attributable to — — — 4 — 4 Total comprehensive income $ 811 $ 417 $ 751 $ 602 $ (1,770 ) $ 811 Consolidating Statement of Comprehensive Income Six Months Ended October 28, 2016 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 14,511 $ — $ 14,511 Costs and expenses: Cost of products sold — — — 4,587 — 4,587 Research and development expense — — — 1,110 — 1,110 Selling, general, and administrative expense 6 — 1 4,837 — 4,844 Amortization of intangible assets — — — 987 — 987 Restructuring charges, net — — — 141 — 141 Certain litigation charges — — — 82 — 82 Acquisition-related items — — — 80 — 80 Other (income) expense, net (74 ) — — 202 — 128 Operating profit (loss) 68 — (1 ) 2,485 — 2,552 Interest income — (47 ) (324 ) (207 ) 394 (184 ) Interest expense 41 56 13 820 (394 ) 536 Interest expense, net 41 9 (311 ) 613 — 352 Equity in net (income) loss of subsidiaries (2,013 ) (1,249 ) (1,703 ) — 4,965 — Income before income taxes 2,040 1,240 2,013 1,872 (4,965 ) 2,200 Income tax (benefit) provision (4 ) — — 164 — 160 Net income 2,044 1,240 2,013 1,708 (4,965 ) 2,040 Net loss attributable to noncontrolling interests — — — 4 — 4 Net income attributable to Medtronic 2,044 1,240 2,013 1,712 (4,965 ) 2,044 Other comprehensive income (loss), net of tax (460 ) 19 (460 ) (460 ) 901 (460 ) Other comprehensive loss attributable to — — — 4 — 4 Total comprehensive income $ 1,584 $ 1,259 $ 1,553 $ 1,252 $ (4,064 ) $ 1,584 Condensed Consolidating Balance Sheet October 27, 2017 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ — $ 823 $ 4,706 $ — $ 5,529 Investments — — — 7,997 — 7,997 Accounts receivable, net — — — 5,752 — 5,752 Inventories, net — — — 3,638 — 3,638 Intercompany receivable 55 — 60 11 (126 ) — Other current assets 10 — 1 2,235 — 2,246 Total current assets 65 — 884 24,339 (126 ) 25,162 Property, plant, and equipment, net — — — 4,441 — 4,441 Goodwill — — — 39,077 — 39,077 Other intangible assets, net — — — 22,625 — 22,625 Tax assets — — — 1,749 — 1,749 Investment in subsidiaries 59,762 35,680 59,284 — (154,726 ) — Intercompany loans receivable 3,112 2,332 19,005 23,967 (48,416 ) — Other assets — — — 1,404 — 1,404 Total assets $ 62,939 $ 38,012 $ 79,173 $ 117,602 $ (203,268 ) $ 94,458 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ — $ 699 $ 2,432 $ — $ 3,131 Accounts payable — — — 1,718 — 1,718 Intercompany payable 11 — — 115 (126 ) — Accrued compensation 6 — — 1,496 — 1,502 Accrued income taxes 14 — — 858 — 872 Other accrued expenses 88 21 8 3,156 — 3,273 Total current liabilities 119 21 707 9,775 (126 ) 10,496 Long-term debt — 2,122 1,842 21,977 — 25,941 Accrued compensation and retirement benefits — — — 1,475 — 1,475 Accrued income taxes 10 — — 2,184 — 2,194 Intercompany loans payable 11,316 1,374 23,868 11,858 (48,416 ) — Deferred tax liabilities — — — 1,841 — 1,841 Other liabilities 25 — 1 907 — 933 Total liabilities 11,470 3,517 26,418 50,017 (48,542 ) 42,880 Shareholders’ equity 51,469 34,495 52,755 67,476 (154,726 ) 51,469 Noncontrolling interests — — — 109 — 109 Total equity 51,469 34,495 52,755 67,585 (154,726 ) 51,578 Total liabilities and equity $ 62,939 $ 38,012 $ 79,173 $ 117,602 $ (203,268 ) $ 94,458 Condensed Consolidating Balance Sheet April 28, 2017 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 33 $ 5 $ 4,929 $ — $ 4,967 Investments — — — 8,741 — 8,741 Accounts receivable, net — — — 5,591 — 5,591 Inventories, net — — — 3,338 — 3,338 Intercompany receivable 63 — 60 12 (135 ) — Other current assets 10 — — 1,855 — 1,865 Current assets held for sale — — — 371 — 371 Total current assets 73 33 65 24,837 (135 ) 24,873 Property, plant, and equipment, net — — — 4,361 — 4,361 Goodwill — — — 38,515 — 38,515 Other intangible assets, net — — — 23,407 — 23,407 Tax assets — — — 1,509 — 1,509 Investment in subsidiaries 55,833 31,055 51,294 — (138,182 ) — Intercompany loans receivable 3,000 2,978 17,383 17,260 (40,621 ) — Other assets — — — 1,232 — 1,232 Noncurrent assets held for sale — — — 5,919 — 5,919 Total assets $ 58,906 $ 34,066 $ 68,742 $ 117,040 $ (178,938 ) $ 99,816 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ 1,176 $ 901 $ 5,443 $ — $ 7,520 Accounts payable — — — 1,731 — 1,731 Intercompany payable 12 — — 123 (135 ) — Accrued compensation 9 — — 1,851 — 1,860 Accrued income taxes 13 — — 620 — 633 Other accrued expenses — 23 8 2,411 — 2,442 Current liabilities held for sale — — — 34 — 34 Total current liabilities 34 1,199 909 12,213 (135 ) 14,220 Long-term debt — 2,133 1,842 21,946 — 25,921 Accrued compensation and retirement benefits — — — 1,641 — 1,641 Accrued income taxes 10 — — 2,395 — 2,405 Intercompany loans payable 8,568 1,369 17,161 13,523 (40,621 ) — Deferred tax liabilities — — — 2,978 — 2,978 Other liabilities — — — 1,515 — 1,515 Noncurrent liabilities held for sale — — — 720 — 720 Total liabilities 8,612 4,701 19,912 56,931 (40,756 ) 49,400 Shareholders' equity 50,294 29,365 48,830 59,987 (138,182 ) 50,294 Noncontrolling interests — — — 122 — 122 Total Equity 50,294 29,365 48,830 60,109 (138,182 ) 50,416 Total liabilities and equity $ 58,906 $ 34,066 $ 68,742 $ 117,040 $ (178,938 ) $ 99,816 Condensed Consolidating Statement of Cash Flows Six Months Ended October 27, 2017 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ 269 $ 997 $ 135 $ 1,291 $ (1,048 ) $ 1,644 Investing Activities: Acquisitions, net of cash acquired — — — (76 ) — (76 ) Proceeds from sale of businesses — — — 6,058 — 6,058 Additions to property, plant, and equipment — — — (524 ) — (524 ) Purchases of investments — — — (1,685 ) — (1,685 ) Sales and maturities of investments — — — 2,354 — 2,354 Net (increase) decrease in intercompany loans (112 ) 646 (1,622 ) (6,707 ) 7,795 — Capital contribution paid — (531 ) (4,200 ) — 4,731 — Other investing activities, net — — — (2 ) — (2 ) Net cash provided by (used in) investing activities (112 ) 115 (5,822 ) (582 ) 12,526 6,125 Financing Activities: Acquisition-related contingent consideration — — — (39 ) — (39 ) Change in current debt obligations, net — — (202 ) 12 — (190 ) Issuance of long-term debt — — — 20 — 20 Payments on long-term debt — (1,150 ) — (3,011 ) — (4,161 ) Dividends to shareholders (1,247 ) — — — — (1,247 ) Issuance of ordinary shares 230 — — — — 230 Repurchase of ordinary shares (1,888 ) — — — — (1,888 ) Net intercompany loan borrowings (repayments) 2,748 5 6,707 (1,665 ) (7,795 ) — Intercompany dividend paid — — — (1,048 ) 1,048 — Capital contribution received — — — 4,731 (4,731 ) — Other financing activities — — — (2 ) — (2 ) Net cash provided by (used in) financing activities (157 ) (1,145 ) 6,505 (1,002 ) (11,478 ) (7,277 ) Effect of exchange rate changes on cash and cash equivalents — — — 70 — 70 Net change in cash and cash equivalents — (33 ) 818 (223 ) — 562 Cash and cash equivalents at beginning of period — 33 5 4,929 — 4,967 Cash and cash equivalents at end of period $ — $ — $ 823 $ 4,706 $ — $ 5,529 Condensed Consolidating Statement of Cash Flows Six Months Ended October 28, 2016 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ 644 $ 879 $ 162 $ 2,257 $ (920 ) $ 3,022 Investing Activities: Acquisitions, net of cash acquired — — — (1,306 ) — (1,306 ) Additions to property, plant, and equipment — — — (598 ) — (598 ) Purchases of investments — — — (2,110 ) — (2,110 ) Sales and maturities of investments — — — 3,625 — 3,625 Net (increase) decrease in intercompany loans — 3,198 (2,117 ) 2,707 (3,788 ) — Capital contributions paid — (325 ) — — 325 — Other investing activities, net — — — 32 — 32 Net cash provided by (used in) investing activities — 2,873 (2,117 ) 2,350 (3,463 ) (357 ) Financing Activities: Acquisition-related contingent consideration — — — (36 ) — (36 ) Change in current debt obligations, net — — 1,130 24 — 1,154 Proceeds from current debt obligations (maturities greater than 90 days) — — 4 — — 4 Issuance of long-term debt — — — 131 — 131 Payments on long-term debt — — — (252 ) — (252 ) Dividends to shareholders (1,192 ) — — — — (1,192 ) Issuance of ordinary shares 260 — — — — 260 Repurchase of ordinary shares (2,794 ) — — — — (2,794 ) Net intercompany loan borrowings (repayments) 3,082 (3,634 ) 929 (4,165 ) 3,788 — Intercompany dividend paid — — — (920 ) 920 — Capital contributions received — — — 325 (325 ) — Other financing activities — — — 74 — 74 Net cash provided by (used in) financing activities (644 ) (3,634 ) 2,063 (4,819 ) 4,383 (2,651 ) Effect of exchange rate changes on cash and cash equivalents — — — 64 — 64 Net change in cash and cash equivalents — 118 108 (148 ) — 78 Cash and cash equivalents at beginning of period — 208 — 2,668 — 2,876 Cash and cash equivalents at end of period $ — $ 326 $ 108 $ 2,520 $ — $ 2,954

Basis of Presentation (Policies

Basis of Presentation (Policies)	6 Months Ended
	Oct. 27, 2017
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	The accompanying unaudited consolidated financial statements of Medtronic plc and its subsidiaries (Medtronic plc, Medtronic, or the Company) have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S.) (U.S. GAAP) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of management, the consolidated financial statements include all of the adjustments necessary for a fair statement in conformity with U.S. GAAP. Certain reclassifications have been made to prior year financial statements to conform to classifications used in the current year. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Actual results could materially differ from these estimates.
Consolidation	The accompanying unaudited consolidated financial statements include the accounts of Medtronic plc, its wholly-owned subsidiaries, entities for which the Company has a controlling financial interest, and variable interest entities for which the Company is the primary beneficiary. Intercompany transactions and balances have been fully eliminated in consolidation.
Fiscal Period	The Company’s fiscal years 2018 , 2017 , and 2016 will end or ended on April 27, 2018 , April 28, 2017 , and April 29, 2016 , respectively.
New Accounting Pronouncements	Recently Adopted In March 2016, the Financial Accounting Standards Board (FASB) issued guidance to simplify the accounting for share-based payment transactions by requiring all excess tax benefits and deficiencies to be recognized in income tax expense or benefit in earnings; eliminating the requirement to classify the excess tax benefits and deficiencies as additional paid-in capital. Cash flows related to excess tax benefits are to be classified in operating activities in the statement of cash flows rather than financing. Under the new guidance, an entity makes an accounting policy election to either estimate the expected forfeiture awards or account for forfeitures as they occur. The standard also allows an entity to withhold up to the maximum statutory tax rate and classify the awards as equity. The Company prospectively adopted this guidance in the first quarter of fiscal year 2018. The Company has elected to continue to estimate forfeitures. The adoption of this guidance resulted in no cumulative adjustment to retained earnings and increases to net income of $17 million and $41 million , respectively, and increases to diluted earnings per share of $0.01 and $0.03 , respectively, for the three and six months ended October 27, 2017 . In October 2016, the FASB issued guidance that requires the tax effect of intra-entity transactions, other than sales of inventory, to be recognized when the transaction occurs. Previously, U.S. GAAP prohibited the recognition of current and deferred income taxes associated with an intra-entity asset transfer until an asset had been sold to a third-party. This update requires an entity to recognize the income tax consequences of an intra-entity transfer of an asset, such as equipment or intangibles, when the transfer occurs. The adoption of this pronouncement is to be applied on a modified retrospective basis through a cumulative-effect adjustment directly to retained earnings as of the beginning of the period of adoption. The Company has early adopted this guidance, as permitted, in the first quarter of fiscal year 2018. As a result of this adoption, the Company increased its beginning retained earnings by $296 million . The adoption of this guidance also resulted in increases to net income of $582 million and $557 million , respectively, and increases to diluted earnings per share of $0.43 and $0.41 , respectively, for the three and six months ended October 27, 2017 . Not Yet Adopted In May 2014, the FASB issued amended revenue recognition guidance to clarify the principles for recognizing revenue from contracts with customers. The guidance requires an entity to recognize revenue in an amount that reflects the consideration to which an entity expects to be entitled in exchange for the transfer of goods or services. The guidance also requires expanded disclosures relating to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. Additionally, qualitative and quantitative disclosures are required about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2019, and may be applied either retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of the change recognized at the date of initial application (modified retrospective method). The Company intends to adopt this guidance under the modified retrospective method. Based on the Company's evaluation performed of the amended revenue recognition guidance to date, the Company does not expect the adoption of the amended guidance to have a material impact on the Company's consolidated financial statements. The Company is continuing to evaluate the impact of the amended guidance in the areas of performance obligations, presentation, and new disclosure requirements. Additionally, the Company will continue to monitor any modifications, clarifications, and interpretations communicated by the FASB that may impact its conclusions. In January 2016, the FASB issued guidance which requires equity investments (except those accounted for under the equity method of accounting or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income. The guidance also includes a simplified impairment assessment of equity investments without readily determinable fair values and presentation and disclosure changes. This accounting guidance is effective for the Company beginning in the first quarter of fiscal year 2019. The Company is unable to estimate the impact of the future adoption of this guidance on its financial statements as it will depend on the equity investments at the adoption date. In February 2016, the FASB issued guidance which requires lessees to recognize right-of-use assets and lease liabilities on the balance sheet. The guidance is to be applied using a modified retrospective approach at the beginning of the earliest comparative period in the financial statements and is effective for the Company beginning in the first quarter of fiscal year 2020. Early adoption is permitted. The Company is evaluating the impact of the lease guidance on the Company's consolidated financial statements and anticipates recording additional assets and corresponding liabilities on its consolidated balance sheets related to operating leases within its lease portfolio upon adoption of the guidance. In January 2017, the FASB issued guidance which simplifies the accounting for goodwill impairment. The guidance requires a goodwill impairment to be measured as the amount by which a reporting unit's carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. The Company is required to adopt this guidance beginning in the first quarter of fiscal year 2021. Early adoption is permitted, and the guidance must be applied prospectively. The Company is unable to estimate the impact of the future adoption of this guidance on its financial statements, as it is dependent on the specific facts and circumstances of future impairments, if any.

Acquisitions and Acquisition-27

Acquisitions and Acquisition-Related Items (Tables)	6 Months Ended
	Oct. 27, 2017
Business Combinations [Abstract]
Fair Value of Assets Acquired and Liabilities Assumed	The acquisition date fair values of the assets and liabilities acquired were as follows: (in millions) HeartWare International, Inc. All Other Other current assets $ 351 $ 2 Property, plant, and equipment 14 6 Other intangible assets 625 68 Goodwill 481 15 Other assets 84 — Total assets acquired 1,555 91 Current liabilities 143 1 Deferred tax liabilities 6 — Long-term debt 245 — Other liabilities 89 — Total liabilities assumed 483 1 Net assets acquired $ 1,072 $ 90
Fair Value Measurements, Contingent Consideration, Significant Unobservable Inputs	The recurring Level 3 fair value measurements of contingent consideration include the following significant unobservable inputs: Fair Value at (in millions) October 27, 2017 Valuation Technique Unobservable Input Range Discount rate 11% - 32.5% Revenue-based payments $85 Discounted cash flow Probability of payment 30% - 100% Projected fiscal year of payment 2018 - 2026 Discount rate 0.7% - 5.5% Product development and other milestone-based payments $105 Discounted cash flow Probability of payment 50% - 100% Projected fiscal year of payment 2018 - 2025
Reconciliation of Beginning and Ending Balances of Contingent Consideration Associated with Acquisitions	The following table provides a reconciliation of the beginning and ending balances of contingent consideration: Three months ended Six months ended (in millions) October 27, 2017 October 28, 2016 October 27, 2017 October 28, 2016 Beginning Balance $ 242 $ 379 $ 246 $ 377 Purchase price contingent consideration 15 11 15 32 Payments (43 ) (25 ) (46 ) (39 ) Change in fair value (24 ) (80 ) (25 ) (85 ) Ending Balance $ 190 $ 285 $ 190 $ 285

Divestiture and Divestiture-R28

Divestiture and Divestiture-Related Items (Tables)	6 Months Ended
	Oct. 27, 2017
Discontinued Operations and Disposal Groups [Abstract]
Assets and Liabilities Classified as Held for Sale	The following table presents information related to the assets and liabilities that were classified as held for sale in the consolidated balance sheets: (in millions) April 28, 2017 Inventories, net $ 371 Property, plant, and equipment, net 689 Goodwill 2,910 Other intangible assets, net 2,320 Total assets held for sale $ 6,290 Other accrued expenses $ 34 Accrued compensation and retirement benefits 12 Deferred tax liabilities 707 Other liabilities 1 Total liabilities held for sale $ 754

Restructuring Charges (Tables)

Restructuring Charges (Tables)	6 Months Ended
	Oct. 27, 2017
Cost Synergies Initiative
Restructuring Cost and Reserve [Line Items]
Restructuring Reserve	A summary of the restructuring accrual, recorded within other accrued expenses and other liabilities in the consolidated balance sheets, and related activity is presented below: (in millions) Employee Termination Costs Other Costs Total April 28, 2017 $ 261 $ 30 $ 291 Charges 25 20 45 Cash payments (85 ) (26 ) (111 ) Accrual adjustments (14 ) 1 (13 ) October 27, 2017 $ 187 $ 25 $ 212

Financial Instruments (Tables)

Financial Instruments (Tables)	6 Months Ended
	Oct. 27, 2017
Investments [Abstract]
Investments by Category and Related Balance Sheet Classification	The following table summarizes the Company's investments by significant investment category and the related consolidated balance sheet classification at October 27, 2017 : Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Available-for-sale securities: Level 1: U.S. government and agency securities $ 613 $ 1 $ (8 ) $ 606 $ 606 $ — Marketable equity securities 84 115 (1 ) 198 — 198 Total Level 1 697 116 (9 ) 804 606 198 Level 2: Corporate debt securities 4,165 64 (16 ) 4,213 4,213 — U.S. government and agency securities 870 — (12 ) 858 858 — Mortgage-backed securities 768 7 (19 ) 756 756 — Foreign government and agency securities 52 — — 52 52 — Other asset-backed securities 341 1 (1 ) 341 341 — Debt funds 939 6 (168 ) 777 777 — Total Level 2 7,135 78 (216 ) 6,997 6,997 — Level 3: Corporate debt securities 1 — — 1 — 1 Auction rate securities 47 — (3 ) 44 — 44 Total Level 3 48 — (3 ) 45 — 45 Investments measured at net asset value (1) : Debt Funds 400 — (6 ) 394 394 — Total available-for-sale securities 8,280 194 (234 ) 8,240 7,997 243 Cost method, equity method, and other investments: Level 3: Cost method, equity method, and other investments 626 — — N/A — 626 Total Level 3 626 — — N/A — 626 Total cost method, equity method, and other investments 626 — — N/A — 626 Total investments $ 8,906 $ 194 $ (234 ) $ 8,240 $ 7,997 $ 869 (1) Certain investments that are measured at the net asset value per share (or its equivalent) as a practical expedient are excluded from the fair value hierarchy. The fair value amounts presented herein are intended to permit reconciliation to the consolidated balance sheets. The following table summarizes the Company's investments by significant investment category and the related consolidated balance sheet classification at April 28, 2017 : Valuation Balance Sheet Classification (in millions) Cost Unrealized Gains Unrealized Losses Fair Value Investments Other Assets Available-for-sale securities: Level 1: U.S. government and agency securities $ 613 $ 2 $ (5 ) $ 610 $ 610 $ — Marketable equity securities 58 49 (4 ) 103 — 103 Total Level 1 671 51 (9 ) 713 610 103 Level 2: Corporate debt securities 4,643 62 (23 ) 4,682 4,682 — U.S. government and agency securities 860 — (10 ) 850 850 — Mortgage-backed securities 766 9 (16 ) 759 759 — Foreign government and agency securities 49 — — 49 49 — Other asset-backed securities 228 1 (1 ) 228 228 — Debt funds 1,246 4 (178 ) 1,072 1,072 — Total Level 2 7,792 76 (228 ) 7,640 7,640 — Level 3: Corporate debt securities 1 — — 1 — 1 Auction rate securities 47 — (3 ) 44 — 44 Total Level 3 48 — (3 ) 45 — 45 Investments measured at net asset value (1) : Debt funds 497 — (6 ) 491 491 — Total available-for-sale securities 9,008 127 (246 ) 8,889 8,741 148 Cost method, equity method, and other investments: Level 3: Cost method, equity method, and other investments 589 — — N/A — 589 Total Level 3 589 — — N/A — 589 Total cost method, equity method, and other investments 589 — — N/A — 589 Total investments $ 9,597 $ 127 $ (246 ) $ 8,889 $ 8,741 $ 737 (1) Certain investments that are measured at the net asset value per share (or its equivalent) as a practical expedient are excluded from the fair value hierarchy. The fair value amounts presented herein are intended to permit reconciliation to the consolidated balance sheets.
Available-For-Sale Securities in Continuous Unrealized Loss Position	The following tables present the gross unrealized losses and fair values of the Company’s available-for-sale securities that have been in a continuous unrealized loss position deemed to be temporary, aggregated by investment category at October 27, 2017 and April 28, 2017 : October 27, 2017 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 946 $ (9 ) $ 209 $ (7 ) Auction rate securities — — 44 (3 ) Mortgage-backed securities 296 (4 ) 97 (15 ) U.S. government and agency securities 877 (15 ) 216 (5 ) Debt funds 7 (1 ) 958 (173 ) Other asset-backed securities 201 (1 ) — — Marketable equity securities — — 2 (1 ) Total $ 2,327 $ (30 ) $ 1,526 $ (204 ) April 28, 2017 Less than 12 months More than 12 months (in millions) Fair Value Unrealized Losses Fair Value Unrealized Losses Corporate debt securities $ 1,263 $ (19 ) $ 46 $ (4 ) Auction rate securities — — 44 (3 ) Mortgage-backed securities 276 (4 ) 95 (12 ) U.S. government and agency securities 896 (15 ) — — Other asset-backed securities 127 (1 ) — — Debt funds 173 (1 ) 1,125 (183 ) Marketable equity securities 14 (3 ) 2 (1 ) Total $ 2,749 $ (43 ) $ 1,312 $ (203 )
Unobservable Inputs Utilized in the Fair Value Measurement of Auction Rate Securities Classified as Level 3	The following table presents the unobservable inputs utilized in the fair value measurement of the auction rate securities classified as Level 3 at October 27, 2017 : Valuation Technique Unobservable Input Range (Weighted Average) Auction rate securities Discounted cash flow Years to principal recovery 2 yrs. - 12 yrs. (3 yrs.) Illiquidity premium 6%
Reconciliation of Beginning and Ending Balances of Items Measured at Fair Value on a Recurring Basis that Used Significant Unobservable Inputs (Level 3)	The following tables provide a reconciliation of the beginning and ending balances of items measured at fair value on a recurring basis that used significant unobservable inputs (Level 3): Three months ended October 27, 2017 (in millions) Total Level 3 Corporate Debt Auction Rate July 28, 2017 $ 45 $ 1 $ 44 Total unrealized gains (losses) included in other comprehensive income — — — October 27, 2017 $ 45 $ 1 $ 44 Three months ended October 28, 2016 (in millions) Total Level 3 Corporate Debt Auction Rate July 29, 2016 $ 45 $ 1 $ 44 Total unrealized gains (losses) included in other comprehensive income — — — October 28, 2016 $ 45 $ 1 $ 44 Six months ended October 27, 2017 (in millions) Total Level 3 Corporate Debt Auction Rate April 28, 2017 $ 45 $ 1 $ 44 Total unrealized gains (losses) included in other comprehensive income — — — October 27, 2017 $ 45 $ 1 $ 44 Six months ended October 28, 2016 (in millions) Total Level 3 Corporate Debt Auction Rate April 29, 2016 $ 45 $ 1 $ 44 Total unrealized gains (losses) included in other comprehensive income — — — October 28, 2016 $ 45 $ 1 $ 44
Activity Related to the Company's Investment Portfolio	Activity related to the Company’s investment portfolio is as follows: Three months ended October 27, 2017 October 28, 2016 (in millions) Debt (1) Equity (2) Debt (1) Equity (2) Proceeds from sales $ 1,383 $ — $ 2,444 $ 76 Gross realized gains 11 — 57 25 Gross realized losses (12 ) — (37 ) — Impairment losses recognized — (1 ) — (7 ) Six months ended October 27, 2017 October 28, 2016 (in millions) Debt (1) Equity (2) Debt (1) Equity (2) Proceeds from sales $ 2,354 $ — $ 3,542 $ 82 Gross realized gains 19 7 64 29 Gross realized losses (15 ) — (49 ) — Impairment losses recognized — (1 ) — (10 ) (1) Includes available-for-sale debt securities and debt funds. (2) Includes marketable equity securities and cost and equity method investments.
Available-for-sale Debt Securities Contractual Maturities	The October 27, 2017 balance of available-for-sale debt securities, excluding debt funds which have no single maturity date, by contractual maturity is shown in the following table. Within the table, maturities of mortgage-backed securities have been allocated based upon timing of estimated cash flows assuming no change in the current interest rate environment. Actual maturities may differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. (in millions) October 27, 2017 Due in one year or less $ 865 Due after one year through five years 2,601 Due after five years through ten years 3,298 Due after ten years 107 Total $ 6,871

Financing Arrangements (Tables)

Financing Arrangements (Tables)	6 Months Ended
	Oct. 27, 2017
Debt Disclosure [Abstract]
Long-term Debt	The Company's debt obligations consisted of the following: (in millions, except interest rates) Maturity by Fiscal Year October 27, 2017 April 28, 2017 Current debt obligations 2018 $ 3,131 $ 7,520 Long-term debt 5.600 percent ten-year 2009 senior notes 2019 400 400 1.700 percent two-year 2017 senior notes 2019 1,000 1,000 4.450 percent ten-year 2010 senior notes 2020 766 766 2.500 percent five-year 2015 senior notes 2020 2,500 2,500 Floating rate five-year 2015 senior notes 2020 500 500 4.200 percent ten-year 2010 CIFSA senior notes 2021 600 600 4.125 percent ten-year 2011 senior notes 2021 500 500 3.125 percent ten-year 2012 senior notes 2022 675 675 3.150 percent seven-year 2015 senior notes 2022 2,500 2,500 3.200 percent ten-year 2012 CIFSA senior notes 2023 650 650 2.750 percent ten-year 2013 senior notes 2023 530 530 2.950 percent ten-year 2013 CIFSA senior notes 2024 310 310 3.625 percent ten-year 2014 senior notes 2024 850 850 3.500 percent ten-year 2015 senior notes 2025 4,000 4,000 3.350 percent ten-year 2017 senior notes 2027 850 850 4.375 percent twenty-year 2015 senior notes 2035 2,382 2,382 6.550 percent thirty-year 2008 CIFSA senior notes 2038 374 374 6.500 percent thirty-year 2009 senior notes 2039 300 300 5.550 percent thirty-year 2010 senior notes 2040 500 500 4.500 percent thirty-year 2012 senior notes 2042 400 400 4.000 percent thirty-year 2013 senior notes 2043 325 325 4.625 percent thirty-year 2014 senior notes 2044 650 650 4.625 percent thirty-year 2015 senior notes 2045 4,150 4,150 Interest rate swaps (Note 9) 2021 - 2022 30 40 Capital lease obligations 2019 - 2025 22 23 Bank borrowings 2019 - 2021 169 139 Debt premium, net 2019 - 2045 127 135 Deferred financing costs 2019 - 2045 (119 ) (128 ) Long-term debt $ 25,941 $ 25,921

Derivatives and Currency Exch32

Derivatives and Currency Exchange Risk Management (Tables)	6 Months Ended
	Oct. 27, 2017
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Amount and Location of Gains (Losses) in Statements of Income, Derivative Instruments Not Designated as Hedging Instruments	The amounts and classification of the losses in the consolidated statements of income related to derivative instruments, not designated as hedging instruments, for the three and six months ended October 27, 2017 and October 28, 2016 were as follows: Three months ended Six months ended (in millions) Classification October 27, 2017 October 28, 2016 October 27, 2017 October 28, 2016 Currency exchange rate contract losses Other expense, net $ 42 $ 38 $ 137 $ 41
Amount and Location of Gains (Losses) in Statements of Income and OCI, Derivative Instruments Designated as Cash Flow Hedges	The amount of gross gains (losses), classification of the gains (losses) in the consolidated statements of income, and the accumulated other comprehensive income (loss) (AOCI) related to the effective portion of currency exchange rate contract derivative instruments designated as cash flow hedges for the three and six months ended October 27, 2017 and October 28, 2016 were as follows: Three months ended October 27, 2017 Recognized in AOCI Recognized in Income (in millions) Amount Classification Amount Currency exchange rate contracts $ 30 Other expense, net $ (10 ) Total $ 30 $ (10 ) Three months ended October 28, 2016 Recognized in AOCI Recognized in Income (in millions) Amount Classification Amount Currency exchange rate contracts $ 69 Other expense, net $ 6 Total $ 69 $ 6 Six months ended October 27, 2017 Recognized in AOCI Recognized in Income (in millions) Amount Classification Amount Currency exchange rate contracts $ (220 ) Other expense, net $ 12 Total $ (220 ) $ 12 Six months ended October 28, 2016 Recognized in AOCI Recognized in Income (in millions) Amount Classification Amount Currency exchange rate contracts $ 190 Other expense, net $ 22 Total $ 190 $ 22
Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets	The following tables summarize the balance sheet classification and fair value of derivative instruments included in the consolidated balance sheets at October 27, 2017 and April 28, 2017 . The fair value amounts are presented on a gross basis and are segregated between derivatives that are designated and qualify as hedging instruments and those that are not designated and do not qualify as hedging instruments, and are further segregated by type of contract within those two categories. October 27, 2017 Derivative Assets Derivative Liabilities (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments Currency exchange rate contracts Prepaid expenses and other current assets $ 61 Other accrued expenses $ 113 Interest rate contracts Other assets 30 Other liabilities — Currency exchange rate contracts Other assets 41 Other liabilities 63 Total derivatives designated as hedging instruments $ 132 $ 176 Derivatives not designated as hedging instruments Currency exchange rate contracts Prepaid expenses and other current assets $ 35 Other accrued expenses $ 27 Total return swap Prepaid expenses and other current assets 8 Other accrued expenses — Stock warrants Other assets 25 Other liabilities — Cross currency interest rate contracts Other assets 6 Other liabilities 8 Total derivatives not designated as hedging instruments $ 74 $ 35 Total derivatives $ 206 $ 211 April 28, 2017 Asset Derivatives Liability Derivatives (in millions) Balance Sheet Classification Fair Value Balance Sheet Classification Fair Value Derivatives designated as hedging instruments Currency exchange rate contracts Prepaid expenses and other current assets $ 152 Other accrued expenses $ 43 Interest rate contracts Other assets 41 Other liabilities — Currency exchange rate contracts Other assets 48 Other liabilities 14 Total derivatives designated as hedging instruments $ 241 $ 57 Derivatives not designated as hedging instruments Currency exchange rate contracts Prepaid expenses and other current assets 16 Other accrued expenses 36 Cross currency interest rate contracts Other assets 5 Other liabilities 11 Total derivatives not designated as hedging instruments $ 21 $ 47 Total derivatives $ 262 $ 104
Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis	The following table provides information by level for the derivative assets and liabilities that are measured at fair value on a recurring basis. October 27, 2017 April 28, 2017 (in millions) Level 1 Level 2 Level 1 Level 2 Derivative assets $ 137 $ 69 $ 216 $ 46 Derivative liabilities 203 8 93 11
Offsetting Assets	The following table provides information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. October 27, 2017 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Collateral (Received) Posted Net Amount Derivative assets: Currency exchange rate contracts $ 137 $ (110 ) $ — $ 27 Interest rate contracts 30 (13 ) — 17 Cross currency interest rate contracts 6 (2 ) — 4 Stock warrants 25 — — 25 Total return swap 8 — — 8 $ 206 $ (125 ) $ — $ 81 Derivative liabilities: Currency exchange rate contracts $ (203 ) $ 123 $ — $ (80 ) Cross currency interest rate contracts (8 ) 2 — (6 ) (211 ) 125 — (86 ) Total $ (5 ) $ — $ — $ (5 ) April 28, 2017 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Collateral (Received) Posted Net Amount Derivative assets: Currency exchange rate contracts $ 216 $ (58 ) $ (55 ) $ 103 Interest rate contracts 41 (15 ) (5 ) 21 Cross currency interest rate contracts 5 (2 ) — 3 $ 262 $ (75 ) $ (60 ) $ 127 Derivative liabilities: Currency exchange rate contracts $ (93 ) $ 73 $ — $ (20 ) Cross currency interest rate contracts (11 ) 2 — (9 ) (104 ) 75 — (29 ) Total $ 158 $ — $ (60 ) $ 98
Offsetting Liabilities	The following table provides information as if the Company had elected to offset the asset and liability balances of derivative instruments, netted in accordance with various criteria as stipulated by the terms of the master netting arrangements with each of the counterparties. Derivatives not subject to master netting arrangements are not eligible for net presentation. October 27, 2017 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Collateral (Received) Posted Net Amount Derivative assets: Currency exchange rate contracts $ 137 $ (110 ) $ — $ 27 Interest rate contracts 30 (13 ) — 17 Cross currency interest rate contracts 6 (2 ) — 4 Stock warrants 25 — — 25 Total return swap 8 — — 8 $ 206 $ (125 ) $ — $ 81 Derivative liabilities: Currency exchange rate contracts $ (203 ) $ 123 $ — $ (80 ) Cross currency interest rate contracts (8 ) 2 — (6 ) (211 ) 125 — (86 ) Total $ (5 ) $ — $ — $ (5 ) April 28, 2017 Gross Amount Not Offset on the Balance Sheet (in millions) Gross Amount of Recorded Assets (Liabilities) Financial Instruments Collateral (Received) Posted Net Amount Derivative assets: Currency exchange rate contracts $ 216 $ (58 ) $ (55 ) $ 103 Interest rate contracts 41 (15 ) (5 ) 21 Cross currency interest rate contracts 5 (2 ) — 3 $ 262 $ (75 ) $ (60 ) $ 127 Derivative liabilities: Currency exchange rate contracts $ (93 ) $ 73 $ — $ (20 ) Cross currency interest rate contracts (11 ) 2 — (9 ) (104 ) 75 — (29 ) Total $ 158 $ — $ (60 ) $ 98

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Oct. 27, 2017
Inventory Disclosure [Abstract]
Inventory Balances	Inventory balances, net of reserves, were as follows: (in millions) October 27, 2017 April 28, 2017 Finished goods $ 2,368 $ 2,211 Work in-process 515 458 Raw materials 755 669 Total $ 3,638 $ 3,338

Goodwill and Other Intangible34

Goodwill and Other Intangible Assets (Tables)	6 Months Ended
	Oct. 27, 2017
Goodwill and Intangible Assets Disclosure [Abstract]
Changes in the Carrying Amount of Goodwill	The following table presents the changes in the carrying amount of goodwill by reportable segment: (in millions) Cardiac and Vascular Group Minimally Invasive Therapies Group Restorative Therapies Group Diabetes Group Total April 28, 2017 $ 6,651 $ 20,411 $ 9,600 $ 1,853 $ 38,515 Goodwill as a result of acquisitions — — 9 6 15 Purchase accounting adjustments 54 — — — 54 Currency and other adjustments, net 48 405 41 (1 ) 493 October 27, 2017 $ 6,753 $ 20,816 $ 9,650 $ 1,858 $ 39,077
Gross Carrying Amount of Indefinite-Lived Intangible Assets	The following table presents the gross carrying amount and accumulated amortization of intangible assets: October 27, 2017 April 28, 2017 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Definite-lived: Customer-related $ 16,964 $ (2,652 ) $ 16,862 $ (2,166 ) Purchased technology and patents 11,479 (4,038 ) 11,461 (3,690 ) Trademarks and tradenames 821 (544 ) 772 (461 ) Other 80 (46 ) 77 (42 ) Total $ 29,344 $ (7,280 ) $ 29,172 $ (6,359 ) Indefinite-lived: IPR&D $ 561 $ 594
Gross Carrying Amount and Accumulated Amortization of Definite-Lived Intangible Assets	The following table presents the gross carrying amount and accumulated amortization of intangible assets: October 27, 2017 April 28, 2017 (in millions) Gross Carrying Amount Accumulated Amortization Gross Carrying Amount Accumulated Amortization Definite-lived: Customer-related $ 16,964 $ (2,652 ) $ 16,862 $ (2,166 ) Purchased technology and patents 11,479 (4,038 ) 11,461 (3,690 ) Trademarks and tradenames 821 (544 ) 772 (461 ) Other 80 (46 ) 77 (42 ) Total $ 29,344 $ (7,280 ) $ 29,172 $ (6,359 ) Indefinite-lived: IPR&D $ 561 $ 594
Estimated Future Aggregate Amortization Expense, Definite-Lived Intangible Assets	Estimated aggregate amortization expense by fiscal year based on the carrying value of definite-lived intangible assets at October 27, 2017 , excluding any possible future amortization associated with acquired IPR&D which has not yet met technological feasibility, is as follows: (in millions) Amortization Expense Remaining 2018 $ 871 2019 1,672 2020 1,622 2021 1,601 2022 1,561 2023 1,490

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Oct. 27, 2017
Earnings Per Share [Abstract]
Computation of Basic and Diluted Earnings Per Share	The table below sets forth the computation of basic and diluted earnings per share: Three months ended Six months ended (in millions, except per share data) October 27, 2017 October 28, 2016 October 27, 2017 October 28, 2016 Numerator: Net income attributable to ordinary shareholders $ 2,017 $ 1,115 $ 3,033 $ 2,044 Denominator: Basic – weighted average shares outstanding 1,355.1 1,380.0 1,358.5 1,386.5 Effect of dilutive securities: Employee stock options 7.7 9.3 8.5 9.9 Employee restricted stock units 3.0 3.2 3.5 3.6 Other — — 0.3 0.2 Diluted – weighted average shares outstanding 1,365.8 1,392.5 1,370.8 1,400.2 Basic earnings per share $ 1.49 $ 0.81 $ 2.23 $ 1.47 Diluted earnings per share $ 1.48 $ 0.80 $ 2.21 $ 1.46

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Oct. 27, 2017
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Components and Classification of Stock-based Compensation Expense	The following table presents the components and classification of stock-based compensation expense for stock options, restricted stock, and employee stock purchase plan shares recognized for the three and six months ended October 27, 2017 and October 28, 2016 : Three months ended Six months ended (in millions) October 27, 2017 October 28, 2016 October 27, 2017 October 28, 2016 Stock options $ 42 $ 53 $ 77 $ 91 Restricted stock 59 54 107 88 Employee stock purchase plan 5 4 14 11 Total stock-based compensation expense $ 106 $ 111 $ 198 $ 190 Cost of products sold $ 14 $ 15 $ 24 $ 26 Research and development expense 12 13 21 22 Selling, general, and administrative expense 79 73 134 124 Restructuring charges — 1 — 2 Acquisition-related items 1 9 3 16 Divestiture-related items — — 16 — Total stock-based compensation expense 106 111 198 190 Income tax benefits (32 ) (33 ) (57 ) (54 ) Total stock-based compensation expense, net of tax $ 74 $ 78 $ 141 $ 136

Retirement Benefit Plans (Table

Retirement Benefit Plans (Tables)	6 Months Ended
	Oct. 27, 2017
Retirement Benefits [Abstract]
Components of Net Periodic Benefit Cost	The net periodic benefit cost of the defined benefit pension plans included the following components for the three and six months ended October 27, 2017 and October 28, 2016 : U.S. Pension Benefits Non-U.S. Pension Benefits Three months ended Three months ended (in millions) October 27, 2017 October 28, 2016 October 27, 2017 October 28, 2016 Service cost $ 29 $ 29 $ 17 $ 19 Interest cost 30 27 7 6 Expected return on plan assets (52 ) (47 ) (13 ) (12 ) Amortization of net actuarial loss 20 23 4 4 Net periodic benefit cost $ 27 $ 32 $ 15 $ 17 U.S. Pension Benefits Non-U.S. Pension Benefits Six months ended Six months ended (in millions) October 27, 2017 October 28, 2016 October 27, 2017 October 28, 2016 Service cost $ 58 $ 58 34 $ 38 Interest cost 60 54 14 12 Expected return on plan assets (104 ) (94 ) (26 ) (24 ) Amortization of net actuarial loss 40 46 8 8 Net periodic benefit cost $ 54 $ 64 $ 30 $ 34

Accumulated Other Comprehensi38

Accumulated Other Comprehensive (Loss) Income and Supplemental Equity Disclosure (Tables)	6 Months Ended
	Oct. 27, 2017
Equity [Abstract]
Changes in AOCI by Component	The following table provides changes in AOCI, net of tax and by component. (in millions) Unrealized Gain (Loss) on Available-for-Sale Securities Cumulative Translation Adjustment Net Change in Retirement Obligations Unrealized Gain (Loss) on Derivative Financial Instruments Total Accumulated Other Comprehensive (Loss) Income April 28, 2017 $ (69 ) $ (1,452 ) $ (1,129 ) $ 37 $ (2,613 ) Other comprehensive income (loss) before reclassifications 63 662 (19 ) (140 ) 566 Reclassifications (8 ) (34 ) 33 (4 ) (13 ) Other comprehensive income (loss) 55 628 14 (144 ) 553 October 27, 2017 $ (14 ) $ (824 ) $ (1,115 ) $ (107 ) $ (2,060 ) (in millions) Unrealized Gain (Loss) on Available-for-Sale Securities Cumulative Translation Adjustment Net Change in Retirement Obligations Unrealized Gain (Loss) on Derivative Financial Instruments Total Accumulated Other Comprehensive (Loss) Income April 29, 2016 $ (107 ) $ (474 ) $ (1,197 ) $ (90 ) $ (1,868 ) Other comprehensive income (loss) before reclassifications 88 (686 ) — 118 (480 ) Reclassifications (13 ) — 44 (11 ) 20 Other comprehensive income (loss) 75 (686 ) 44 107 (460 ) October 28, 2016 $ (32 ) $ (1,160 ) $ (1,153 ) $ 17 $ (2,328 )
Supplemental Equity Schedule	The supplemental equity schedule below presents changes in the Company's total shareholders' equity and noncontrolling interests for the six months ended October 27, 2017 and October 28, 2016 . (in millions) Total Shareholders' Equity Noncontrolling Interests Total Equity April 28, 2017 $ 50,294 $ 122 $ 50,416 Net income (loss) 3,033 (11 ) 3,022 Other comprehensive income 553 — 553 Dividends to shareholders (1,247 ) — (1,247 ) Issuance of shares under stock purchase and award plans 177 — 177 Repurchase of ordinary shares (1,835 ) — (1,835 ) Stock-based compensation 198 — 198 Cumulative effect of change in accounting principle 296 — 296 Additions (reductions) of noncontrolling ownership interests — (2 ) (2 ) October 27, 2017 $ 51,469 $ 109 $ 51,578 (in millions) Total Shareholders' Equity Noncontrolling Interests Total Equity April 29, 2016 $ 52,063 $ — $ 52,063 Net income (loss) 2,044 (4 ) 2,040 Other comprehensive loss (460 ) — (460 ) Dividends to shareholders (1,192 ) — (1,192 ) Issuance of shares under stock purchase and award plans 260 — 260 Repurchase of ordinary shares (2,794 ) — (2,794 ) Tax benefit from exercise of stock-based awards 75 — 75 Stock-based compensation 190 — 190 Additions (reductions) of noncontrolling ownership interests — 111 111 October 28, 2016 $ 50,186 $ 107 $ 50,293

Segment and Geographic Inform39

Segment and Geographic Information (Tables)	6 Months Ended
	Oct. 27, 2017
Segment Reporting [Abstract]
Net Sales by Segment	Net sales and earnings before interest expense, net, income tax (benefit) provision, and amortization of intangible assets, not including centralized distribution costs and corporate charges by reportable segments are as follows: Three months ended Six months ended (in millions) October 27, 2017 October 28, 2016 October 27, 2017 October 28, 2016 Cardiac and Vascular Group $ 2,773 $ 2,584 $ 5,419 $ 5,102 Minimally Invasive Therapies Group 1,952 2,473 4,438 4,897 Restorative Therapies Group 1,863 1,826 3,672 3,598 Diabetes Group 462 462 911 914 Net Sales $ 7,050 $ 7,345 $ 14,440 $ 14,511
Income From Operations Before Income Taxes by Reportable Segment and Reconciliation to Consolidated	Three months ended Six months ended (in millions) October 27, 2017 October 28, 2016 October 27, 2017 October 28, 2016 Cardiac and Vascular Group $ 1,104 $ 1,017 $ 2,115 $ 1,971 Minimally Invasive Therapies Group 761 886 1,636 1,710 Restorative Therapies Group 750 700 1,430 1,370 Diabetes Group 91 158 202 317 Reportable segments' EBITA before other adjustments 2,706 2,761 5,383 5,368 Amortization of intangible assets (460 ) (500 ) (914 ) (987 ) Restructuring charges, net (18 ) (47 ) (32 ) (151 ) Acquisition-related items (18 ) (28 ) (71 ) (80 ) Certain litigation charges — — — (82 ) Divestiture-related items (67 ) — (115 ) — Gain on sale of businesses 697 — 697 — Special charge (80 ) — (80 ) — Hurricane Maria (34 ) — (34 ) — Impact of inventory step-up — (38 ) — (38 ) Centralized distribution costs (486 ) (446 ) (928 ) (847 ) Interest expense, net (173 ) (173 ) (367 ) (352 ) Corporate (339 ) (317 ) (616 ) (631 ) Income before income taxes $ 1,728 $ 1,212 $ 2,923 $ 2,200
Net Sales to External Customers by Geography	Net sales to external customers by geography are as follows: Three months ended Six months ended (in millions) October 27, 2017 October 28, 2016 October 27, 2017 October 28, 2016 Americas (1) $ 4,090 $ 4,471 $ 8,457 $ 8,768 EMEA (2) 1,692 1,592 3,424 3,243 Asia-Pacific 434 890 1,691 1,712 Greater China 834 392 868 788 Net Sales $ 7,050 $ 7,345 $ 14,440 $ 14,511 (1) The U.S., which is included in the Americas, had net sales to external customers of $3.7 billion and $7.8 billion for the three and six months ended October 27, 2017 , respectively, compared to $4.2 billion and $8.2 billion for the three and six months ended October 28, 2016 , respectively. (2) EMEA consists of Europe, Middle East, and Africa. Sales to Ireland were insignificant during all periods presented.

Guarantor Financial Informati40

Guarantor Financial Information (Tables)	6 Months Ended
	Oct. 27, 2017
Condensed Financial Information of Parent Company Only Disclosure [Abstract]
Consolidating Statement of Comprehensive Income	Consolidating Statement of Comprehensive Income Three Months Ended October 27, 2017 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 300 $ — $ 7,050 $ (300 ) $ 7,050 Costs and expenses: Cost of products sold — 228 — 2,204 (312 ) 2,120 Research and development expense — 169 — 386 — 555 Selling, general, and administrative expense 3 375 — 2,060 — 2,438 Amortization of intangible assets — 2 — 458 — 460 Restructuring charges, net — — — 8 — 8 Acquisition-related items — 14 — (7 ) — 7 Divestiture-related items — 6 — 61 — 67 Gain on sale of businesses — — — (697 ) — (697 ) Special charge — 80 — — — 80 Other (income) expense, net 12 (392 ) — 491 — 111 Operating profit (loss) (15 ) (182 ) — 2,086 12 1,901 Interest income — (64 ) (103 ) (348 ) 415 (100 ) Interest expense 60 425 48 155 (415 ) 273 Interest expense, net 60 361 (55 ) (193 ) — 173 Equity in net (income) loss of subsidiaries (2,091 ) (1,809 ) (2,036 ) — 5,936 — Income before income taxes 2,016 1,266 2,091 2,279 (5,924 ) 1,728 Income tax (benefit) provision (1 ) (158 ) — (126 ) — (285 ) Net income 2,017 1,424 2,091 2,405 (5,924 ) 2,013 Net loss attributable to noncontrolling interests — — — 4 — 4 Net income attributable to Medtronic 2,017 1,424 2,091 2,409 (5,924 ) 2,017 Other comprehensive income (loss), net of tax (136 ) (308 ) (136 ) (150 ) 594 (136 ) Other comprehensive loss attributable to noncontrolling interests — — — 4 — 4 Total comprehensive income $ 1,881 $ 1,116 $ 1,955 $ 2,259 $ (5,330 ) $ 1,881 Consolidating Statement of Comprehensive Income Six Months Ended October 27, 2017 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 604 $ — $ 14,439 $ (603 ) $ 14,440 Costs and expenses: Cost of products sold — 450 — 4,638 (619 ) 4,469 Research and development expense — 327 — 776 — 1,103 Selling, general, and administrative expense 5 675 — 4,243 — 4,923 Amortization of intangible assets — 4 — 910 — 914 Restructuring charges, net — 2 — 14 — 16 Acquisition-related items — 44 — 7 — 51 Divestiture-related items — 15 — 99 — 114 Gain on sale of businesses — — — (697 ) — (697 ) Special charge — 80 — — — 80 Other (income) expense, net 25 (870 ) — 1,022 — 177 Operating profit (loss) (30 ) (123 ) — 3,427 16 3,290 Interest income — (135 ) (212 ) (679 ) 834 (192 ) Interest expense 109 865 82 337 (834 ) 559 Interest expense, net 109 730 (130 ) (342 ) — 367 Equity in net (income) loss of subsidiaries (3,169 ) (2,623 ) (3,039 ) — 8,831 — Income before income taxes 3,030 1,770 3,169 3,769 (8,815 ) 2,923 Income tax (benefit) provision (3 ) (236 ) — 140 — (99 ) Net income 3,033 2,006 3,169 3,629 (8,815 ) 3,022 Net loss attributable to noncontrolling interests — — — 11 — 11 Net income attributable to Medtronic 3,033 2,006 3,169 3,640 (8,815 ) 3,033 Other comprehensive income (loss), net of tax 553 (317 ) 553 530 (766 ) 553 Other comprehensive loss attributable to noncontrolling interests — — — 11 — 11 Total comprehensive income $ 3,586 $ 1,689 $ 3,722 $ 4,170 $ (9,581 ) $ 3,586 Consolidating Statement of Comprehensive Income Three Months Ended October 28, 2016 Medtronic Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 337 $ — $ 7,344 $ (336 ) $ 7,345 Costs and expenses: Cost of products sold — 243 — 2,412 (329 ) 2,326 Research and development expense — 158 — 396 — 554 Selling, general, and administrative expense 3 284 — 2,129 — 2,416 Amortization of intangible assets — 3 — 497 — 500 Restructuring charges, net — 1 — 46 — 47 Acquisition-related items — 37 — (9 ) — 28 Other (income) expense, net (86 ) (597 ) — 772 — 89 Operating profit (loss) 83 208 — 1,101 (7 ) 1,385 Interest income — (59 ) (165 ) (286 ) 419 (91 ) Interest expense 25 396 11 251 (419 ) 264 Interest expense, net 25 337 (154 ) (35 ) — 173 Equity in net (income) loss of subsidiaries (1,055 ) (859 ) (901 ) — 2,815 — Income before income taxes 1,113 730 1,055 1,136 (2,822 ) 1,212 Income tax (benefit) provision (2 ) 28 — 75 — 101 Net income 1,115 702 1,055 1,061 (2,822 ) 1,111 Net loss attributable to noncontrolling interests — — — 4 — 4 Net income attributable to Medtronic 1,115 702 1,055 1,065 (2,822 ) 1,115 Other comprehensive income (loss), net of tax (304 ) 47 (304 ) (329 ) 586 (304 ) Other comprehensive loss attributable to noncontrolling interests — — — 4 — 4 Total comprehensive income $ 811 $ 749 $ 751 $ 736 $ (2,236 ) $ 811 Consolidating Statement of Comprehensive Income Six Months Ended October 28, 2016 Medtronic Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Net sales $ — $ 685 $ — $ 14,510 $ (684 ) $ 14,511 Costs and expenses: Cost of products sold — 492 — 4,779 (684 ) 4,587 Research and development expense — 321 — 789 — 1,110 Selling, general, and administrative expense 6 564 — 4,274 — 4,844 Amortization of intangible assets — 6 — 981 — 987 Restructuring charges, net — 18 — 123 — 141 Certain litigation charges — — — 82 — 82 Acquisition-related items — 60 — 20 — 80 Other (income) expense, net (74 ) (1,306 ) — 1,508 — 128 Operating profit (loss) 68 530 — 1,954 — 2,552 Interest income — (121 ) (321 ) (424 ) 682 (184 ) Interest expense 41 806 12 359 (682 ) 536 Interest expense, net 41 685 (309 ) (65 ) — 352 Equity in net (income) loss of subsidiaries (2,013 ) (2,095 ) (1,704 ) — 5,812 — Income before income taxes 2,040 1,940 2,013 2,019 (5,812 ) 2,200 Income tax (benefit) provision (4 ) 50 — 114 — 160 Net income 2,044 1,890 2,013 1,905 (5,812 ) 2,040 Net loss attributable to noncontrolling interests — — — 4 — 4 Net income attributable to Medtronic 2,044 1,890 2,013 1,909 (5,812 ) 2,044 Other comprehensive income (loss), net of tax (460 ) 142 (460 ) (500 ) 818 (460 ) Other comprehensive loss attributable to noncontrolling interests — — — 4 — 4 Total comprehensive income $ 1,584 $ 2,032 $ 1,553 $ 1,409 $ (4,994 ) $ 1,584 Consolidating Statement of Comprehensive Income Three Months Ended October 27, 2017 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Net sales $ — $ — $ — $ 7,050 $ — $ 7,050 Costs and expenses: Cost of products sold — — — 2,120 — 2,120 Research and development expense — — — 555 — 555 Selling, general, and administrative expense 3 — — 2,435 — 2,438 Amortization of intangible assets — — — 460 — 460 Restructuring charges, net — — — 8 — 8 Acquisition-related items — — — 7 — 7 Divestiture-related items — — — 67 — 67 Gain on sale of businesses — — — (697 ) — (697 ) Special charge — — — 80 — 80 Other (income) expense, net 12 — — 99 — 111 Operating profit (loss) (15 ) — — 1,916 — 1,901 Interest income — (16 ) (107 ) (128 ) 151 (100 ) Interest expense 60 21 48 295 (151 ) 273 Interest expense, net 60 5 (59 ) 167 — 173 Equity in net (income) loss of subsidiaries (2,091 ) (811 ) (2,032 ) — 4,934 — Income before income taxes 2,016 806 2,091 1,749 (4,934 ) 1,728 Income tax (benefit) provision (1 ) — — (284 ) — (285 ) Net income 2,017 806 2,091 2,033 (4,934 ) 2,013 Net loss attributable to noncontrolling interests — — — 4 — 4 Net income attributable to Medtronic 2,017 806 2,091 2,037 (4,934 ) 2,017 Other comprehensive income (loss), net of tax (136 ) (295 ) (136 ) (136 ) 567 (136 ) Other comprehensive loss attributable to non-controlling interests — — — 4 — 4 Total comprehensive income $ 1,881 $ 511 $ 1,955 $ 1,901 $ (4,367 ) $ 1,881 Consolidating Statement of Comprehensive Income Six Months Ended October 27, 2017 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 14,440 $ — $ 14,440 Costs and expenses: Cost of products sold — — — 4,469 — 4,469 Research and development expense — — — 1,103 — 1,103 Selling, general, and administrative expense 5 — 1 4,917 — 4,923 Amortization of intangible assets — — — 914 — 914 Restructuring charges, net — — — 16 — 16 Acquisition-related items — — — 51 — 51 Divestiture-related items — — — 114 — 114 Gain on sale of businesses — — — (697 ) — (697 ) Special charge — — — 80 — 80 Other (income) expense, net 25 1 — 151 — 177 Operating profit (loss) (30 ) (1 ) (1 ) 3,322 — 3,290 Interest income — (32 ) (219 ) (239 ) 298 (192 ) Interest expense 109 44 82 622 (298 ) 559 Interest expense, net 109 12 (137 ) 383 — 367 Equity in net (income) loss of subsidiaries (3,169 ) (1,200 ) (3,033 ) — 7,402 — Income before income taxes 3,030 1,187 3,169 2,939 (7,402 ) 2,923 Income tax (benefit) provision (3 ) — — (96 ) — (99 ) Net income 3,033 1,187 3,169 3,035 (7,402 ) 3,022 Net loss attributable to noncontrolling interests — — — 11 — 11 Net income attributable to Medtronic 3,033 1,187 3,169 3,046 (7,402 ) 3,033 Other comprehensive loss, net of tax 553 (201 ) 553 553 (905 ) 553 Other comprehensive loss attributable to noncontrolling interests — — — 11 — 11 Total comprehensive income (loss) $ 3,586 $ 986 $ 3,722 $ 3,599 $ (8,307 ) $ 3,586 Consolidating Statement of Comprehensive Income Three Months Ended October 28, 2016 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 7,345 $ — $ 7,345 Costs and expenses: Cost of products sold — — — 2,326 — 2,326 Research and development expense — — — 554 — 554 Selling, general, and administrative expense 3 — 1 2,412 — 2,416 Amortization of intangible assets — — — 500 — 500 Restructuring charges, net — — — 47 — 47 Acquisition-related items — — — 28 — 28 Other (income) expense, net (86 ) — — 175 — 89 Operating profit (loss) 83 — (1 ) 1,303 — 1,385 Interest income — (18 ) (166 ) (102 ) 195 (91 ) Interest expense 25 23 11 400 (195 ) 264 Interest expense, net 25 5 (155 ) 298 — 173 Equity in net (income) loss of subsidiaries (1,055 ) (445 ) (901 ) — 2,401 — Income before income taxes 1,113 440 1,055 1,005 (2,401 ) 1,212 Income tax (benefit) provision (2 ) — — 103 — 101 Net income 1,115 440 1,055 902 (2,401 ) 1,111 Net loss attributable to noncontrolling interests — — — 4 — 4 Net income attributable to Medtronic 1,115 440 1,055 906 (2,401 ) 1,115 Other comprehensive income (loss), net of tax (304 ) (23 ) (304 ) (304 ) 631 (304 ) Other comprehensive loss attributable to — — — 4 — 4 Total comprehensive income $ 811 $ 417 $ 751 $ 602 $ (1,770 ) $ 811 Consolidating Statement of Comprehensive Income Six Months Ended October 28, 2016 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total Net sales $ — $ — $ — $ 14,511 $ — $ 14,511 Costs and expenses: Cost of products sold — — — 4,587 — 4,587 Research and development expense — — — 1,110 — 1,110 Selling, general, and administrative expense 6 — 1 4,837 — 4,844 Amortization of intangible assets — — — 987 — 987 Restructuring charges, net — — — 141 — 141 Certain litigation charges — — — 82 — 82 Acquisition-related items — — — 80 — 80 Other (income) expense, net (74 ) — — 202 — 128 Operating profit (loss) 68 — (1 ) 2,485 — 2,552 Interest income — (47 ) (324 ) (207 ) 394 (184 ) Interest expense 41 56 13 820 (394 ) 536 Interest expense, net 41 9 (311 ) 613 — 352 Equity in net (income) loss of subsidiaries (2,013 ) (1,249 ) (1,703 ) — 4,965 — Income before income taxes 2,040 1,240 2,013 1,872 (4,965 ) 2,200 Income tax (benefit) provision (4 ) — — 164 — 160 Net income 2,044 1,240 2,013 1,708 (4,965 ) 2,040 Net loss attributable to noncontrolling interests — — — 4 — 4 Net income attributable to Medtronic 2,044 1,240 2,013 1,712 (4,965 ) 2,044 Other comprehensive income (loss), net of tax (460 ) 19 (460 ) (460 ) 901 (460 ) Other comprehensive loss attributable to — — — 4 — 4 Total comprehensive income $ 1,584 $ 1,259 $ 1,553 $ 1,252 $ (4,064 ) $ 1,584
Condensed Consolidating Balance Sheet	Condensed Consolidating Balance Sheet October 27, 2017 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ 47 $ 822 $ 4,660 $ — $ 5,529 Investments — — — 7,997 — 7,997 Accounts receivable, net — — — 5,752 — 5,752 Inventories, net — 175 — 3,625 (162 ) 3,638 Intercompany receivable 55 — — 13,784 (13,839 ) — Other current assets 10 195 1 2,040 — 2,246 Total current assets 65 417 823 37,858 (14,001 ) 25,162 Property, plant, and equipment, net — 1,333 — 3,108 — 4,441 Goodwill — — — 39,077 — 39,077 Other intangible assets, net — 15 — 22,610 — 22,625 Tax assets — 792 — 957 — 1,749 Investment in subsidiaries 59,762 74,787 60,612 — (195,161 ) — Intercompany loans receivable 3,112 9,958 17,731 40,469 (71,270 ) — Other assets — 439 — 965 — 1,404 Total assets $ 62,939 $ 87,741 $ 79,166 $ 145,044 $ (280,432 ) $ 94,458 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ 2,000 $ 699 $ 432 $ — $ 3,131 Accounts payable — 317 — 1,401 — 1,718 Intercompany payable 11 13,828 — — (13,839 ) — Accrued compensation 6 604 — 892 — 1,502 Accrued income taxes 14 — — 858 — 872 Other accrued expenses 88 472 4 2,709 — 3,273 Total current liabilities 119 17,221 703 6,292 (13,839 ) 10,496 Long-term debt — 21,785 1,842 2,314 — 25,941 Accrued compensation and retirement benefits — 966 — 509 — 1,475 Accrued income taxes 10 1,620 — 564 — 2,194 Intercompany loans payable 11,316 14,835 23,868 21,251 (71,270 ) — Deferred tax liabilities — — — 1,841 — 1,841 Other liabilities 25 63 — 845 — 933 Total liabilities 11,470 56,490 26,413 33,616 (85,109 ) 42,880 Shareholders’ equity 51,469 31,251 52,753 111,319 (195,323 ) 51,469 Noncontrolling interests — — — 109 — 109 Total equity 51,469 31,251 52,753 111,428 (195,323 ) 51,578 Total liabilities and equity $ 62,939 $ 87,741 $ 79,166 $ 145,044 $ (280,432 ) $ 94,458 Condensed Consolidating Balance Sheet April 28, 2017 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 45 $ 5 $ 4,917 $ — $ 4,967 Investments — — — 8,741 — 8,741 Accounts receivable, net — — — 5,591 — 5,591 Inventories, net — 155 — 3,361 (178 ) 3,338 Intercompany receivable 63 — — 12,618 (12,681 ) — Other current assets 10 227 — 1,628 — 1,865 Current assets held for sale — — — 371 — 371 Total current assets 73 427 5 37,227 (12,859 ) 24,873 Property, plant, and equipment, net — 1,311 — 3,050 — 4,361 Goodwill — — — 38,515 — 38,515 Other intangible assets, net — 20 — 23,387 — 23,407 Tax assets — 727 — 782 — 1,509 Investment in subsidiaries 55,833 71,909 52,618 — (180,360 ) — Intercompany loans receivable 3,000 12,162 16,114 32,774 (64,050 ) — Other assets — 434 — 798 — 1,232 Noncurrent assets held for sale — — — 5,919 — 5,919 Total assets $ 58,906 $ 86,990 $ 68,737 $ 142,452 $ (257,269 ) $ 99,816 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ 5,000 $ 901 $ 1,619 $ — $ 7,520 Accounts payable — 304 — 1,427 — 1,731 Intercompany payable 12 12,669 — — (12,681 ) — Accrued compensation 9 734 — 1,117 — 1,860 Accrued income taxes 13 — — 620 — 633 Other accrued expenses — 352 4 2,086 — 2,442 Current liabilities held for sale — — — 34 — 34 Total current liabilities 34 19,059 905 6,903 (12,681 ) 14,220 Long-term debt — 21,782 1,842 2,297 — 25,921 Accrued compensation and retirement benefits — 1,120 — 521 — 1,641 Accrued income taxes 10 1,658 — 737 — 2,405 Intercompany loans payable 8,568 13,151 17,160 25,171 (64,050 ) — Deferred tax liabilities — — — 2,978 — 2,978 Other liabilities — 153 — 1,362 — 1,515 Noncurrent liabilities held for sale — — — 720 — 720 Total liabilities 8,612 56,923 19,907 40,689 (76,731 ) 49,400 Shareholders' equity 50,294 30,067 48,830 101,641 (180,538 ) 50,294 Noncontrolling interests — — — 122 — 122 Total equity 50,294 30,067 48,830 101,763 (180,538 ) 50,416 Total liabilities and equity $ 58,906 $ 86,990 $ 68,737 $ 142,452 $ (257,269 ) $ 99,816 Condensed Consolidating Balance Sheet October 27, 2017 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Total ASSETS Current assets: Cash and cash equivalents $ — $ — $ 823 $ 4,706 $ — $ 5,529 Investments — — — 7,997 — 7,997 Accounts receivable, net — — — 5,752 — 5,752 Inventories, net — — — 3,638 — 3,638 Intercompany receivable 55 — 60 11 (126 ) — Other current assets 10 — 1 2,235 — 2,246 Total current assets 65 — 884 24,339 (126 ) 25,162 Property, plant, and equipment, net — — — 4,441 — 4,441 Goodwill — — — 39,077 — 39,077 Other intangible assets, net — — — 22,625 — 22,625 Tax assets — — — 1,749 — 1,749 Investment in subsidiaries 59,762 35,680 59,284 — (154,726 ) — Intercompany loans receivable 3,112 2,332 19,005 23,967 (48,416 ) — Other assets — — — 1,404 — 1,404 Total assets $ 62,939 $ 38,012 $ 79,173 $ 117,602 $ (203,268 ) $ 94,458 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ — $ 699 $ 2,432 $ — $ 3,131 Accounts payable — — — 1,718 — 1,718 Intercompany payable 11 — — 115 (126 ) — Accrued compensation 6 — — 1,496 — 1,502 Accrued income taxes 14 — — 858 — 872 Other accrued expenses 88 21 8 3,156 — 3,273 Total current liabilities 119 21 707 9,775 (126 ) 10,496 Long-term debt — 2,122 1,842 21,977 — 25,941 Accrued compensation and retirement benefits — — — 1,475 — 1,475 Accrued income taxes 10 — — 2,184 — 2,194 Intercompany loans payable 11,316 1,374 23,868 11,858 (48,416 ) — Deferred tax liabilities — — — 1,841 — 1,841 Other liabilities 25 — 1 907 — 933 Total liabilities 11,470 3,517 26,418 50,017 (48,542 ) 42,880 Shareholders’ equity 51,469 34,495 52,755 67,476 (154,726 ) 51,469 Noncontrolling interests — — — 109 — 109 Total equity 51,469 34,495 52,755 67,585 (154,726 ) 51,578 Total liabilities and equity $ 62,939 $ 38,012 $ 79,173 $ 117,602 $ (203,268 ) $ 94,458 Condensed Consolidating Balance Sheet April 28, 2017 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total ASSETS Current assets: Cash and cash equivalents $ — $ 33 $ 5 $ 4,929 $ — $ 4,967 Investments — — — 8,741 — 8,741 Accounts receivable, net — — — 5,591 — 5,591 Inventories, net — — — 3,338 — 3,338 Intercompany receivable 63 — 60 12 (135 ) — Other current assets 10 — — 1,855 — 1,865 Current assets held for sale — — — 371 — 371 Total current assets 73 33 65 24,837 (135 ) 24,873 Property, plant, and equipment, net — — — 4,361 — 4,361 Goodwill — — — 38,515 — 38,515 Other intangible assets, net — — — 23,407 — 23,407 Tax assets — — — 1,509 — 1,509 Investment in subsidiaries 55,833 31,055 51,294 — (138,182 ) — Intercompany loans receivable 3,000 2,978 17,383 17,260 (40,621 ) — Other assets — — — 1,232 — 1,232 Noncurrent assets held for sale — — — 5,919 — 5,919 Total assets $ 58,906 $ 34,066 $ 68,742 $ 117,040 $ (178,938 ) $ 99,816 LIABILITIES AND EQUITY Current liabilities: Current debt obligations $ — $ 1,176 $ 901 $ 5,443 $ — $ 7,520 Accounts payable — — — 1,731 — 1,731 Intercompany payable 12 — — 123 (135 ) — Accrued compensation 9 — — 1,851 — 1,860 Accrued income taxes 13 — — 620 — 633 Other accrued expenses — 23 8 2,411 — 2,442 Current liabilities held for sale — — — 34 — 34 Total current liabilities 34 1,199 909 12,213 (135 ) 14,220 Long-term debt — 2,133 1,842 21,946 — 25,921 Accrued compensation and retirement benefits — — — 1,641 — 1,641 Accrued income taxes 10 — — 2,395 — 2,405 Intercompany loans payable 8,568 1,369 17,161 13,523 (40,621 ) — Deferred tax liabilities — — — 2,978 — 2,978 Other liabilities — — — 1,515 — 1,515 Noncurrent liabilities held for sale — — — 720 — 720 Total liabilities 8,612 4,701 19,912 56,931 (40,756 ) 49,400 Shareholders' equity 50,294 29,365 48,830 59,987 (138,182 ) 50,294 Noncontrolling interests — — — 122 — 122 Total Equity 50,294 29,365 48,830 60,109 (138,182 ) 50,416 Total liabilities and equity $ 58,906 $ 34,066 $ 68,742 $ 117,040 $ (178,938 ) $ 99,816
Condensed Consolidating Statement of Cash Flows	Condensed Consolidating Statement of Cash Flows Six Months Ended October 27, 2017 Medtronic Senior Notes and Medtronic Luxco Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Total Operating Activities: Net cash provided by (used in) operating activities $ 269 $ (743 ) $ 128 $ 1,990 $ — $ 1,644 Investing Activities: Acquisitions, net of cash acquired — — — (76 ) — (76 ) Proceeds from sale of businesses — — — 6,058 — 6,058 Additions to property, plant, and equipment — (132 ) — (392 ) — (524 ) Purchases of investments — — — (1,685 ) — (1,685 ) Sales and maturities of investments — — — 2,354 — 2,354 Net (increase) decrease in intercompany loans (112 ) 2,204 (1,617 ) (7,695 ) 7,220 — Capital contribution paid — (12 ) (4,200 ) — 4,212 — Other investing activities, net — — — (2 ) — (2 ) Net cash provided by (used in) investing activities (112 ) 2,060 (5,817 ) (1,438 ) 11,432 6,125 Financing Activities: Acquisition-related contingent consideration — — — (39 ) — (39 ) Change in current debt obligations, net — — (202 ) 12 — (190 ) Issuance of long-term debt — — — 20 — 20 Payments on long-term debt — (3,000 ) — (1,161 ) — (4,161 ) Dividends to shareholders (1,247 ) — — — — (1,247 ) Issuance of ordinary shares 230 — — — — 230 Repurchase of ordinary shares (1,888 ) — — — — (1,888 ) Net intercompany loan borrowings (repayments) 2,748 1,685 6,708 (3,921 ) (7,220 ) — Capital contribution received — — — 4,212 (4,212 ) — Other financing activities — — — (2 ) — (2 ) Net cash provided by (used in) financing activities (157 ) (1,315 ) 6,506 (879 ) (11,432 ) (7,277 ) Effect of exchange rate changes on cash and cash equivalents — — — 70 — 70 Net change in cash and cash equivalents — 2 817 (257 ) — 562 Cash and cash equivalents at beginning of period — 45 5 4,917 — 4,967 Cash and cash equivalents at end of period $ — $ 47 $ 822 $ 4,660 $ — $ 5,529 Condensed Consolidating Statement of Cash Flows Six Months Ended October 28, 2016 Medtronic Senior Notes (in millions) Medtronic plc Medtronic, Inc. Medtronic Luxco Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ 644 $ 513 $ 163 $ 1,702 $ — $ 3,022 Investing Activities: Acquisitions, net of cash acquired — (918 ) — (388 ) — (1,306 ) Additions to property, plant, and equipment — (161 ) — (437 ) — (598 ) Purchases of investments — — — (2,272 ) 162 (2,110 ) Sales and maturities of investments — 210 — 3,577 (162 ) 3,625 Net (increase) decrease in intercompany loans — 496 (2,117 ) (1,855 ) 3,476 — Capital contribution paid — (233 ) — — 233 — Other investing activities, net — — — 32 — 32 Net cash provided by (used in) investing activities — (606 ) (2,117 ) (1,343 ) 3,709 (357 ) Financing Activities: Acquisition-related contingent consideration — — — (36 ) — (36 ) Change in current debt obligations, net — — 1,130 24 — 1,154 Proceeds from current debt obligations (maturities greater than 90 days) — — 4 — — 4 Issuance of long-term debt — — — 131 — 131 Payments on long-term debt — — — (252 ) — (252 ) Dividends to shareholders (1,192 ) — — — — (1,192 ) Issuance of ordinary shares 260 — — — — 260 Repurchase of ordinary shares (2,794 ) — — — — (2,794 ) Net intercompany loan borrowings (repayments) 3,082 109 928 (643 ) (3,476 ) — Capital contribution received — — — 233 (233 ) — Other financing activities — — — 74 — 74 Net cash provided by (used in) financing activities (644 ) 109 2,062 (469 ) (3,709 ) (2,651 ) Effect of exchange rate changes on cash and cash equivalents — — — 64 — 64 Net change in cash and cash equivalents — 16 108 (46 ) — 78 Cash and cash equivalents at beginning of period — 55 — 2,821 — 2,876 Cash and cash equivalents at end of period $ — $ 71 $ 108 $ 2,775 $ — $ 2,954 Condensed Consolidating Statement of Cash Flows Six Months Ended October 27, 2017 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ 269 $ 997 $ 135 $ 1,291 $ (1,048 ) $ 1,644 Investing Activities: Acquisitions, net of cash acquired — — — (76 ) — (76 ) Proceeds from sale of businesses — — — 6,058 — 6,058 Additions to property, plant, and equipment — — — (524 ) — (524 ) Purchases of investments — — — (1,685 ) — (1,685 ) Sales and maturities of investments — — — 2,354 — 2,354 Net (increase) decrease in intercompany loans (112 ) 646 (1,622 ) (6,707 ) 7,795 — Capital contribution paid — (531 ) (4,200 ) — 4,731 — Other investing activities, net — — — (2 ) — (2 ) Net cash provided by (used in) investing activities (112 ) 115 (5,822 ) (582 ) 12,526 6,125 Financing Activities: Acquisition-related contingent consideration — — — (39 ) — (39 ) Change in current debt obligations, net — — (202 ) 12 — (190 ) Issuance of long-term debt — — — 20 — 20 Payments on long-term debt — (1,150 ) — (3,011 ) — (4,161 ) Dividends to shareholders (1,247 ) — — — — (1,247 ) Issuance of ordinary shares 230 — — — — 230 Repurchase of ordinary shares (1,888 ) — — — — (1,888 ) Net intercompany loan borrowings (repayments) 2,748 5 6,707 (1,665 ) (7,795 ) — Intercompany dividend paid — — — (1,048 ) 1,048 — Capital contribution received — — — 4,731 (4,731 ) — Other financing activities — — — (2 ) — (2 ) Net cash provided by (used in) financing activities (157 ) (1,145 ) 6,505 (1,002 ) (11,478 ) (7,277 ) Effect of exchange rate changes on cash and cash equivalents — — — 70 — 70 Net change in cash and cash equivalents — (33 ) 818 (223 ) — 562 Cash and cash equivalents at beginning of period — 33 5 4,929 — 4,967 Cash and cash equivalents at end of period $ — $ — $ 823 $ 4,706 $ — $ 5,529 Condensed Consolidating Statement of Cash Flows Six Months Ended October 28, 2016 CIFSA Senior Notes (in millions) Medtronic plc CIFSA CIFSA Subsidiary Guarantors Subsidiary Non-guarantors Consolidating Adjustments Total Operating Activities: Net cash provided by (used in) operating activities $ 644 $ 879 $ 162 $ 2,257 $ (920 ) $ 3,022 Investing Activities: Acquisitions, net of cash acquired — — — (1,306 ) — (1,306 ) Additions to property, plant, and equipment — — — (598 ) — (598 ) Purchases of investments — — — (2,110 ) — (2,110 ) Sales and maturities of investments — — — 3,625 — 3,625 Net (increase) decrease in intercompany loans — 3,198 (2,117 ) 2,707 (3,788 ) — Capital contributions paid — (325 ) — — 325 — Other investing activities, net — — — 32 — 32 Net cash provided by (used in) investing activities — 2,873 (2,117 ) 2,350 (3,463 ) (357 ) Financing Activities: Acquisition-related contingent consideration — — — (36 ) — (36 ) Change in current debt obligations, net — — 1,130 24 — 1,154 Proceeds from current debt obligations (maturities greater than 90 days) — — 4 — — 4 Issuance of long-term debt — — — 131 — 131 Payments on long-term debt — — — (252 ) — (252 ) Dividends to shareholders (1,192 ) — — — — (1,192 ) Issuance of ordinary shares 260 — — — — 260 Repurchase of ordinary shares (2,794 ) — — — — (2,794 ) Net intercompany loan borrowings (repayments) 3,082 (3,634 ) 929 (4,165 ) 3,788 — Intercompany dividend paid — — — (920 ) 920 — Capital contributions received — — — 325 (325 ) — Other financing activities — — — 74 — 74 Net cash provided by (used in) financing activities (644 ) (3,634 ) 2,063 (4,819 ) 4,383 (2,651 ) Effect of exchange rate changes on cash and cash equivalents — — — 64 — 64 Net change in cash and cash equivalents — 118 108 (148 ) — 78 Cash and cash equivalents at beginning of period — 208 — 2,668 — 2,876 Cash and cash equivalents at end of period $ — $ 326 $ 108 $ 2,520 $ — $ 2,954

New Accounting Pronouncements (

New Accounting Pronouncements (Details) - USD ($)	3 Months Ended	6 Months Ended
	Oct. 27, 2017	Oct. 27, 2017	Jul. 28, 2017	Apr. 28, 2017
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of change in accounting principle				$ 296,000,000
Accounting Standards Update 2016-09
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase (decrease) to net income	$ 17,000,000	$ 41,000,000
Increase (decrease) to diluted earnings per share (in dollars per share)	$ 0.01	$ 0.03
Accounting Standards Update 2016-09 | Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of change in accounting principle			$ 0
Accounting Standards Update 2016-16
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Increase (decrease) to net income	$ 582,000,000	$ 557,000,000
Increase (decrease) to diluted earnings per share (in dollars per share)	$ 0.43	$ 0.41
Accounting Standards Update 2016-16 | Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative effect of change in accounting principle			$ 296,000,000

Acquisitions and Acquisition-42

Acquisitions and Acquisition-Related Items - Fair Value of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Millions	Oct. 27, 2017	Apr. 28, 2017	Aug. 23, 2016
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Goodwill	$ 39,077	$ 38,515
Heartware International, Inc.
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Other current assets			$ 351
Property, plant, and equipment			14
Other intangible assets			625
Goodwill			481
Other assets			84
Total assets acquired			1,555
Current liabilities			143
Deferred tax liabilities			6
Long-term debt			245
Other liabilities			89
Total liabilities assumed			483
Net assets acquired			$ 1,072
All Other
Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract]
Other current assets	2
Property, plant, and equipment	6
Other intangible assets	68
Goodwill	15
Other assets	0
Total assets acquired	91
Current liabilities	1
Deferred tax liabilities	0
Long-term debt	0
Other liabilities	0
Total liabilities assumed	1
Net assets acquired	$ 90

Acquisitions and Acquisition-43

Acquisitions and Acquisition-Related Items - Fair Value Measurement, Contingent Consideration, Significant Unobservable Inputs (Details) - USD ($) $ in Millions	6 Months Ended
	Oct. 27, 2017	Jul. 28, 2017	Apr. 28, 2017	Oct. 28, 2016	Jul. 29, 2016	Apr. 29, 2016
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration, fair value	$ 190	$ 242	$ 246	$ 285	$ 379	$ 377
Revenue-based payments | Recurring | Level 3 | Discounted cash flow
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration, fair value	$ 85
Revenue-based payments | Minimum | Recurring | Level 3 | Discounted cash flow
Fair Value Inputs
Discount rate	11.00%
Probability of payment	30.00%
Revenue-based payments | Maximum | Recurring | Level 3 | Discounted cash flow
Fair Value Inputs
Discount rate	32.50%
Probability of payment	100.00%
Product development and other milestone-based payments | Recurring | Level 3 | Discounted cash flow
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Contingent consideration, fair value	$ 105
Product development and other milestone-based payments | Minimum | Recurring | Level 3 | Discounted cash flow
Fair Value Inputs
Discount rate	0.70%
Probability of payment	50.00%
Product development and other milestone-based payments | Maximum | Recurring | Level 3 | Discounted cash flow
Fair Value Inputs
Discount rate	5.50%
Probability of payment	100.00%

Acquisitions and Acquisition-44

Acquisitions and Acquisition-Related Items - Reconciliation of Beginning and Ending Balances of Contingent Consideration (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 27, 2017	Oct. 28, 2016	Oct. 27, 2017	Oct. 28, 2016
Reconciliation of Beginning and Ending Balances of Contingent Milestone Payments Associated with Acquisitions [Roll Forward]
Beginning Balance	$ 242	$ 379	$ 246	$ 377
Purchase price contingent consideration	15	11	15	32
Payments	(43)	(25)	(46)	(39)
Change in fair value	(24)	(80)	(25)	(85)
Ending Balance	$ 190	$ 285	$ 190	$ 285

Acquisitions and Acquisition-45

Acquisitions and Acquisition-Related Items - Narrative (Details) - USD ($) $ in Millions	Aug. 23, 2016	Oct. 27, 2017	Oct. 28, 2016	Apr. 24, 2015	Oct. 27, 2017	Oct. 28, 2016	Jul. 28, 2017	Apr. 28, 2017	Aug. 31, 2016	Jul. 29, 2016	Apr. 29, 2016
Business Acquisition [Line Items]
Goodwill		$ 39,077			$ 39,077			$ 38,515
Cost of products sold		2,120	$ 2,326		4,469	$ 4,587
Acquisition-related items		7	28		51	80
Fair value of contingent consideration		190	285		190	285	$ 242	246		$ 379	$ 377
Other liabilities
Business Acquisition [Line Items]
Fair value of contingent consideration		70			70			180
Other accrued expenses
Business Acquisition [Line Items]
Fair value of contingent consideration		120			120			$ 66
Heartware International, Inc.
Business Acquisition [Line Items]
Acquisition consideration	$ 1,100
Other intangible assets	625
Goodwill	481
Long-term debt	245
Debt Instrument, Repurchase Amount									$ 203
Heartware International, Inc. | Bank borrowings | Debt due December 2017
Business Acquisition [Line Items]
Long-term debt	42
Heartware International, Inc. | Customer-related and technology-related
Business Acquisition [Line Items]
Other intangible assets	$ 602
Estimated useful lives	15 years
Heartware International, Inc. | Tradenames
Business Acquisition [Line Items]
Other intangible assets	$ 23
Estimated useful lives	5 years
Covidien plc
Business Acquisition [Line Items]
Acquisition-related items				$ 50,000
All Other
Business Acquisition [Line Items]
Other intangible assets		68			68
Goodwill		15			15
Long-term debt		0			0
Acquisition-related items and other		18			71
Cost of products sold		11			20
Acquisition-related items		$ 44			$ 90
Integration costs			59			102
Accelerated and incremental stock compensation expense			$ 9			$ 16

Divestiture and Divestiture-R46

Divestiture and Divestiture-Related Items (Details)	Jul. 29, 2017USD ($)site	Oct. 27, 2017USD ($)	Oct. 28, 2016USD ($)	Oct. 27, 2017USD ($)	Oct. 28, 2016USD ($)	Apr. 28, 2017USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of businesses				$ 6,058,000,000	$ 0
Gain on sale of businesses		$ (697,000,000)	$ 0	(697,000,000)	0
Divestiture-related items		67,000,000	$ 0	114,000,000	$ 0
Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from sale of businesses	$ 6,100,000,000
Gain on sale of businesses	$ (697,000,000)
Sale of businesses, number of dedicated manufacturing sites | site	17
Sale of businesses, transitional agreement, manufacture and supply services, term	5 years
Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency Business | Disposal Group, Held-for-sale, Not Discontinued Operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Inventories, net						$ 371,000,000
Property, plant, and equipment, net						689,000,000
Goodwill						2,910,000,000
Other intangible assets, net						2,320,000,000
Total assets held for sale						6,290,000,000
Other accrued expenses						34,000,000
Accrued compensation and retirement benefits						12,000,000
Deferred tax liabilities						707,000,000
Other liabilities						1,000,000
Total liabilities held for sale						$ 754,000,000
Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency Business | Disposal group, disposed of by sale, not discontinued operations
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Divestiture-related items		$ 67,000,000
Accelerated and incremental stock compensation expense				$ 16,000,000
Maximum | Patient Care, Deep Vein Thrombosis, and Nutritional Insufficiency Business
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Sale of businesses, transitional agreement, administrative services, term	12 months

Special Charge (Details)

Special Charge (Details) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 27, 2017	Oct. 28, 2016	Oct. 27, 2017	Oct. 28, 2016
Commitments and Contingencies Disclosure [Abstract]
Special charge	$ 80,000,000	$ 0	$ 80,000,000	$ 0

Restructuring Charges - Restruc

Restructuring Charges - Restructuring Reserve (Details) - Cost Synergies Initiative - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 27, 2017	Oct. 28, 2016	Oct. 27, 2017	Oct. 28, 2016
Restructuring Reserve [Roll Forward]
Beginning balance			$ 291
Charges	$ 26	$ 47	45	$ 158
Cash payments			(111)
Accrual adjustments	(8)		(13)	$ (7)
Ending balance	212		212
Employee Termination Costs
Restructuring Reserve [Roll Forward]
Beginning balance			261
Charges			25
Cash payments			(85)
Accrual adjustments			(14)
Ending balance	187		187
Other Costs
Restructuring Reserve [Roll Forward]
Beginning balance			30
Charges			20
Cash payments			(26)
Accrual adjustments			1
Ending balance	$ 25		$ 25

Restructuring Charges - Narrati

Restructuring Charges - Narrative (Details) - Cost Synergies Initiative - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 27, 2017	Oct. 28, 2016	Oct. 27, 2017	Oct. 28, 2016
Restructuring Cost and Reserve [Line Items]
Charges	$ 26	$ 47	$ 45	$ 158
Accrual (reversal of accrual) for restructuring reserves	(8)		(13)	(7)
Restructuring reserve, payments and write-downs			111
Cost of products sold
Restructuring Cost and Reserve [Line Items]
Charges	7		12
Selling, general, and administrative expense
Restructuring Cost and Reserve [Line Items]
Charges	$ 3		4
Covidien plc
Restructuring Cost and Reserve [Line Items]
Expected cost synergies			$ 850
Impairment of property, plant, and equipment
Restructuring Cost and Reserve [Line Items]
Restructuring reserve, payments and write-downs		3		7
Inventory write-offs | Cost of products sold
Restructuring Cost and Reserve [Line Items]
Restructuring reserve, payments and write-downs		$ 10		$ 10

Financial Instruments - Investm

Financial Instruments - Investments by Category and Related Balance Sheet Classification (Details) - USD ($) $ in Millions	Oct. 27, 2017	Apr. 28, 2017
Total available-for sale securities and investments measured at net asset value:
Cost	$ 8,280	$ 9,008
Unrealized Gains	194	127
Unrealized Losses	(234)	(246)
Fair Value	8,240	8,889
Cost method, equity method, and other investments:
Cost	626	589
Total investments [Abstract]
Cost	8,906	9,597
Unrealized Gains	194	127
Unrealized Losses	(234)	(246)
Fair Value	8,240	8,889
Investments
Total available-for sale securities and investments measured at net asset value:
Fair Value	7,997	8,741
Cost method, equity method, and other investments:
Cost	0	0
Total investments [Abstract]
Fair Value	7,997	8,741
Other Assets
Total available-for sale securities and investments measured at net asset value:
Fair Value	243	148
Cost method, equity method, and other investments:
Cost	626	589
Total investments [Abstract]
Fair Value	869	737
Level 1
Available-for-sale securities:
Cost	697	671
Unrealized Gains	116	51
Unrealized Losses	(9)	(9)
Fair Value	804	713
Level 1 | Investments
Available-for-sale securities:
Fair Value	606	610
Level 1 | Other Assets
Available-for-sale securities:
Fair Value	198	103
Level 2
Available-for-sale securities:
Cost	7,135	7,792
Unrealized Gains	78	76
Unrealized Losses	(216)	(228)
Fair Value	6,997	7,640
Level 2 | Investments
Available-for-sale securities:
Fair Value	6,997	7,640
Level 2 | Other Assets
Available-for-sale securities:
Fair Value	0	0
Level 3
Available-for-sale securities:
Cost	48	48
Unrealized Gains	0	0
Unrealized Losses	(3)	(3)
Fair Value	45	45
Cost method, equity method, and other investments:
Cost	626	589
Level 3 | Investments
Available-for-sale securities:
Fair Value	0	0
Cost method, equity method, and other investments:
Cost	0	0
Level 3 | Other Assets
Available-for-sale securities:
Fair Value	45	45
Cost method, equity method, and other investments:
Cost	626	589
U.S. government and agency securities | Level 1
Available-for-sale securities:
Cost	613	613
Unrealized Gains	1	2
Unrealized Losses	(8)	(5)
Fair Value	606	610
U.S. government and agency securities | Level 1 | Investments
Available-for-sale securities:
Fair Value	606	610
U.S. government and agency securities | Level 1 | Other Assets
Available-for-sale securities:
Fair Value	0	0
U.S. government and agency securities | Level 2
Available-for-sale securities:
Cost	870	860
Unrealized Gains	0	0
Unrealized Losses	(12)	(10)
Fair Value	858	850
U.S. government and agency securities | Level 2 | Investments
Available-for-sale securities:
Fair Value	858	850
U.S. government and agency securities | Level 2 | Other Assets
Available-for-sale securities:
Fair Value	0	0
Marketable equity securities | Other Assets
Available-for-sale securities:
Fair Value	198	103
Marketable equity securities | Level 1
Available-for-sale securities:
Cost	84	58
Unrealized Gains	115	49
Unrealized Losses	(1)	(4)
Fair Value	198	103
Marketable equity securities | Level 1 | Investments
Available-for-sale securities:
Fair Value	0	0
Marketable equity securities | Level 1 | Other Assets
Available-for-sale securities:
Fair Value	198	103
Corporate debt securities | Level 2
Available-for-sale securities:
Cost	4,165	4,643
Unrealized Gains	64	62
Unrealized Losses	(16)	(23)
Fair Value	4,213	4,682
Corporate debt securities | Level 2 | Investments
Available-for-sale securities:
Fair Value	4,213	4,682
Corporate debt securities | Level 2 | Other Assets
Available-for-sale securities:
Fair Value	0	0
Corporate debt securities | Level 3
Available-for-sale securities:
Cost	1	1
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	1	1
Corporate debt securities | Level 3 | Investments
Available-for-sale securities:
Fair Value	0	0
Corporate debt securities | Level 3 | Other Assets
Available-for-sale securities:
Fair Value	1	1
Mortgage-backed securities | Level 2
Available-for-sale securities:
Cost	768	766
Unrealized Gains	7	9
Unrealized Losses	(19)	(16)
Fair Value	756	759
Mortgage-backed securities | Level 2 | Investments
Available-for-sale securities:
Fair Value	756	759
Mortgage-backed securities | Level 2 | Other Assets
Available-for-sale securities:
Fair Value	0	0
Foreign government and agency securities | Level 2
Available-for-sale securities:
Cost	52	49
Unrealized Gains	0	0
Unrealized Losses	0	0
Fair Value	52	49
Foreign government and agency securities | Level 2 | Investments
Available-for-sale securities:
Fair Value	52	49
Foreign government and agency securities | Level 2 | Other Assets
Available-for-sale securities:
Fair Value	0	0
Other asset-backed securities | Level 2
Available-for-sale securities:
Cost	341	228
Unrealized Gains	1	1
Unrealized Losses	(1)	(1)
Fair Value	341	228
Other asset-backed securities | Level 2 | Investments
Available-for-sale securities:
Fair Value	341	228
Other asset-backed securities | Level 2 | Other Assets
Available-for-sale securities:
Fair Value	0	0
Debt funds
Investments measured at net asset value:
Cost	400	497
Unrealized Gains	0	0
Unrealized Losses	(6)	(6)
Fair Value	394	491
Debt funds | Investments
Investments measured at net asset value:
Fair Value	394	491
Debt funds | Other Assets
Investments measured at net asset value:
Fair Value	0	0
Debt funds | Level 2
Available-for-sale securities:
Cost	939	1,246
Unrealized Gains	6	4
Unrealized Losses	(168)	(178)
Fair Value	777	1,072
Debt funds | Level 2 | Investments
Available-for-sale securities:
Fair Value	777	1,072
Debt funds | Level 2 | Other Assets
Available-for-sale securities:
Fair Value	0	0
Auction rate securities | Level 3
Available-for-sale securities:
Cost	47	47
Unrealized Gains	0	0
Unrealized Losses	(3)	(3)
Fair Value	44	44
Auction rate securities | Level 3 | Investments
Available-for-sale securities:
Fair Value	0	0
Auction rate securities | Level 3 | Other Assets
Available-for-sale securities:
Fair Value	$ 44	$ 44

Financial Instruments - Availab

Financial Instruments - Available-For-Sale Securities in Continuous Unrealized Loss Position (Details) - USD ($) $ in Millions	Oct. 27, 2017	Apr. 28, 2017
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	$ 2,327	$ 2,749
Less than 12 months, Unrealized Losses	(30)	(43)
More than 12 months, Fair Value	1,526	1,312
More than 12 months, Unrealized Losses	(204)	(203)
Corporate debt securities
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	946	1,263
Less than 12 months, Unrealized Losses	(9)	(19)
More than 12 months, Fair Value	209	46
More than 12 months, Unrealized Losses	(7)	(4)
Auction rate securities
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	0	0
Less than 12 months, Unrealized Losses	0	0
More than 12 months, Fair Value	44	44
More than 12 months, Unrealized Losses	(3)	(3)
Mortgage-backed securities
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	296	276
Less than 12 months, Unrealized Losses	(4)	(4)
More than 12 months, Fair Value	97	95
More than 12 months, Unrealized Losses	(15)	(12)
U.S. government and agency securities
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	877	896
Less than 12 months, Unrealized Losses	(15)	(15)
More than 12 months, Fair Value	216	0
More than 12 months, Unrealized Losses	(5)	0
Debt funds
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	7	173
Less than 12 months, Unrealized Losses	(1)	(1)
More than 12 months, Fair Value	958	1,125
More than 12 months, Unrealized Losses	(173)	(183)
Other asset-backed securities
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	201	127
Less than 12 months, Unrealized Losses	(1)	(1)
More than 12 months, Fair Value	0	0
More than 12 months, Unrealized Losses	0	0
Marketable equity securities
AFS Continuous Unrealized Loss Position
Less than 12 months, Fair Value	0	14
Less than 12 months, Unrealized Losses	0	(3)
More than 12 months, Fair Value	2	2
More than 12 months, Unrealized Losses	$ (1)	$ (1)

Financial Instruments - Unobser

Financial Instruments - Unobservable Inputs, and Items Measured at Fair Value on a Recurring Basis that Used Significant Unobservable Inputs (Level 3) (Details) - Recurring - Level 3 - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 27, 2017	Oct. 28, 2016	Oct. 27, 2017	Oct. 28, 2016
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 45	$ 45	$ 45	$ 45
Total unrealized gains (losses) included in other comprehensive income	0	0	0	0
Ending balance	45	45	45	45
Corporate debt securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	1	1	1	1
Total unrealized gains (losses) included in other comprehensive income	0	0	0	0
Ending balance	1	1	1	1
Auction rate securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	44	44	44	44
Total unrealized gains (losses) included in other comprehensive income	0	0	0	0
Ending balance	$ 44	$ 44	$ 44	$ 44
Discounted cash flow | Auction rate securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Years to principal recovery			3 years
Illiquidity premium			6.00%
Minimum | Discounted cash flow | Auction rate securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Years to principal recovery			2 years
Maximum | Discounted cash flow | Auction rate securities
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Years to principal recovery			12 years

Financial Instruments - Activit

Financial Instruments - Activity Related to the Company's Investment Portfolio and Available-for-sale Debt Securities Contractual Maturities (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 27, 2017	Oct. 28, 2016	Oct. 27, 2017	Oct. 28, 2016
AFS Debt Maturities
Due in one year or less	$ 865		$ 865
Due after one year through five years	2,601		2,601
Due after five years through ten years	3,298		3,298
Due after ten years	107		107
Total	6,871		6,871
Debt
AFS Gross Realized Gain (Loss)
Proceeds from sales	1,383	$ 2,444	2,354	$ 3,542
Gross realized gains	11	57	19	64
Gross realized losses	(12)	(37)	(15)	(49)
Impairment losses recognized	0	0	0	0
Equity
AFS Gross Realized Gain (Loss)
Proceeds from sales	0	76	0	82
Gross realized gains	0	25	7	29
Gross realized losses	0	0	0	0
Impairment losses recognized	$ (1)	$ (7)	$ (1)	$ (10)

Financial Instruments - Narrati

Financial Instruments - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 27, 2017	Oct. 28, 2016	Oct. 27, 2017	Oct. 28, 2016	Apr. 28, 2017
Schedule of Investments [Line Items]
Carrying amount of cost and equity method investments	$ 626,000,000		$ 626,000,000		$ 589,000,000
Impairment, cost method investments	0	$ 7,000,000	0	$ 10,000,000
Other assets
Schedule of Investments [Line Items]
Carrying amount of cost and equity method investments	626,000,000		626,000,000		589,000,000
Debt securities
Schedule of Investments [Line Items]
Credit loss portion of other-than-temporary impairments	0		0		0
Reductions for available-for-sale securities sold	0	0	0	0
Marketable equity securities | Other expense, net
Schedule of Investments [Line Items]
Impairment charges, marketable securities	0	$ 0	0	$ 0
Marketable equity securities | Other assets
Schedule of Investments [Line Items]
Marketable securities	$ 198,000,000		$ 198,000,000		$ 103,000,000

Financing Arrangements - Long-T

Financing Arrangements - Long-Term Debt (Details) - USD ($) $ in Millions	6 Months Ended
	Oct. 27, 2017	Apr. 28, 2017
Debt Instrument [Line Items]
Current debt obligations	$ 3,131	$ 7,520
Long-term debt
Debt premium, net	127	135
Deferred financing costs	(119)	(128)
Long-term debt	$ 25,941	25,921
Senior notes | 5.600 percent ten-year 2009 senior notes
Long-term debt
Stated interest rate	5.60%
Term of debt instrument	10 years
Long-term debt, gross	$ 400	400
Senior notes | 1.700 percent two-year 2017 senior notes
Long-term debt
Stated interest rate	1.70%
Term of debt instrument	2 years
Long-term debt, gross	$ 1,000	1,000
Senior notes | 4.450 percent ten-year 2010 senior notes
Long-term debt
Stated interest rate	4.45%
Term of debt instrument	10 years
Long-term debt, gross	$ 766	766
Senior notes | 2.500 percent five-year 2015 senior notes
Long-term debt
Stated interest rate	2.50%
Term of debt instrument	5 years
Long-term debt, gross	$ 2,500	2,500
Senior notes | Floating rate five-year 2015 senior notes
Long-term debt
Term of debt instrument	5 years
Long-term debt, gross	$ 500	500
Senior notes | 4.200 percent ten-year 2010 CIFSA senior notes
Long-term debt
Stated interest rate	4.20%
Term of debt instrument	10 years
Long-term debt, gross	$ 600	600
Senior notes | 4.125 percent ten-year 2011 senior notes
Long-term debt
Stated interest rate	4.125%
Term of debt instrument	10 years
Long-term debt, gross	$ 500	500
Senior notes | 3.125 percent ten-year 2012 senior notes
Long-term debt
Stated interest rate	3.125%
Term of debt instrument	10 years
Long-term debt, gross	$ 675	675
Senior notes | 3.150 percent seven-year 2015 senior notes
Long-term debt
Stated interest rate	3.15%
Term of debt instrument	7 years
Long-term debt, gross	$ 2,500	2,500
Senior notes | 3.200 percent ten-year 2012 CIFSA senior notes
Long-term debt
Stated interest rate	3.20%
Term of debt instrument	10 years
Long-term debt, gross	$ 650	650
Senior notes | 2.750 percent ten-year 2013 senior notes
Long-term debt
Stated interest rate	2.75%
Term of debt instrument	10 years
Long-term debt, gross	$ 530	530
Senior notes | 2.950 percent ten-year 2013 CIFSA senior notes
Long-term debt
Stated interest rate	2.95%
Term of debt instrument	10 years
Long-term debt, gross	$ 310	310
Senior notes | 3.625 percent ten-year 2014 senior notes
Long-term debt
Stated interest rate	3.625%
Term of debt instrument	10 years
Long-term debt, gross	$ 850	850
Senior notes | 3.500 percent ten-year 2015 senior notes
Long-term debt
Stated interest rate	3.50%
Term of debt instrument	10 years
Long-term debt, gross	$ 4,000	4,000
Senior notes | 3.350 percent ten-year 2017 senior notes
Long-term debt
Stated interest rate	3.35%
Term of debt instrument	10 years
Long-term debt, gross	$ 850	850
Senior notes | 4.375 percent twenty-year 2015 senior notes
Long-term debt
Stated interest rate	4.375%
Term of debt instrument	20 years
Long-term debt, gross	$ 2,382	2,382
Senior notes | 6.550 percent thirty-year 2008 CIFSA senior notes
Long-term debt
Stated interest rate	6.55%
Term of debt instrument	30 years
Long-term debt, gross	$ 374	374
Senior notes | 6.500 percent thirty-year 2009 senior notes
Long-term debt
Stated interest rate	6.50%
Term of debt instrument	30 years
Long-term debt, gross	$ 300	300
Senior notes | 5.550 percent thirty-year 2010 senior notes
Long-term debt
Stated interest rate	5.55%
Term of debt instrument	30 years
Long-term debt, gross	$ 500	500
Senior notes | 4.500 percent thirty-year 2012 senior notes
Long-term debt
Stated interest rate	4.50%
Term of debt instrument	30 years
Long-term debt, gross	$ 400	400
Senior notes | 4.000 percent thirty-year 2013 senior notes
Long-term debt
Stated interest rate	4.00%
Term of debt instrument	30 years
Long-term debt, gross	$ 325	325
Senior notes | 4.625 percent thirty-year 2014 senior notes
Long-term debt
Stated interest rate	4.625%
Term of debt instrument	30 years
Long-term debt, gross	$ 650	650
Senior notes | 4.625 percent thirty-year 2015 senior notes
Long-term debt
Stated interest rate	4.625%
Term of debt instrument	30 years
Long-term debt, gross	$ 4,150	4,150
Interest rate swaps
Long-term debt
Long-term debt, gross	30	40
Capital lease obligations
Long-term debt
Capital lease obligations	22	23
Bank borrowings
Long-term debt
Long-term debt, gross	$ 169	$ 139

Financing Arrangements - Narrat

Financing Arrangements - Narrative (Details) - USD ($)	3 Months Ended	6 Months Ended
	Oct. 27, 2017	Oct. 27, 2017	Apr. 28, 2017
Debt Instrument, Fair Value Disclosure [Abstract]
Long-term debt, including the current portion, fair value	$ 29,500,000,000	$ 29,500,000,000	$ 30,400,000,000
Long-term debt, including the current portion, principal value	27,800,000,000	27,800,000,000	28,900,000,000
2015 Commercial Paper Program | Commercial Paper
Commercial Paper [Abstract]
Commercial paper, maximum borrowing amount	3,500,000,000	3,500,000,000
Commercial paper, amount outstanding	$ 700,000,000	$ 700,000,000	901,000,000
Weighted average original maturity	30 days	31 days
Weighted average interest rate	1.31%	1.27%
Amended and Restated Revolving Credit Agreement | Line of Credit
Line of Credit Facility
Line of credit, maximum capacity	$ 3,500,000,000	$ 3,500,000,000
Term of debt instrument		5 years
Line of credit, amount outstanding	$ 0	$ 0	$ 0

Derivatives and Currency Exch57

Derivatives and Currency Exchange Risk Management - Gains (Losses) on Derivatives and Amounts Reclassified into Income (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 27, 2017	Oct. 28, 2016	Oct. 27, 2017	Oct. 28, 2016
Cash flow hedging
Derivative Instruments, Gain (Loss) [Line Items]
Recognized in AOCI	$ 30	$ 69	$ (220)	$ 190
Recognized in Income	(10)	6	12	22
Currency exchange rate contracts | Cash flow hedging
Derivative Instruments, Gain (Loss) [Line Items]
Recognized in AOCI	30	69	(220)	190
Other expense, net | Currency exchange rate contracts
Derivative Instruments, Gain (Loss) [Line Items]
Currency exchange rate contract losses	42	38	137	41
Other expense, net | Currency exchange rate contracts | Cash flow hedging
Derivative Instruments, Gain (Loss) [Line Items]
Recognized in Income	$ (10)	$ 6	$ 12	$ 22

Derivatives and Currency Exch58

Derivatives and Currency Exchange Risk Management - Classification and Fair Value Amounts of Derivative Instruments in Balance Sheets (Details) - USD ($) $ in Millions	Oct. 27, 2017	Apr. 28, 2017
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	$ 206	$ 262
Liability Derivatives, Fair Value	211	104
Currency exchange rate contracts
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	137	216
Liability Derivatives, Fair Value	203	93
Interest rate contracts
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	30	41
Total return swap
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	8
Stock warrants
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	25
Cross currency interest rate contracts
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	6	5
Liability Derivatives, Fair Value	8	11
Derivatives designated as hedging instruments
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	132	241
Liability Derivatives, Fair Value	176	57
Derivatives designated as hedging instruments | Currency exchange rate contracts | Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	61	152
Derivatives designated as hedging instruments | Currency exchange rate contracts | Other assets
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	41	48
Derivatives designated as hedging instruments | Currency exchange rate contracts | Other accrued expenses
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	113	43
Derivatives designated as hedging instruments | Currency exchange rate contracts | Other liabilities
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	63	14
Derivatives designated as hedging instruments | Interest rate contracts | Other assets
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	30	41
Derivatives designated as hedging instruments | Interest rate contracts | Other liabilities
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	0	0
Derivatives not designated as hedging instruments
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	74	21
Liability Derivatives, Fair Value	35	47
Derivatives not designated as hedging instruments | Currency exchange rate contracts | Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	35	16
Derivatives not designated as hedging instruments | Currency exchange rate contracts | Other accrued expenses
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	27	36
Derivatives not designated as hedging instruments | Total return swap | Prepaid expenses and other current assets
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	8
Derivatives not designated as hedging instruments | Total return swap | Other accrued expenses
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	0
Derivatives not designated as hedging instruments | Stock warrants | Other assets
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	25
Derivatives not designated as hedging instruments | Stock warrants | Other liabilities
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	0
Derivatives not designated as hedging instruments | Cross currency interest rate contracts | Other assets
Derivatives, Fair Value [Line Items]
Asset Derivatives, Fair Value	6	5
Derivatives not designated as hedging instruments | Cross currency interest rate contracts | Other liabilities
Derivatives, Fair Value [Line Items]
Liability Derivatives, Fair Value	$ 8	$ 11

Derivatives and Currency Exch59

Derivatives and Currency Exchange Risk Management - Derivative Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - Recurring - USD ($) $ in Millions	Oct. 27, 2017	Apr. 28, 2017
Level 1
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	$ 137	$ 216
Derivative liabilities	203	93
Level 2
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative assets	69	46
Derivative liabilities	$ 8	$ 11

Derivatives and Currency Exch60

Derivatives and Currency Exchange Risk Management - Offsetting Assets and Liabilities (Details) - USD ($) $ in Millions	Oct. 27, 2017	Apr. 28, 2017
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recorded Assets (Liabilities)	$ 206	$ 262
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(125)	(75)
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	(60)
Derivative Assets, Net Amount	81	127
Derivative Liabilities, Gross Amount of Recorded Assets (Liabilities)	(211)	(104)
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	125	75
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	0
Derivative Liabilities, Net Amount	(86)	(29)
Gross Amount of Recorded Assets (Liabilities)	(5)	158
Gross Amount Not Offset on the Balance Sheet, Financial Instruments	0	0
Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	(60)
Net Amount	(5)	98
Currency exchange rate contracts
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recorded Assets (Liabilities)	137	216
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(110)	(58)
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	(55)
Derivative Assets, Net Amount	27	103
Derivative Liabilities, Gross Amount of Recorded Assets (Liabilities)	(203)	(93)
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	123	73
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	0
Derivative Liabilities, Net Amount	(80)	(20)
Interest rate contracts
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recorded Assets (Liabilities)	30	41
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(13)	(15)
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	(5)
Derivative Assets, Net Amount	17	21
Cross currency interest rate contracts
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recorded Assets (Liabilities)	6	5
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	(2)	(2)
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	0
Derivative Assets, Net Amount	4	3
Derivative Liabilities, Gross Amount of Recorded Assets (Liabilities)	(8)	(11)
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	2	2
Derivative Liabilities, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0	0
Derivative Liabilities, Net Amount	(6)	$ (9)
Stock warrants
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recorded Assets (Liabilities)	25
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	0
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0
Derivative Assets, Net Amount	25
Total return swap
Offsetting Assets and Liabilities [Line Items]
Derivative Assets, Gross Amount of Recorded Assets (Liabilities)	8
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Financial Instruments	0
Derivative Assets, Gross Amount Not Offset on the Balance Sheet, Collateral (Received) or Posted	0
Derivative Assets, Net Amount	$ 8

Derivatives and Currency Exch61

Derivatives and Currency Exchange Risk Management - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 27, 2017	Oct. 28, 2016	Oct. 27, 2017	Oct. 28, 2016	Apr. 28, 2017	Jan. 27, 2017
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gains (losses) relating to ineffectiveness of cash flow hedges	$ 0	$ 0	$ 0	$ 0
Gains (losses) relating to ineffectiveness of forward starting interest rate derivatives		0		0
After-tax net unrealized gains (losses) associated with cash flow hedging instruments recorded in AOCI	(107,000,000)		(107,000,000)		$ 37,000,000
Cash flow hedge unrealized losses to be reclassified over the next 12 months			33,000,000
Debt, face amount	27,800,000,000		27,800,000,000		28,900,000,000
Gains (losses) relating to ineffectiveness of interest rate fair value hedges	0	0	0	0
Gains (losses) on firm commitments that no longer qualify as fair value hedges	0	0	0	0
Cash flow hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gains (losses) recognized in AOCI	30,000,000	69,000,000	(220,000,000)	190,000,000
Effective portion of net gains (losses) on derivative instruments reclassified from accumulated other comprehensive loss	(10,000,000)	6,000,000	12,000,000	22,000,000
Currency exchange rate contracts
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	12,000,000,000		12,000,000,000		10,800,000,000
Currency exchange rate contracts | Cash flow hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gains (losses) recognized in AOCI	30,000,000	69,000,000	(220,000,000)	190,000,000
Currency exchange rate contracts | Derivatives not designated as hedging instruments
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	5,700,000,000		5,700,000,000		4,900,000,000
Currency exchange rate contracts | Derivatives designated as hedging instruments | Cash flow hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	6,200,000,000		$ 6,200,000,000		5,800,000,000
Maximum remaining maturity of foreign currency derivatives			3 years
Interest rate swaps
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Gains (losses) recognized in AOCI		17,000,000		(6,000,000)
Interest rate swaps | Cash flow hedging | Interest expense, net
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Effective portion of net gains (losses) on derivative instruments reclassified from accumulated other comprehensive loss		$ 0		$ 0
Interest rate swaps | Derivatives designated as hedging instruments | Cash flow hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount						$ 300,000,000
Average interest rate						3.10%
Interest rate swaps | Derivatives designated as hedging instruments | Fair value hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative, notional amount	1,200,000,000		$ 1,200,000,000		1,200,000,000
Market value of outstanding interest rate swap agreements - net unrealized gain	(30,000,000)		(30,000,000)		(41,000,000)
Market value of hedged item - net unrealized loss	$ 30,000,000		$ 30,000,000		41,000,000
4.125 percent ten-year 2011 senior notes | Senior notes
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Stated interest rate	4.125%		4.125%
4.125 percent ten-year 2011 senior notes | Senior notes | Interest rate swaps | Derivatives designated as hedging instruments | Fair value hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Debt, face amount	$ 500,000,000		$ 500,000,000		$ 500,000,000
Stated interest rate	4.125%		4.125%		4.125%
3.125 percent ten-year 2012 senior notes | Senior notes
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Stated interest rate	3.125%		3.125%
3.125 percent ten-year 2012 senior notes | Senior notes | Interest rate swaps | Derivatives designated as hedging instruments | Fair value hedging
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Debt, face amount	$ 675,000,000		$ 675,000,000		$ 675,000,000
Stated interest rate	3.125%		3.125%		3.125%

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Oct. 27, 2017	Apr. 28, 2017
Inventory Disclosure [Abstract]
Finished goods	$ 2,368	$ 2,211
Work in-process	515	458
Raw materials	755	669
Total	$ 3,638	$ 3,338

Goodwill and Other Intangible63

Goodwill and Other Intangible Assets - Changes in the Carrying Amount of Goodwill (Details) $ in Millions	6 Months Ended
	Oct. 27, 2017USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 38,515
Goodwill as a result of acquisitions	15
Purchase accounting adjustments	54
Currency and other adjustments, net	493
Ending balance	39,077
Cardiac and Vascular Group
Goodwill [Roll Forward]
Beginning balance	6,651
Goodwill as a result of acquisitions	0
Purchase accounting adjustments	54
Currency and other adjustments, net	48
Ending balance	6,753
Minimally Invasive Therapies Group
Goodwill [Roll Forward]
Beginning balance	20,411
Goodwill as a result of acquisitions	0
Purchase accounting adjustments	0
Currency and other adjustments, net	405
Ending balance	20,816
Restorative Therapies Group
Goodwill [Roll Forward]
Beginning balance	9,600
Goodwill as a result of acquisitions	9
Purchase accounting adjustments	0
Currency and other adjustments, net	41
Ending balance	9,650
Diabetes Group
Goodwill [Roll Forward]
Beginning balance	1,853
Goodwill as a result of acquisitions	6
Purchase accounting adjustments	0
Currency and other adjustments, net	(1)
Ending balance	$ 1,858

Goodwill and Other Intangible64

Goodwill and Other Intangible Assets - Carrying Amount and Accumulated Amortization of Intangible Assets (Details) - USD ($) $ in Millions	Oct. 27, 2017	Apr. 28, 2017
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	$ 29,344	$ 29,172
Accumulated Amortization	(7,280)	(6,359)
IPR&D
Indefinite-lived Intangible Assets [Line Items]
Gross Carrying Amount, Non-Amortizable	561	594
Customer-related
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	16,964	16,862
Accumulated Amortization	(2,652)	(2,166)
Purchased technology and patents
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	11,479	11,461
Accumulated Amortization	(4,038)	(3,690)
Trademarks and tradenames
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	821	772
Accumulated Amortization	(544)	(461)
Other
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount, Amortizable	80	77
Accumulated Amortization	$ (46)	$ (42)

Goodwill and Other Intangible65

Goodwill and Other Intangible Assets - Estimated Future Aggregate Amortization Expense of Amortizable Intangible Assets (Details) $ in Millions	Oct. 27, 2017USD ($)
Goodwill and Intangible Assets Disclosure [Abstract]
Remaining 2,018	$ 871
2,019	1,672
2,020	1,622
2,021	1,601
2,022	1,561
2,023	$ 1,490

Goodwill and Other Intangible66

Goodwill and Other Intangible Assets - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 27, 2017	Oct. 28, 2016	Oct. 27, 2017	Oct. 28, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill impairment	$ 0	$ 0	$ 0	$ 0
Impairment of definite-lived intangible assets	0	0	0	0
Impairment of indefinite-lived intangible assets	0	0	0	0
Amortization expense	$ 460,000,000	$ 500,000,000	$ 914,000,000	$ 987,000,000

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended		6 Months Ended		9 Months Ended
	Aug. 31, 2017	Oct. 27, 2017	Oct. 28, 2016	Oct. 27, 2017	Oct. 28, 2016	Oct. 27, 2017	Apr. 28, 2017
Income Tax Contingency [Line Items]
Effective tax rate		(16.50%)	8.30%	(3.40%)	7.30%
Certain tax adjustments, settlements and other				$ (344)	$ (31)
Tax benefit from sales of intellectual property				(398)
Tax expense from sale of business				54
Tax adjustment related to divestiture						$ 175
Charge, redemption of an intercompany minority interest					29
Gross unrecognized tax benefits		$ 1,800		1,800		1,800	$ 1,900
Accrued gross interest and penalties		394		394		394
Unrecognized tax benefits that would impact effective tax rate		1,700		1,700		1,700
Accrued income taxes
Income Tax Contingency [Line Items]
Gross unrecognized tax benefits		$ 16		$ 16		$ 16
Ardian, CoreValve and Ablation
Income Tax Contingency [Line Items]
Charge (benefit), settlements					371
Subsidiaries
Income Tax Contingency [Line Items]
Charge (benefit), settlements					$ 431
Foreign Tax Authority
Income Tax Contingency [Line Items]
Non-U.S. special deductions	$ 12,000

Earnings Per Share (Details)

Earnings Per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Oct. 27, 2017	Oct. 28, 2016	Oct. 27, 2017	Oct. 28, 2016
Numerator:
Net income attributable to ordinary shareholders	$ 2,017	$ 1,115	$ 3,033	$ 2,044
Denominator:
Basic weighted average shares outstanding (shares)	1,355.1	1,380	1,358.5	1,386.5
Effect of dilutive securities:
Employee stock options (shares)	7.7	9.3	8.5	9.9
Employee restricted stock units (shares)	3	3.2	3.5	3.6
Other (shares)	0	0	0.3	0.2
Diluted weighted average shares outstanding (shares)	1,365.8	1,392.5	1,370.8	1,400.2
Basic earnings per share (usd per share)	$ 1.49	$ 0.81	$ 2.23	$ 1.47
Diluted earnings per share (usd per share)	$ 1.48	$ 0.80	$ 2.21	$ 1.46
Stock options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share (shares)	12	5	8	4

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 27, 2017	Oct. 28, 2016	Oct. 27, 2017	Oct. 28, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 106	$ 111	$ 198	$ 190
Income tax benefits	(32)	(33)	(57)	(54)
Total stock-based compensation expense, net of tax	74	78	141	136
Cost of products sold
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	14	15	24	26
Research and development expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	12	13	21	22
Selling, general, and administrative expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	79	73	134	124
Restructuring charges
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	0	1	0	2
Acquisition-related items
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	1	9	3	16
Divestiture-related items
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	0	0	16	0
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	42	53	77	91
Restricted stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	59	54	107	88
Employee stock purchase plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 5	$ 4	$ 14	$ 11

Retirement Benefit Plans (Detai

Retirement Benefit Plans (Details) - Pension plans - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 27, 2017	Oct. 28, 2016	Oct. 27, 2017	Oct. 28, 2016
U.S. Pension Benefits
Net Periodic Benefit Cost
Service cost	$ 29	$ 29	$ 58	$ 58
Interest cost	30	27	60	54
Expected return on plan assets	(52)	(47)	(104)	(94)
Amortization of net actuarial loss	20	23	40	46
Net periodic benefit cost	27	32	54	64
Non-U.S. Pension Benefits
Net Periodic Benefit Cost
Service cost	17	19	34	38
Interest cost	7	6	14	12
Expected return on plan assets	(13)	(12)	(26)	(24)
Amortization of net actuarial loss	4	4	8	8
Net periodic benefit cost	$ 15	$ 17	$ 30	$ 34

Accumulated Other Comprehensi71

Accumulated Other Comprehensive (Loss) Income and Supplemental Equity Disclosure - Changes in AOCI (Details) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 27, 2017	Oct. 28, 2016	Oct. 27, 2017	Oct. 28, 2016
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance			$ 50,416,000,000	$ 52,063,000,000
Other comprehensive (loss) income	$ (136,000,000)	$ (304,000,000)	553,000,000	(460,000,000)
Balance	51,578,000,000	50,293,000,000	51,578,000,000	50,293,000,000
Unrealized Gain (Loss) on Available-for-Sale Securities
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance			(69,000,000)	(107,000,000)
Other comprehensive income (loss) before reclassifications			63,000,000	88,000,000
Reclassifications			(8,000,000)	(13,000,000)
Other comprehensive (loss) income			55,000,000	75,000,000
Balance	(14,000,000)	(32,000,000)	(14,000,000)	(32,000,000)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)			27,000,000	44,000,000
Reclassifications, tax expense (benefit)			4,000,000	7,000,000
Cumulative Translation Adjustment
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance			(1,452,000,000)	(474,000,000)
Other comprehensive income (loss) before reclassifications			662,000,000	(686,000,000)
Reclassifications			(34,000,000)	0
Other comprehensive (loss) income			628,000,000	(686,000,000)
Balance	(824,000,000)	(1,160,000,000)	(824,000,000)	(1,160,000,000)
Net Change in Retirement Obligations
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance			(1,129,000,000)	(1,197,000,000)
Other comprehensive income (loss) before reclassifications			(19,000,000)	0
Reclassifications			33,000,000	44,000,000
Other comprehensive (loss) income			14,000,000	44,000,000
Balance	(1,115,000,000)	(1,153,000,000)	(1,115,000,000)	(1,153,000,000)
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)			(4,000,000)	0
Reclassifications, tax expense (benefit)			15,000,000	10,000,000
Unrealized Gain (Loss) on Derivative Financial Instruments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance			37,000,000	(90,000,000)
Other comprehensive income (loss) before reclassifications			(140,000,000)	118,000,000
Reclassifications			(4,000,000)	(11,000,000)
Other comprehensive (loss) income			(144,000,000)	107,000,000
Balance	(107,000,000)	17,000,000	(107,000,000)	17,000,000
Other Comprehensive Income (Loss), Tax [Abstract]
Other comprehensive income (loss) before reclassifications, tax expense (benefit)			(81,000,000)	66,000,000
Reclassifications, tax expense (benefit)			4,000,000	8,000,000
Total Accumulated Other Comprehensive (Loss) Income
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Balance			(2,613,000,000)	(1,868,000,000)
Other comprehensive income (loss) before reclassifications			566,000,000	(480,000,000)
Reclassifications			(13,000,000)	20,000,000
Other comprehensive (loss) income			553,000,000	(460,000,000)
Balance	$ (2,060,000,000)	$ (2,328,000,000)	$ (2,060,000,000)	$ (2,328,000,000)

Accumulated Other Comprehensi72

Accumulated Other Comprehensive (Loss) Income and Supplemental Equity Disclosure - Supplemental Equity Schedule (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Oct. 27, 2017	Oct. 28, 2016	Oct. 27, 2017	Oct. 28, 2016	Apr. 28, 2017
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance			$ 50,416	$ 52,063
Net income (loss)	$ 2,013	$ 1,111	3,022	2,040
Other comprehensive income (loss)	(136)	(304)	553	(460)
Dividends to shareholders			(1,247)	(1,192)
Issuance of shares under stock purchase and award plans			177	260
Repurchase of ordinary shares			(1,835)	(2,794)
Tax benefit from exercise of stock-based awards				75
Stock-based compensation			198	190
Cumulative effect of change in accounting principle					$ 296
Reductions of noncontrolling ownership interests			(2)
Additions of noncontrolling ownership interests				111
Balance	51,578	50,293	51,578	50,293
Total Shareholders' Equity
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance			50,294	52,063
Net income (loss)			3,033	2,044
Other comprehensive income (loss)			553	(460)
Dividends to shareholders			(1,247)	(1,192)
Issuance of shares under stock purchase and award plans			177	260
Repurchase of ordinary shares			(1,835)	(2,794)
Tax benefit from exercise of stock-based awards				75
Stock-based compensation			198	190
Cumulative effect of change in accounting principle					$ 296
Balance	51,469	50,186	51,469	50,186
Noncontrolling Interests
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Balance			122	0
Net income (loss)			(11)	(4)
Other comprehensive income (loss)			0	0
Reductions of noncontrolling ownership interests			(2)
Additions of noncontrolling ownership interests				111
Balance	$ 109	$ 107	$ 109	$ 107

Commitments and Contingencies (

Commitments and Contingencies (Details) $ in Millions	Dec. 01, 2017claim	Dec. 14, 2011patent	Jun. 29, 2007	May 31, 2017claim	Oct. 27, 2017USD ($)landfillclaim	Apr. 29, 2016USD ($)claim	Apr. 28, 2017USD ($)	Apr. 26, 2013USD ($)
Loss Contingencies [Line Items]
Accrued certain litigation charges					$ 1,000		$ 1,100
Covidien plc
Loss Contingencies [Line Items]
Tax sharing percentage, parent			42.00%
Tax sharing percentage, former parent			27.00%
Tax sharing percentage, former affiliate			31.00%
Orrington, Maine chemical manufacturing facility
Loss Contingencies [Line Items]
Number of landfills requiring removal | landfill					2
Number of landfills requiring capping | landfill					3
Indemnification agreement | Covidien plc | Tax Years Prior To 2013
Loss Contingencies [Line Items]
Maximum potential loss for tax indemnification								$ 200
INFUSE | Product liability litigation
Loss Contingencies [Line Items]
Number of pending claims | claim					6,000
Pelvic mesh | Product liability litigation
Loss Contingencies [Line Items]
Number of pending claims | claim					15,800
Settlement receivable						$ 121
Number of claims settled | claim				5,000		11,000
Pelvic mesh | Product liability litigation | Subsequent Event
Loss Contingencies [Line Items]
Number of claims settled | claim	13,400
Ethicon
Loss Contingencies [Line Items]
Patents infringed | patent		1
Minimum | Penobscot River and Bay remediation
Loss Contingencies [Line Items]
Cost estimate for potential remediation					$ 25
Maximum | Penobscot River and Bay remediation
Loss Contingencies [Line Items]
Cost estimate for potential remediation					$ 235

Segment and Geographic Inform74

Segment and Geographic Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 27, 2017	Oct. 28, 2016	Oct. 27, 2017	Oct. 28, 2016
Segment Reporting Information [Line Items]
Net sales	$ 7,050,000,000	$ 7,345,000,000	$ 14,440,000,000	$ 14,511,000,000
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	1,728,000,000	1,212,000,000	2,923,000,000	2,200,000,000
Amortization of intangible assets	(460,000,000)	(500,000,000)	(914,000,000)	(987,000,000)
Restructuring charges, net	(8,000,000)	(47,000,000)	(16,000,000)	(141,000,000)
Acquisition-related items	(7,000,000)	(28,000,000)	(51,000,000)	(80,000,000)
Certain litigation charges	0	0	0	(82,000,000)
Divestiture-related items	(67,000,000)	0	(114,000,000)	0
Gain on sale of businesses	697,000,000	0	697,000,000	0
Special charge	(80,000,000)	0	(80,000,000)	0
Interest expense, net	(173,000,000)	(173,000,000)	(367,000,000)	(352,000,000)
Americas
Segment Reporting Information [Line Items]
Net sales	4,090,000,000	4,471,000,000	8,457,000,000	8,768,000,000
U.S.
Segment Reporting Information [Line Items]
Net sales	3,700,000,000	4,200,000,000	7,800,000,000	8,200,000,000
EMEA
Segment Reporting Information [Line Items]
Net sales	1,692,000,000	1,592,000,000	3,424,000,000	3,243,000,000
Asia-Pacific
Segment Reporting Information [Line Items]
Net sales	434,000,000	890,000,000	1,691,000,000	1,712,000,000
Greater China
Segment Reporting Information [Line Items]
Net sales	834,000,000	392,000,000	868,000,000	788,000,000
Operating Segments
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	2,706,000,000	2,761,000,000	5,383,000,000	5,368,000,000
Segment Reconciling Items
Income before Income Taxes by Reportable Segment
Amortization of intangible assets	(460,000,000)	(500,000,000)	(914,000,000)	(987,000,000)
Restructuring charges, net	(18,000,000)	(47,000,000)	(32,000,000)	(151,000,000)
Acquisition-related items	(18,000,000)	(28,000,000)	(71,000,000)	(80,000,000)
Certain litigation charges	0	0	0	(82,000,000)
Divestiture-related items	(67,000,000)	0	(115,000,000)	0
Gain on sale of businesses	697,000,000	0	697,000,000	0
Special charge	(80,000,000)	0	(80,000,000)	0
Hurricane Maria	(34,000,000)	0	(34,000,000)	0
Impact of inventory step-up	0	(38,000,000)	0	(38,000,000)
Centralized distribution costs	(486,000,000)	(446,000,000)	(928,000,000)	(847,000,000)
Interest expense, net	(173,000,000)	(173,000,000)	(367,000,000)	(352,000,000)
Corporate, Non-Segment
Income before Income Taxes by Reportable Segment
Corporate	(339,000,000)	(317,000,000)	(616,000,000)	(631,000,000)
Cardiac and Vascular Group
Segment Reporting Information [Line Items]
Net sales	2,773,000,000	2,584,000,000	5,419,000,000	5,102,000,000
Cardiac and Vascular Group | Operating Segments
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	1,104,000,000	1,017,000,000	2,115,000,000	1,971,000,000
Minimally Invasive Therapies Group
Segment Reporting Information [Line Items]
Net sales	1,952,000,000	2,473,000,000	4,438,000,000	4,897,000,000
Minimally Invasive Therapies Group | Operating Segments
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	761,000,000	886,000,000	1,636,000,000	1,710,000,000
Restorative Therapies Group
Segment Reporting Information [Line Items]
Net sales	1,863,000,000	1,826,000,000	3,672,000,000	3,598,000,000
Restorative Therapies Group | Operating Segments
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	750,000,000	700,000,000	1,430,000,000	1,370,000,000
Diabetes Group
Segment Reporting Information [Line Items]
Net sales	462,000,000	462,000,000	911,000,000	914,000,000
Diabetes Group | Operating Segments
Income before Income Taxes by Reportable Segment
Income from operations before income taxes	$ 91,000,000	$ 158,000,000	$ 202,000,000	$ 317,000,000

Guarantor Financial Informati75

Guarantor Financial Information - Consolidating Statement of Comprehensive Income (Details) - USD ($)	3 Months Ended		6 Months Ended
	Oct. 27, 2017	Oct. 28, 2016	Oct. 27, 2017	Oct. 28, 2016
Condensed Statement of Income Captions [Line Items]
Net sales	$ 7,050,000,000	$ 7,345,000,000	$ 14,440,000,000	$ 14,511,000,000
Costs and expenses:
Cost of products sold	2,120,000,000	2,326,000,000	4,469,000,000	4,587,000,000
Research and development expense	555,000,000	554,000,000	1,103,000,000	1,110,000,000
Selling, general, and administrative expense	2,438,000,000	2,416,000,000	4,923,000,000	4,844,000,000
Special charge	80,000,000	0	80,000,000	0
Restructuring charges, net	8,000,000	47,000,000	16,000,000	141,000,000
Certain litigation charges	0	0	0	82,000,000
Acquisition-related items	7,000,000	28,000,000	51,000,000	80,000,000
Divestiture-related items	67,000,000	0	114,000,000	0
Amortization of intangible assets	460,000,000	500,000,000	914,000,000	987,000,000
Gain on sale of businesses	(697,000,000)	0	(697,000,000)	0
Other (income) expense, net	111,000,000	89,000,000	177,000,000	128,000,000
Operating profit	1,901,000,000	1,385,000,000	3,290,000,000	2,552,000,000
Interest income	(100,000,000)	(91,000,000)	(192,000,000)	(184,000,000)
Interest expense	273,000,000	264,000,000	559,000,000	536,000,000
Interest expense, net	173,000,000	173,000,000	367,000,000	352,000,000
Equity in net (income) loss of subsidiaries	0	0	0	0
Income before income taxes	1,728,000,000	1,212,000,000	2,923,000,000	2,200,000,000
Income tax (benefit) provision	(285,000,000)	101,000,000	(99,000,000)	160,000,000
Net income	2,013,000,000	1,111,000,000	3,022,000,000	2,040,000,000
Net loss attributable to noncontrolling interests	4,000,000	4,000,000	11,000,000	4,000,000
Net income attributable to Medtronic	2,017,000,000	1,115,000,000	3,033,000,000	2,044,000,000
Other comprehensive income (loss), net of tax	(136,000,000)	(304,000,000)	553,000,000	(460,000,000)
Other comprehensive loss attributable to noncontrolling interests	4,000,000	4,000,000	11,000,000	4,000,000
Comprehensive income attributable to Medtronic	1,881,000,000	811,000,000	3,586,000,000	1,584,000,000
Consolidating Adjustments | Medtronic Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	(300,000,000)	(336,000,000)	(603,000,000)	(684,000,000)
Costs and expenses:
Cost of products sold	(312,000,000)	(329,000,000)	(619,000,000)	(684,000,000)
Research and development expense	0	0	0	0
Selling, general, and administrative expense	0	0	0	0
Special charge	0		0
Restructuring charges, net	0	0	0	0
Certain litigation charges				0
Acquisition-related items	0	0	0	0
Divestiture-related items	0		0
Amortization of intangible assets	0	0	0	0
Gain on sale of businesses	0		0
Other (income) expense, net	0	0	0	0
Operating profit	12,000,000	(7,000,000)	16,000,000	0
Interest income	415,000,000	419,000,000	834,000,000	682,000,000
Interest expense	(415,000,000)	(419,000,000)	(834,000,000)	(682,000,000)
Interest expense, net	0	0	0	0
Equity in net (income) loss of subsidiaries	5,936,000,000	2,815,000,000	8,831,000,000	5,812,000,000
Income before income taxes	(5,924,000,000)	(2,822,000,000)	(8,815,000,000)	(5,812,000,000)
Income tax (benefit) provision	0	0	0	0
Net income	(5,924,000,000)	(2,822,000,000)	(8,815,000,000)	(5,812,000,000)
Net loss attributable to noncontrolling interests	0	0	0	0
Net income attributable to Medtronic	(5,924,000,000)	(2,822,000,000)	(8,815,000,000)	(5,812,000,000)
Other comprehensive income (loss), net of tax	594,000,000	586,000,000	(766,000,000)	818,000,000
Other comprehensive loss attributable to noncontrolling interests	0	0	0	0
Comprehensive income attributable to Medtronic	(5,330,000,000)	(2,236,000,000)	(9,581,000,000)	(4,994,000,000)
Consolidating Adjustments | CIFSA Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0	0	0	0
Costs and expenses:
Cost of products sold	0	0	0	0
Research and development expense	0	0	0	0
Selling, general, and administrative expense	0	0	0	0
Special charge	0		0
Restructuring charges, net	0	0	0	0
Certain litigation charges				0
Acquisition-related items	0	0	0	0
Divestiture-related items	0		0
Amortization of intangible assets	0	0	0	0
Gain on sale of businesses	0		0
Other (income) expense, net	0	0	0	0
Operating profit	0	0	0	0
Interest income	151,000,000	195,000,000	298,000,000	394,000,000
Interest expense	(151,000,000)	(195,000,000)	(298,000,000)	(394,000,000)
Interest expense, net	0	0	0	0
Equity in net (income) loss of subsidiaries	4,934,000,000	2,401,000,000	7,402,000,000	4,965,000,000
Income before income taxes	(4,934,000,000)	(2,401,000,000)	(7,402,000,000)	(4,965,000,000)
Income tax (benefit) provision	0	0	0	0
Net income	(4,934,000,000)	(2,401,000,000)	(7,402,000,000)	(4,965,000,000)
Net loss attributable to noncontrolling interests	0	0	0	0
Net income attributable to Medtronic	(4,934,000,000)	(2,401,000,000)	(7,402,000,000)	(4,965,000,000)
Other comprehensive income (loss), net of tax	567,000,000	631,000,000	(905,000,000)	901,000,000
Other comprehensive loss attributable to noncontrolling interests	0	0	0	0
Comprehensive income attributable to Medtronic	(4,367,000,000)	(1,770,000,000)	(8,307,000,000)	(4,064,000,000)
Medtronic plc | Reportable Legal Entities | Medtronic Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0	0	0	0
Costs and expenses:
Cost of products sold	0	0	0	0
Research and development expense	0	0	0	0
Selling, general, and administrative expense	3,000,000	3,000,000	5,000,000	6,000,000
Special charge	0		0
Restructuring charges, net	0	0	0	0
Certain litigation charges				0
Acquisition-related items	0	0	0	0
Divestiture-related items	0		0
Amortization of intangible assets	0	0	0	0
Gain on sale of businesses	0		0
Other (income) expense, net	12,000,000	(86,000,000)	25,000,000	(74,000,000)
Operating profit	(15,000,000)	83,000,000	(30,000,000)	68,000,000
Interest income	0	0	0	0
Interest expense	60,000,000	25,000,000	109,000,000	41,000,000
Interest expense, net	60,000,000	25,000,000	109,000,000	41,000,000
Equity in net (income) loss of subsidiaries	(2,091,000,000)	(1,055,000,000)	(3,169,000,000)	(2,013,000,000)
Income before income taxes	2,016,000,000	1,113,000,000	3,030,000,000	2,040,000,000
Income tax (benefit) provision	(1,000,000)	(2,000,000)	(3,000,000)	(4,000,000)
Net income	2,017,000,000	1,115,000,000	3,033,000,000	2,044,000,000
Net loss attributable to noncontrolling interests	0	0	0	0
Net income attributable to Medtronic	2,017,000,000	1,115,000,000	3,033,000,000	2,044,000,000
Other comprehensive income (loss), net of tax	(136,000,000)	(304,000,000)	553,000,000	(460,000,000)
Other comprehensive loss attributable to noncontrolling interests	0	0	0	0
Comprehensive income attributable to Medtronic	1,881,000,000	811,000,000	3,586,000,000	1,584,000,000
Medtronic plc | Reportable Legal Entities | CIFSA Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0	0	0	0
Costs and expenses:
Cost of products sold	0	0	0	0
Research and development expense	0	0	0	0
Selling, general, and administrative expense	3,000,000	3,000,000	5,000,000	6,000,000
Special charge	0		0
Restructuring charges, net	0	0	0	0
Certain litigation charges				0
Acquisition-related items	0	0	0	0
Divestiture-related items	0		0
Amortization of intangible assets	0	0	0	0
Gain on sale of businesses	0		0
Other (income) expense, net	12,000,000	(86,000,000)	25,000,000	(74,000,000)
Operating profit	(15,000,000)	83,000,000	(30,000,000)	68,000,000
Interest income	0	0	0	0
Interest expense	60,000,000	25,000,000	109,000,000	41,000,000
Interest expense, net	60,000,000	25,000,000	109,000,000	41,000,000
Equity in net (income) loss of subsidiaries	(2,091,000,000)	(1,055,000,000)	(3,169,000,000)	(2,013,000,000)
Income before income taxes	2,016,000,000	1,113,000,000	3,030,000,000	2,040,000,000
Income tax (benefit) provision	(1,000,000)	(2,000,000)	(3,000,000)	(4,000,000)
Net income	2,017,000,000	1,115,000,000	3,033,000,000	2,044,000,000
Net loss attributable to noncontrolling interests	0	0	0	0
Net income attributable to Medtronic	2,017,000,000	1,115,000,000	3,033,000,000	2,044,000,000
Other comprehensive income (loss), net of tax	(136,000,000)	(304,000,000)	553,000,000	(460,000,000)
Other comprehensive loss attributable to noncontrolling interests	0	0	0	0
Comprehensive income attributable to Medtronic	1,881,000,000	811,000,000	3,586,000,000	1,584,000,000
Subsidiary Issuer | Reportable Legal Entities | Medtronic Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	300,000,000	337,000,000	604,000,000	685,000,000
Costs and expenses:
Cost of products sold	228,000,000	243,000,000	450,000,000	492,000,000
Research and development expense	169,000,000	158,000,000	327,000,000	321,000,000
Selling, general, and administrative expense	375,000,000	284,000,000	675,000,000	564,000,000
Special charge	80,000,000		80,000,000
Restructuring charges, net	0	1,000,000	2,000,000	18,000,000
Certain litigation charges				0
Acquisition-related items	14,000,000	37,000,000	44,000,000	60,000,000
Divestiture-related items	6,000,000		15,000,000
Amortization of intangible assets	2,000,000	3,000,000	4,000,000	6,000,000
Gain on sale of businesses	0		0
Other (income) expense, net	(392,000,000)	(597,000,000)	(870,000,000)	(1,306,000,000)
Operating profit	(182,000,000)	208,000,000	(123,000,000)	530,000,000
Interest income	(64,000,000)	(59,000,000)	(135,000,000)	(121,000,000)
Interest expense	425,000,000	396,000,000	865,000,000	806,000,000
Interest expense, net	361,000,000	337,000,000	730,000,000	685,000,000
Equity in net (income) loss of subsidiaries	(1,809,000,000)	(859,000,000)	(2,623,000,000)	(2,095,000,000)
Income before income taxes	1,266,000,000	730,000,000	1,770,000,000	1,940,000,000
Income tax (benefit) provision	(158,000,000)	28,000,000	(236,000,000)	50,000,000
Net income	1,424,000,000	702,000,000	2,006,000,000	1,890,000,000
Net loss attributable to noncontrolling interests	0	0	0	0
Net income attributable to Medtronic	1,424,000,000	702,000,000	2,006,000,000	1,890,000,000
Other comprehensive income (loss), net of tax	(308,000,000)	47,000,000	(317,000,000)	142,000,000
Other comprehensive loss attributable to noncontrolling interests	0	0	0	0
Comprehensive income attributable to Medtronic	1,116,000,000	749,000,000	1,689,000,000	2,032,000,000
Subsidiary Issuer | Reportable Legal Entities | CIFSA Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0	0	0	0
Costs and expenses:
Cost of products sold	0	0	0	0
Research and development expense	0	0	0	0
Selling, general, and administrative expense	0	0	0	0
Special charge	0		0
Restructuring charges, net	0	0	0	0
Certain litigation charges				0
Acquisition-related items	0	0	0	0
Divestiture-related items	0		0
Amortization of intangible assets	0	0	0	0
Gain on sale of businesses	0		0
Other (income) expense, net	0	0	1,000,000	0
Operating profit	0	0	(1,000,000)	0
Interest income	(16,000,000)	(18,000,000)	(32,000,000)	(47,000,000)
Interest expense	21,000,000	23,000,000	44,000,000	56,000,000
Interest expense, net	5,000,000	5,000,000	12,000,000	9,000,000
Equity in net (income) loss of subsidiaries	(811,000,000)	(445,000,000)	(1,200,000,000)	(1,249,000,000)
Income before income taxes	806,000,000	440,000,000	1,187,000,000	1,240,000,000
Income tax (benefit) provision	0	0	0	0
Net income	806,000,000	440,000,000	1,187,000,000	1,240,000,000
Net loss attributable to noncontrolling interests	0	0	0	0
Net income attributable to Medtronic	806,000,000	440,000,000	1,187,000,000	1,240,000,000
Other comprehensive income (loss), net of tax	(295,000,000)	(23,000,000)	(201,000,000)	19,000,000
Other comprehensive loss attributable to noncontrolling interests	0	0	0	0
Comprehensive income attributable to Medtronic	511,000,000	417,000,000	986,000,000	1,259,000,000
Subsidiary Guarantors | Reportable Legal Entities | Medtronic Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0	0	0	0
Costs and expenses:
Cost of products sold	0	0	0	0
Research and development expense	0	0	0	0
Selling, general, and administrative expense	0	0	0	0
Special charge	0		0
Restructuring charges, net	0	0	0	0
Certain litigation charges				0
Acquisition-related items	0	0	0	0
Divestiture-related items	0		0
Amortization of intangible assets	0	0	0	0
Gain on sale of businesses	0		0
Other (income) expense, net	0	0	0	0
Operating profit	0	0	0	0
Interest income	(103,000,000)	(165,000,000)	(212,000,000)	(321,000,000)
Interest expense	48,000,000	11,000,000	82,000,000	12,000,000
Interest expense, net	(55,000,000)	(154,000,000)	(130,000,000)	(309,000,000)
Equity in net (income) loss of subsidiaries	(2,036,000,000)	(901,000,000)	(3,039,000,000)	(1,704,000,000)
Income before income taxes	2,091,000,000	1,055,000,000	3,169,000,000	2,013,000,000
Income tax (benefit) provision	0	0	0	0
Net income	2,091,000,000	1,055,000,000	3,169,000,000	2,013,000,000
Net loss attributable to noncontrolling interests	0	0	0	0
Net income attributable to Medtronic	2,091,000,000	1,055,000,000	3,169,000,000	2,013,000,000
Other comprehensive income (loss), net of tax	(136,000,000)	(304,000,000)	553,000,000	(460,000,000)
Other comprehensive loss attributable to noncontrolling interests	0	0	0	0
Comprehensive income attributable to Medtronic	1,955,000,000	751,000,000	3,722,000,000	1,553,000,000
Subsidiary Guarantors | Reportable Legal Entities | CIFSA Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	0	0	0	0
Costs and expenses:
Cost of products sold	0	0	0	0
Research and development expense	0	0	0	0
Selling, general, and administrative expense	0	1,000,000	1,000,000	1,000,000
Special charge	0		0
Restructuring charges, net	0	0	0	0
Certain litigation charges				0
Acquisition-related items	0	0	0	0
Divestiture-related items	0		0
Amortization of intangible assets	0	0	0	0
Gain on sale of businesses	0		0
Other (income) expense, net	0	0	0	0
Operating profit	0	(1,000,000)	(1,000,000)	(1,000,000)
Interest income	(107,000,000)	(166,000,000)	(219,000,000)	(324,000,000)
Interest expense	48,000,000	11,000,000	82,000,000	13,000,000
Interest expense, net	(59,000,000)	(155,000,000)	(137,000,000)	(311,000,000)
Equity in net (income) loss of subsidiaries	(2,032,000,000)	(901,000,000)	(3,033,000,000)	(1,703,000,000)
Income before income taxes	2,091,000,000	1,055,000,000	3,169,000,000	2,013,000,000
Income tax (benefit) provision	0	0	0	0
Net income	2,091,000,000	1,055,000,000	3,169,000,000	2,013,000,000
Net loss attributable to noncontrolling interests	0	0	0	0
Net income attributable to Medtronic	2,091,000,000	1,055,000,000	3,169,000,000	2,013,000,000
Other comprehensive income (loss), net of tax	(136,000,000)	(304,000,000)	553,000,000	(460,000,000)
Other comprehensive loss attributable to noncontrolling interests	0	0	0	0
Comprehensive income attributable to Medtronic	1,955,000,000	751,000,000	3,722,000,000	1,553,000,000
Subsidiary Non-guarantors | Reportable Legal Entities | Medtronic Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	7,050,000,000	7,344,000,000	14,439,000,000	14,510,000,000
Costs and expenses:
Cost of products sold	2,204,000,000	2,412,000,000	4,638,000,000	4,779,000,000
Research and development expense	386,000,000	396,000,000	776,000,000	789,000,000
Selling, general, and administrative expense	2,060,000,000	2,129,000,000	4,243,000,000	4,274,000,000
Special charge	0		0
Restructuring charges, net	8,000,000	46,000,000	14,000,000	123,000,000
Certain litigation charges				82,000,000
Acquisition-related items	(7,000,000)	(9,000,000)	7,000,000	20,000,000
Divestiture-related items	61,000,000		99,000,000
Amortization of intangible assets	458,000,000	497,000,000	910,000,000	981,000,000
Gain on sale of businesses	(697,000,000)		(697,000,000)
Other (income) expense, net	491,000,000	772,000,000	1,022,000,000	1,508,000,000
Operating profit	2,086,000,000	1,101,000,000	3,427,000,000	1,954,000,000
Interest income	(348,000,000)	(286,000,000)	(679,000,000)	(424,000,000)
Interest expense	155,000,000	251,000,000	337,000,000	359,000,000
Interest expense, net	(193,000,000)	(35,000,000)	(342,000,000)	(65,000,000)
Equity in net (income) loss of subsidiaries	0	0	0	0
Income before income taxes	2,279,000,000	1,136,000,000	3,769,000,000	2,019,000,000
Income tax (benefit) provision	(126,000,000)	75,000,000	140,000,000	114,000,000
Net income	2,405,000,000	1,061,000,000	3,629,000,000	1,905,000,000
Net loss attributable to noncontrolling interests	4,000,000	4,000,000	11,000,000	4,000,000
Net income attributable to Medtronic	2,409,000,000	1,065,000,000	3,640,000,000	1,909,000,000
Other comprehensive income (loss), net of tax	(150,000,000)	(329,000,000)	530,000,000	(500,000,000)
Other comprehensive loss attributable to noncontrolling interests	4,000,000	4,000,000	11,000,000	4,000,000
Comprehensive income attributable to Medtronic	2,259,000,000	736,000,000	4,170,000,000	1,409,000,000
Subsidiary Non-guarantors | Reportable Legal Entities | CIFSA Senior Notes
Condensed Statement of Income Captions [Line Items]
Net sales	7,050,000,000	7,345,000,000	14,440,000,000	14,511,000,000
Costs and expenses:
Cost of products sold	2,120,000,000	2,326,000,000	4,469,000,000	4,587,000,000
Research and development expense	555,000,000	554,000,000	1,103,000,000	1,110,000,000
Selling, general, and administrative expense	2,435,000,000	2,412,000,000	4,917,000,000	4,837,000,000
Special charge	80,000,000		80,000,000
Restructuring charges, net	8,000,000	47,000,000	16,000,000	141,000,000
Certain litigation charges				82,000,000
Acquisition-related items	7,000,000	28,000,000	51,000,000	80,000,000
Divestiture-related items	67,000,000		114,000,000
Amortization of intangible assets	460,000,000	500,000,000	914,000,000	987,000,000
Gain on sale of businesses	(697,000,000)		(697,000,000)
Other (income) expense, net	99,000,000	175,000,000	151,000,000	202,000,000
Operating profit	1,916,000,000	1,303,000,000	3,322,000,000	2,485,000,000
Interest income	(128,000,000)	(102,000,000)	(239,000,000)	(207,000,000)
Interest expense	295,000,000	400,000,000	622,000,000	820,000,000
Interest expense, net	167,000,000	298,000,000	383,000,000	613,000,000
Equity in net (income) loss of subsidiaries	0	0	0	0
Income before income taxes	1,749,000,000	1,005,000,000	2,939,000,000	1,872,000,000
Income tax (benefit) provision	(284,000,000)	103,000,000	(96,000,000)	164,000,000
Net income	2,033,000,000	902,000,000	3,035,000,000	1,708,000,000
Net loss attributable to noncontrolling interests	4,000,000	4,000,000	11,000,000	4,000,000
Net income attributable to Medtronic	2,037,000,000	906,000,000	3,046,000,000	1,712,000,000
Other comprehensive income (loss), net of tax	(136,000,000)	(304,000,000)	553,000,000	(460,000,000)
Other comprehensive loss attributable to noncontrolling interests	4,000,000	4,000,000	11,000,000	4,000,000
Comprehensive income attributable to Medtronic	$ 1,901,000,000	$ 602,000,000	$ 3,599,000,000	$ 1,252,000,000

Guarantor Financial Informati76

Guarantor Financial Information - Condensed Consolidating Balance Sheet (Details) - USD ($) $ in Millions	Oct. 27, 2017	Apr. 28, 2017	Oct. 28, 2016	Apr. 29, 2016
Current assets:
Cash and cash equivalents	$ 5,529	$ 4,967	$ 2,954	$ 2,876
Investments	7,997	8,741
Accounts receivable, net	5,752	5,591
Inventories, net	3,638	3,338
Intercompany receivable	0	0
Other current assets	2,246	1,865
Current assets held for sale	0	371
Total current assets	25,162	24,873
Property, plant, and equipment, net	4,441	4,361
Goodwill	39,077	38,515
Other intangible assets, net	22,625	23,407
Tax assets	1,749	1,509
Investment in subsidiaries	0	0
Intercompany loans receivable	0	0
Other assets	1,404	1,232
Noncurrent assets held for sale	0	5,919
Total assets	94,458	99,816
Current liabilities:
Current debt obligations	3,131	7,520
Accounts payable	1,718	1,731
Intercompany payable	0	0
Accrued compensation	1,502	1,860
Accrued income taxes	872	633
Other accrued expenses	3,273	2,442
Current liabilities held for sale	0	34
Total current liabilities	10,496	14,220
Long-term debt	25,941	25,921
Accrued compensation and retirement benefits	1,475	1,641
Accrued income taxes	2,194	2,405
Intercompany loans payable	0	0
Deferred tax liabilities	1,841	2,978
Other liabilities	933	1,515
Noncurrent liabilities held for sale	0	720
Total liabilities	42,880	49,400
Shareholders’ equity	51,469	50,294
Noncontrolling interests	109	122
Total equity	51,578	50,416	50,293	52,063
Total liabilities and equity	94,458	99,816
Consolidating Adjustments | Medtronic Senior Notes
Current assets:
Cash and cash equivalents	0	0	0	0
Investments	0	0
Accounts receivable, net	0	0
Inventories, net	(162)	(178)
Intercompany receivable	(13,839)	(12,681)
Other current assets	0	0
Current assets held for sale		0
Total current assets	(14,001)	(12,859)
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	(195,161)	(180,360)
Intercompany loans receivable	(71,270)	(64,050)
Other assets	0	0
Noncurrent assets held for sale		0
Total assets	(280,432)	(257,269)
Current liabilities:
Current debt obligations	0	0
Accounts payable	0	0
Intercompany payable	(13,839)	(12,681)
Accrued compensation	0	0
Accrued income taxes	0	0
Other accrued expenses	0	0
Current liabilities held for sale		0
Total current liabilities	(13,839)	(12,681)
Long-term debt	0	0
Accrued compensation and retirement benefits	0	0
Accrued income taxes	0	0
Intercompany loans payable	(71,270)	(64,050)
Deferred tax liabilities	0	0
Other liabilities	0	0
Noncurrent liabilities held for sale		0
Total liabilities	(85,109)	(76,731)
Shareholders’ equity	(195,323)	(180,538)
Noncontrolling interests	0	0
Total equity	(195,323)	(180,538)
Total liabilities and equity	(280,432)	(257,269)
Consolidating Adjustments | CIFSA Senior Notes
Current assets:
Cash and cash equivalents	0	0	0	0
Investments	0	0
Accounts receivable, net	0	0
Inventories, net	0	0
Intercompany receivable	(126)	(135)
Other current assets	0	0
Current assets held for sale		0
Total current assets	(126)	(135)
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	(154,726)	(138,182)
Intercompany loans receivable	(48,416)	(40,621)
Other assets	0	0
Noncurrent assets held for sale		0
Total assets	(203,268)	(178,938)
Current liabilities:
Current debt obligations	0	0
Accounts payable	0	0
Intercompany payable	(126)	(135)
Accrued compensation	0	0
Accrued income taxes	0	0
Other accrued expenses	0	0
Current liabilities held for sale		0
Total current liabilities	(126)	(135)
Long-term debt	0	0
Accrued compensation and retirement benefits	0	0
Accrued income taxes	0	0
Intercompany loans payable	(48,416)	(40,621)
Deferred tax liabilities	0	0
Other liabilities	0	0
Noncurrent liabilities held for sale		0
Total liabilities	(48,542)	(40,756)
Shareholders’ equity	(154,726)	(138,182)
Noncontrolling interests	0	0
Total equity	(154,726)	(138,182)
Total liabilities and equity	(203,268)	(178,938)
Medtronic plc | CIFSA Senior Notes
Current assets:
Cash and cash equivalents			0	0
Medtronic plc | Reportable Legal Entities | Medtronic Senior Notes
Current assets:
Cash and cash equivalents	0	0	0	0
Investments	0	0
Accounts receivable, net	0	0
Inventories, net	0	0
Intercompany receivable	55	63
Other current assets	10	10
Current assets held for sale		0
Total current assets	65	73
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	59,762	55,833
Intercompany loans receivable	3,112	3,000
Other assets	0	0
Noncurrent assets held for sale		0
Total assets	62,939	58,906
Current liabilities:
Current debt obligations	0	0
Accounts payable	0	0
Intercompany payable	11	12
Accrued compensation	6	9
Accrued income taxes	14	13
Other accrued expenses	88	0
Current liabilities held for sale		0
Total current liabilities	119	34
Long-term debt	0	0
Accrued compensation and retirement benefits	0	0
Accrued income taxes	10	10
Intercompany loans payable	11,316	8,568
Deferred tax liabilities	0	0
Other liabilities	25	0
Noncurrent liabilities held for sale		0
Total liabilities	11,470	8,612
Shareholders’ equity	51,469	50,294
Noncontrolling interests	0	0
Total equity	51,469	50,294
Total liabilities and equity	62,939	58,906
Medtronic plc | Reportable Legal Entities | CIFSA Senior Notes
Current assets:
Cash and cash equivalents	0	0
Investments	0	0
Accounts receivable, net	0	0
Inventories, net	0	0
Intercompany receivable	55	63
Other current assets	10	10
Current assets held for sale		0
Total current assets	65	73
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	59,762	55,833
Intercompany loans receivable	3,112	3,000
Other assets	0	0
Noncurrent assets held for sale		0
Total assets	62,939	58,906
Current liabilities:
Current debt obligations	0	0
Accounts payable	0	0
Intercompany payable	11	12
Accrued compensation	6	9
Accrued income taxes	14	13
Other accrued expenses	88	0
Current liabilities held for sale		0
Total current liabilities	119	34
Long-term debt	0	0
Accrued compensation and retirement benefits	0	0
Accrued income taxes	10	10
Intercompany loans payable	11,316	8,568
Deferred tax liabilities	0	0
Other liabilities	25	0
Noncurrent liabilities held for sale		0
Total liabilities	11,470	8,612
Shareholders’ equity	51,469	50,294
Noncontrolling interests	0	0
Total equity	51,469	50,294
Total liabilities and equity	62,939	58,906
Subsidiary Issuer | CIFSA Senior Notes
Current assets:
Cash and cash equivalents			326	208
Subsidiary Issuer | Reportable Legal Entities | Medtronic Senior Notes
Current assets:
Cash and cash equivalents	47	45	71	55
Investments	0	0
Accounts receivable, net	0	0
Inventories, net	175	155
Intercompany receivable	0	0
Other current assets	195	227
Current assets held for sale		0
Total current assets	417	427
Property, plant, and equipment, net	1,333	1,311
Goodwill	0	0
Other intangible assets, net	15	20
Tax assets	792	727
Investment in subsidiaries	74,787	71,909
Intercompany loans receivable	9,958	12,162
Other assets	439	434
Noncurrent assets held for sale		0
Total assets	87,741	86,990
Current liabilities:
Current debt obligations	2,000	5,000
Accounts payable	317	304
Intercompany payable	13,828	12,669
Accrued compensation	604	734
Accrued income taxes	0	0
Other accrued expenses	472	352
Current liabilities held for sale		0
Total current liabilities	17,221	19,059
Long-term debt	21,785	21,782
Accrued compensation and retirement benefits	966	1,120
Accrued income taxes	1,620	1,658
Intercompany loans payable	14,835	13,151
Deferred tax liabilities	0	0
Other liabilities	63	153
Noncurrent liabilities held for sale		0
Total liabilities	56,490	56,923
Shareholders’ equity	31,251	30,067
Noncontrolling interests	0	0
Total equity	31,251	30,067
Total liabilities and equity	87,741	86,990
Subsidiary Issuer | Reportable Legal Entities | CIFSA Senior Notes
Current assets:
Cash and cash equivalents	0	33
Investments	0	0
Accounts receivable, net	0	0
Inventories, net	0	0
Intercompany receivable	0	0
Other current assets	0	0
Current assets held for sale		0
Total current assets	0	33
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	35,680	31,055
Intercompany loans receivable	2,332	2,978
Other assets	0	0
Noncurrent assets held for sale		0
Total assets	38,012	34,066
Current liabilities:
Current debt obligations	0	1,176
Accounts payable	0	0
Intercompany payable	0	0
Accrued compensation	0	0
Accrued income taxes	0	0
Other accrued expenses	21	23
Current liabilities held for sale		0
Total current liabilities	21	1,199
Long-term debt	2,122	2,133
Accrued compensation and retirement benefits	0	0
Accrued income taxes	0	0
Intercompany loans payable	1,374	1,369
Deferred tax liabilities	0	0
Other liabilities	0	0
Noncurrent liabilities held for sale		0
Total liabilities	3,517	4,701
Shareholders’ equity	34,495	29,365
Noncontrolling interests	0	0
Total equity	34,495	29,365
Total liabilities and equity	38,012	34,066
Subsidiary Guarantors | CIFSA Senior Notes
Current assets:
Cash and cash equivalents			108	0
Subsidiary Guarantors | Reportable Legal Entities | Medtronic Senior Notes
Current assets:
Cash and cash equivalents	822	5	108	0
Investments	0	0
Accounts receivable, net	0	0
Inventories, net	0	0
Intercompany receivable	0	0
Other current assets	1	0
Current assets held for sale		0
Total current assets	823	5
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	60,612	52,618
Intercompany loans receivable	17,731	16,114
Other assets	0	0
Noncurrent assets held for sale		0
Total assets	79,166	68,737
Current liabilities:
Current debt obligations	699	901
Accounts payable	0	0
Intercompany payable	0	0
Accrued compensation	0	0
Accrued income taxes	0	0
Other accrued expenses	4	4
Current liabilities held for sale		0
Total current liabilities	703	905
Long-term debt	1,842	1,842
Accrued compensation and retirement benefits	0	0
Accrued income taxes	0	0
Intercompany loans payable	23,868	17,160
Deferred tax liabilities	0	0
Other liabilities	0	0
Noncurrent liabilities held for sale		0
Total liabilities	26,413	19,907
Shareholders’ equity	52,753	48,830
Noncontrolling interests	0	0
Total equity	52,753	48,830
Total liabilities and equity	79,166	68,737
Subsidiary Guarantors | Reportable Legal Entities | CIFSA Senior Notes
Current assets:
Cash and cash equivalents	823	5
Investments	0	0
Accounts receivable, net	0	0
Inventories, net	0	0
Intercompany receivable	60	60
Other current assets	1	0
Current assets held for sale		0
Total current assets	884	65
Property, plant, and equipment, net	0	0
Goodwill	0	0
Other intangible assets, net	0	0
Tax assets	0	0
Investment in subsidiaries	59,284	51,294
Intercompany loans receivable	19,005	17,383
Other assets	0	0
Noncurrent assets held for sale		0
Total assets	79,173	68,742
Current liabilities:
Current debt obligations	699	901
Accounts payable	0	0
Intercompany payable	0	0
Accrued compensation	0	0
Accrued income taxes	0	0
Other accrued expenses	8	8
Current liabilities held for sale		0
Total current liabilities	707	909
Long-term debt	1,842	1,842
Accrued compensation and retirement benefits	0	0
Accrued income taxes	0	0
Intercompany loans payable	23,868	17,161
Deferred tax liabilities	0	0
Other liabilities	1	0
Noncurrent liabilities held for sale		0
Total liabilities	26,418	19,912
Shareholders’ equity	52,755	48,830
Noncontrolling interests	0	0
Total equity	52,755	48,830
Total liabilities and equity	79,173	68,742
Subsidiary Non-guarantors | CIFSA Senior Notes
Current assets:
Cash and cash equivalents			2,520	2,668
Subsidiary Non-guarantors | Reportable Legal Entities | Medtronic Senior Notes
Current assets:
Cash and cash equivalents	4,660	4,917	$ 2,775	$ 2,821
Investments	7,997	8,741
Accounts receivable, net	5,752	5,591
Inventories, net	3,625	3,361
Intercompany receivable	13,784	12,618
Other current assets	2,040	1,628
Current assets held for sale		371
Total current assets	37,858	37,227
Property, plant, and equipment, net	3,108	3,050
Goodwill	39,077	38,515
Other intangible assets, net	22,610	23,387
Tax assets	957	782
Investment in subsidiaries	0	0
Intercompany loans receivable	40,469	32,774
Other assets	965	798
Noncurrent assets held for sale		5,919
Total assets	145,044	142,452
Current liabilities:
Current debt obligations	432	1,619
Accounts payable	1,401	1,427
Intercompany payable	0	0
Accrued compensation	892	1,117
Accrued income taxes	858	620
Other accrued expenses	2,709	2,086
Current liabilities held for sale		34
Total current liabilities	6,292	6,903
Long-term debt	2,314	2,297
Accrued compensation and retirement benefits	509	521
Accrued income taxes	564	737
Intercompany loans payable	21,251	25,171
Deferred tax liabilities	1,841	2,978
Other liabilities	845	1,362
Noncurrent liabilities held for sale		720
Total liabilities	33,616	40,689
Shareholders’ equity	111,319	101,641
Noncontrolling interests	109	122
Total equity	111,428	101,763
Total liabilities and equity	145,044	142,452
Subsidiary Non-guarantors | Reportable Legal Entities | CIFSA Senior Notes
Current assets:
Cash and cash equivalents	4,706	4,929
Investments	7,997	8,741
Accounts receivable, net	5,752	5,591
Inventories, net	3,638	3,338
Intercompany receivable	11	12
Other current assets	2,235	1,855
Current assets held for sale		371
Total current assets	24,339	24,837
Property, plant, and equipment, net	4,441	4,361
Goodwill	39,077	38,515
Other intangible assets, net	22,625	23,407
Tax assets	1,749	1,509
Investment in subsidiaries	0	0
Intercompany loans receivable	23,967	17,260
Other assets	1,404	1,232
Noncurrent assets held for sale		5,919
Total assets	117,602	117,040
Current liabilities:
Current debt obligations	2,432	5,443
Accounts payable	1,718	1,731
Intercompany payable	115	123
Accrued compensation	1,496	1,851
Accrued income taxes	858	620
Other accrued expenses	3,156	2,411
Current liabilities held for sale		34
Total current liabilities	9,775	12,213
Long-term debt	21,977	21,946
Accrued compensation and retirement benefits	1,475	1,641
Accrued income taxes	2,184	2,395
Intercompany loans payable	11,858	13,523
Deferred tax liabilities	1,841	2,978
Other liabilities	907	1,515
Noncurrent liabilities held for sale		720
Total liabilities	50,017	56,931
Shareholders’ equity	67,476	59,987
Noncontrolling interests	109	122
Total equity	67,585	60,109
Total liabilities and equity	$ 117,602	$ 117,040

Guarantor Financial Informati77

Guarantor Financial Information - Condensed Consolidating Statement of Cash Flows (Details) - USD ($) $ in Millions	6 Months Ended
	Oct. 27, 2017	Oct. 28, 2016
Operating Activities:
Net cash provided by (used in) operating activities	$ 1,644	$ 3,022
Investing Activities:
Acquisitions, net of cash acquired	(76)	(1,306)
Proceeds from sale of businesses	6,058	0
Additions to property, plant, and equipment	(524)	(598)
Purchases of investments	(1,685)	(2,110)
Sales and maturities of investments	2,354	3,625
Net (increase) decrease in intercompany loans	0	0
Capital contribution paid	0	0
Other investing activities, net	(2)	32
Net cash provided by (used in) investing activities	6,125	(357)
Financing Activities:
Acquisition-related contingent consideration	(39)	(36)
Change in current debt obligations, net	(190)	1,154
Proceeds from short-term borrowings (maturities greater than 90 days)	0	4
Issuance of long-term debt	20	131
Payments on long-term debt	(4,161)	(252)
Dividends to shareholders	(1,247)	(1,192)
Issuance of ordinary shares	230	260
Repurchase of ordinary shares	(1,888)	(2,794)
Net intercompany loan borrowings (repayments)	0	0
Intercompany dividend paid	0	0
Capital contribution received	0	0
Other financing activities	(2)	74
Net cash used in financing activities	(7,277)	(2,651)
Effect of exchange rate changes on cash and cash equivalents	70	64
Net change in cash and cash equivalents	562	78
Cash and cash equivalents at beginning of period	4,967	2,876
Cash and cash equivalents at end of period	5,529	2,954
Consolidating Adjustments | Medtronic Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	0	0
Investing Activities:
Acquisitions, net of cash acquired	0	0
Proceeds from sale of businesses	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	162
Sales and maturities of investments	0	(162)
Net (increase) decrease in intercompany loans	7,220	3,476
Capital contribution paid	4,212	233
Other investing activities, net	0	0
Net cash provided by (used in) investing activities	11,432	3,709
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in current debt obligations, net	0	0
Proceeds from short-term borrowings (maturities greater than 90 days)		0
Issuance of long-term debt	0	0
Payments on long-term debt	0	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	(7,220)	(3,476)
Capital contribution received	(4,212)	(233)
Other financing activities	0	0
Net cash used in financing activities	(11,432)	(3,709)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Consolidating Adjustments | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	(1,048)	(920)
Investing Activities:
Acquisitions, net of cash acquired	0	0
Proceeds from sale of businesses	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Net (increase) decrease in intercompany loans	7,795	(3,788)
Capital contribution paid	4,731	325
Other investing activities, net	0	0
Net cash provided by (used in) investing activities	12,526	(3,463)
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in current debt obligations, net	0	0
Proceeds from short-term borrowings (maturities greater than 90 days)		0
Issuance of long-term debt	0	0
Payments on long-term debt	0	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	(7,795)	3,788
Intercompany dividend paid	1,048	920
Capital contribution received	(4,731)	(325)
Other financing activities	0	0
Net cash used in financing activities	(11,478)	4,383
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Medtronic plc | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities		644
Investing Activities:
Acquisitions, net of cash acquired		0
Additions to property, plant, and equipment		0
Purchases of investments		0
Sales and maturities of investments		0
Net (increase) decrease in intercompany loans		0
Capital contribution paid		0
Other investing activities, net		0
Net cash provided by (used in) investing activities		0
Financing Activities:
Acquisition-related contingent consideration		0
Change in current debt obligations, net		0
Proceeds from short-term borrowings (maturities greater than 90 days)		0
Issuance of long-term debt		0
Payments on long-term debt		0
Dividends to shareholders		(1,192)
Issuance of ordinary shares		260
Repurchase of ordinary shares		(2,794)
Net intercompany loan borrowings (repayments)		3,082
Intercompany dividend paid		0
Capital contribution received		0
Other financing activities		0
Net cash used in financing activities		(644)
Effect of exchange rate changes on cash and cash equivalents		0
Net change in cash and cash equivalents		0
Cash and cash equivalents at beginning of period		0
Cash and cash equivalents at end of period		0
Medtronic plc | Reportable Legal Entities | Medtronic Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	269	644
Investing Activities:
Acquisitions, net of cash acquired	0	0
Proceeds from sale of businesses	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Net (increase) decrease in intercompany loans	(112)	0
Capital contribution paid	0	0
Other investing activities, net	0	0
Net cash provided by (used in) investing activities	(112)	0
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in current debt obligations, net	0	0
Proceeds from short-term borrowings (maturities greater than 90 days)		0
Issuance of long-term debt	0	0
Payments on long-term debt	0	0
Dividends to shareholders	(1,247)	(1,192)
Issuance of ordinary shares	230	260
Repurchase of ordinary shares	(1,888)	(2,794)
Net intercompany loan borrowings (repayments)	2,748	3,082
Capital contribution received	0	0
Other financing activities	0	0
Net cash used in financing activities	(157)	(644)
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	0	0
Cash and cash equivalents at beginning of period	0	0
Cash and cash equivalents at end of period	0	0
Medtronic plc | Reportable Legal Entities | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	269
Investing Activities:
Acquisitions, net of cash acquired	0
Proceeds from sale of businesses	0
Additions to property, plant, and equipment	0
Purchases of investments	0
Sales and maturities of investments	0
Net (increase) decrease in intercompany loans	(112)
Capital contribution paid	0
Other investing activities, net	0
Net cash provided by (used in) investing activities	(112)
Financing Activities:
Acquisition-related contingent consideration	0
Change in current debt obligations, net	0
Issuance of long-term debt	0
Payments on long-term debt	0
Dividends to shareholders	(1,247)
Issuance of ordinary shares	230
Repurchase of ordinary shares	(1,888)
Net intercompany loan borrowings (repayments)	2,748
Intercompany dividend paid	0
Capital contribution received	0
Other financing activities	0
Net cash used in financing activities	(157)
Effect of exchange rate changes on cash and cash equivalents	0
Net change in cash and cash equivalents	0
Cash and cash equivalents at beginning of period	0
Cash and cash equivalents at end of period	0
Subsidiary Issuer | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities		879
Investing Activities:
Acquisitions, net of cash acquired		0
Additions to property, plant, and equipment		0
Purchases of investments		0
Sales and maturities of investments		0
Net (increase) decrease in intercompany loans		3,198
Capital contribution paid		(325)
Other investing activities, net		0
Net cash provided by (used in) investing activities		2,873
Financing Activities:
Acquisition-related contingent consideration		0
Change in current debt obligations, net		0
Proceeds from short-term borrowings (maturities greater than 90 days)		0
Issuance of long-term debt		0
Payments on long-term debt		0
Dividends to shareholders		0
Issuance of ordinary shares		0
Repurchase of ordinary shares		0
Net intercompany loan borrowings (repayments)		(3,634)
Intercompany dividend paid		0
Capital contribution received		0
Other financing activities		0
Net cash used in financing activities		(3,634)
Effect of exchange rate changes on cash and cash equivalents		0
Net change in cash and cash equivalents		118
Cash and cash equivalents at beginning of period		208
Cash and cash equivalents at end of period		326
Subsidiary Issuer | Reportable Legal Entities | Medtronic Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	(743)	513
Investing Activities:
Acquisitions, net of cash acquired	0	(918)
Proceeds from sale of businesses	0
Additions to property, plant, and equipment	(132)	(161)
Purchases of investments	0	0
Sales and maturities of investments	0	210
Net (increase) decrease in intercompany loans	2,204	496
Capital contribution paid	(12)	(233)
Other investing activities, net	0	0
Net cash provided by (used in) investing activities	2,060	(606)
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in current debt obligations, net	0	0
Proceeds from short-term borrowings (maturities greater than 90 days)		0
Issuance of long-term debt	0	0
Payments on long-term debt	(3,000)	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	1,685	109
Capital contribution received	0	0
Other financing activities	0	0
Net cash used in financing activities	(1,315)	109
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	2	16
Cash and cash equivalents at beginning of period	45	55
Cash and cash equivalents at end of period	47	71
Subsidiary Issuer | Reportable Legal Entities | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	997
Investing Activities:
Acquisitions, net of cash acquired	0
Proceeds from sale of businesses	0
Additions to property, plant, and equipment	0
Purchases of investments	0
Sales and maturities of investments	0
Net (increase) decrease in intercompany loans	646
Capital contribution paid	(531)
Other investing activities, net	0
Net cash provided by (used in) investing activities	115
Financing Activities:
Acquisition-related contingent consideration	0
Change in current debt obligations, net	0
Issuance of long-term debt	0
Payments on long-term debt	(1,150)
Dividends to shareholders	0
Issuance of ordinary shares	0
Repurchase of ordinary shares	0
Net intercompany loan borrowings (repayments)	5
Intercompany dividend paid	0
Capital contribution received	0
Other financing activities	0
Net cash used in financing activities	(1,145)
Effect of exchange rate changes on cash and cash equivalents	0
Net change in cash and cash equivalents	(33)
Cash and cash equivalents at beginning of period	33
Cash and cash equivalents at end of period	0
Subsidiary Guarantors | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities		162
Investing Activities:
Acquisitions, net of cash acquired		0
Additions to property, plant, and equipment		0
Purchases of investments		0
Sales and maturities of investments		0
Net (increase) decrease in intercompany loans		(2,117)
Capital contribution paid		0
Other investing activities, net		0
Net cash provided by (used in) investing activities		(2,117)
Financing Activities:
Acquisition-related contingent consideration		0
Change in current debt obligations, net		1,130
Proceeds from short-term borrowings (maturities greater than 90 days)		4
Issuance of long-term debt		0
Payments on long-term debt		0
Dividends to shareholders		0
Issuance of ordinary shares		0
Repurchase of ordinary shares		0
Net intercompany loan borrowings (repayments)		929
Intercompany dividend paid		0
Capital contribution received		0
Other financing activities		0
Net cash used in financing activities		2,063
Effect of exchange rate changes on cash and cash equivalents		0
Net change in cash and cash equivalents		108
Cash and cash equivalents at beginning of period		0
Cash and cash equivalents at end of period		108
Subsidiary Guarantors | Reportable Legal Entities | Medtronic Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	128	163
Investing Activities:
Acquisitions, net of cash acquired	0	0
Proceeds from sale of businesses	0
Additions to property, plant, and equipment	0	0
Purchases of investments	0	0
Sales and maturities of investments	0	0
Net (increase) decrease in intercompany loans	(1,617)	(2,117)
Capital contribution paid	(4,200)	0
Other investing activities, net	0	0
Net cash provided by (used in) investing activities	(5,817)	(2,117)
Financing Activities:
Acquisition-related contingent consideration	0	0
Change in current debt obligations, net	(202)	1,130
Proceeds from short-term borrowings (maturities greater than 90 days)		4
Issuance of long-term debt	0	0
Payments on long-term debt	0	0
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	6,708	928
Capital contribution received	0	0
Other financing activities	0	0
Net cash used in financing activities	6,506	2,062
Effect of exchange rate changes on cash and cash equivalents	0	0
Net change in cash and cash equivalents	817	108
Cash and cash equivalents at beginning of period	5	0
Cash and cash equivalents at end of period	822	108
Subsidiary Guarantors | Reportable Legal Entities | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	135
Investing Activities:
Acquisitions, net of cash acquired	0
Proceeds from sale of businesses	0
Additions to property, plant, and equipment	0
Purchases of investments	0
Sales and maturities of investments	0
Net (increase) decrease in intercompany loans	(1,622)
Capital contribution paid	(4,200)
Other investing activities, net	0
Net cash provided by (used in) investing activities	(5,822)
Financing Activities:
Acquisition-related contingent consideration	0
Change in current debt obligations, net	(202)
Issuance of long-term debt	0
Payments on long-term debt	0
Dividends to shareholders	0
Issuance of ordinary shares	0
Repurchase of ordinary shares	0
Net intercompany loan borrowings (repayments)	6,707
Intercompany dividend paid	0
Capital contribution received	0
Other financing activities	0
Net cash used in financing activities	6,505
Effect of exchange rate changes on cash and cash equivalents	0
Net change in cash and cash equivalents	818
Cash and cash equivalents at beginning of period	5
Cash and cash equivalents at end of period	823
Subsidiary Non-guarantors | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities		2,257
Investing Activities:
Acquisitions, net of cash acquired		(1,306)
Additions to property, plant, and equipment		(598)
Purchases of investments		(2,110)
Sales and maturities of investments		3,625
Net (increase) decrease in intercompany loans		2,707
Capital contribution paid		0
Other investing activities, net		32
Net cash provided by (used in) investing activities		2,350
Financing Activities:
Acquisition-related contingent consideration		(36)
Change in current debt obligations, net		24
Proceeds from short-term borrowings (maturities greater than 90 days)		0
Issuance of long-term debt		131
Payments on long-term debt		(252)
Dividends to shareholders		0
Issuance of ordinary shares		0
Repurchase of ordinary shares		0
Net intercompany loan borrowings (repayments)		(4,165)
Intercompany dividend paid		(920)
Capital contribution received		325
Other financing activities		74
Net cash used in financing activities		(4,819)
Effect of exchange rate changes on cash and cash equivalents		64
Net change in cash and cash equivalents		(148)
Cash and cash equivalents at beginning of period		2,668
Cash and cash equivalents at end of period		2,520
Subsidiary Non-guarantors | Reportable Legal Entities | Medtronic Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	1,990	1,702
Investing Activities:
Acquisitions, net of cash acquired	(76)	(388)
Proceeds from sale of businesses	6,058
Additions to property, plant, and equipment	(392)	(437)
Purchases of investments	(1,685)	(2,272)
Sales and maturities of investments	2,354	3,577
Net (increase) decrease in intercompany loans	(7,695)	(1,855)
Capital contribution paid	0	0
Other investing activities, net	(2)	32
Net cash provided by (used in) investing activities	(1,438)	(1,343)
Financing Activities:
Acquisition-related contingent consideration	(39)	(36)
Change in current debt obligations, net	12	24
Proceeds from short-term borrowings (maturities greater than 90 days)		0
Issuance of long-term debt	20	131
Payments on long-term debt	(1,161)	(252)
Dividends to shareholders	0	0
Issuance of ordinary shares	0	0
Repurchase of ordinary shares	0	0
Net intercompany loan borrowings (repayments)	(3,921)	(643)
Capital contribution received	4,212	233
Other financing activities	(2)	74
Net cash used in financing activities	(879)	(469)
Effect of exchange rate changes on cash and cash equivalents	70	64
Net change in cash and cash equivalents	(257)	(46)
Cash and cash equivalents at beginning of period	4,917	2,821
Cash and cash equivalents at end of period	4,660	$ 2,775
Subsidiary Non-guarantors | Reportable Legal Entities | CIFSA Senior Notes
Operating Activities:
Net cash provided by (used in) operating activities	1,291
Investing Activities:
Acquisitions, net of cash acquired	(76)
Proceeds from sale of businesses	6,058
Additions to property, plant, and equipment	(524)
Purchases of investments	(1,685)
Sales and maturities of investments	2,354
Net (increase) decrease in intercompany loans	(6,707)
Capital contribution paid	0
Other investing activities, net	(2)
Net cash provided by (used in) investing activities	(582)
Financing Activities:
Acquisition-related contingent consideration	(39)
Change in current debt obligations, net	12
Issuance of long-term debt	20
Payments on long-term debt	(3,011)
Dividends to shareholders	0
Issuance of ordinary shares	0
Repurchase of ordinary shares	0
Net intercompany loan borrowings (repayments)	(1,665)
Intercompany dividend paid	(1,048)
Capital contribution received	4,731
Other financing activities	(2)
Net cash used in financing activities	(1,002)
Effect of exchange rate changes on cash and cash equivalents	70
Net change in cash and cash equivalents	(223)
Cash and cash equivalents at beginning of period	4,929
Cash and cash equivalents at end of period	$ 4,706